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Résumé 
Oligomérisation d’ASIC1a et structure-fonction de son vestibule extracellulaire 
Caractérisation fonctionnelle d’S243P  
Delphine Huser, Département de Pharmacologie et Toxicologie 
Quatre cristaux du canal ASIC1a ont été publiés et soutiennent une stœchiométrie 
trimérique. Cependant, ces données contredisant de précédentes analyses fonctionnelles 
effectuées sur des canaux de la même famille, notre intérêt fut porté sur l’oligomérisation 
d’ASIC1a. Dans ce sens, un nouvel essai couplant la méthode d’analyse par substitution de 
cystéines (SCAM) avec l’utilisation de réactifs sulfhydryls bifonctionnels (crosslinkers) a été 
mis en place. Le but étant de stabiliser, puis sélectionner les canaux fonctionnels, pour ensuite 
les séparer selon leur taille par SDS-PAGE. Grâce à cette technique, nous avons démontré que 
le complexe stabilisé a une taille coïncidant avec une organisation tétramérique. 
En plus de son oligomérisation, le chemin emprunté par les ions pour traverser le canal n’est 
pas clairement défini dans ces structures. De ce fait, utilisant une approche 
électrophysiologique, nous avons étudié le lien entre la structure et la fonction du vestibule 
extracellulaire d’ASIC1a. Dans ce but, nous nous sommes intéressés l’accessibilité de 
cystéines spécifiques localisées dans ce vestibule pour des réactifs méthanethiosulfonates 
(MTS). Ainsi, nous avons pu corréler les cinétiques de modification de ces cystéines par les 
MTS avec les effets sur le courant sodique, et donc avoir des informations supplémentaires 
sur la voie empruntée par les ions. De plus, la simulation informatique de liaison de ces 
réactifs illustre le remplissage total de ce vestibule. Fonctionnellement, cette interaction ne 
perturbe pas le passage de ions, c’est pourquoi il nous apparaît probable que le vestibule 
présente une taille plus large que celle illustrée par les cristaux.  
Dans un deuxième temps, notre intérêt fut porté sur ENaC. Ce canal est composé des 
trois sous-unités (,  et  et est exprimé dans divers épithéliums, dont les tubules des reins. 
Il participe à l’homéostasie sodique et est essentiellement régulé par voie hormonale via 
l’aldostérone et la vasopressine, mais également par des sérines protéases ou le Na+. Nous 
avons étudié la répercussion fonctionnelle de la mutation S243P, découverte chez un 
nouveau-né prématuré atteint de pseudohypoaldostéronisme de type 1. Cette maladie 
autosomale récessive se caractérise, généralement, par une hyponatrémie liée à d’importantes 
pertes de sel dans les urines, une hyperkaliémie, ainsi qu’un niveau élevé d’aldostérone.  
Tout d’abord aucune des expériences biochimiques et électrophysiologiques n’a pu 
démontrer un défaut d’expression ou une forte diminution de l’activité soutenant les données 
cliniques. Cependant, en challengeant S243PENaC avec une forte concentration de Na+ 
externe, une hypersensibilité de canal fut observée. En effet, ni les phénomènes régulateurs de 
« feedback inhibition » ou de « Na
+
 self-inhibition » n’étaient semblables au canal sauvage. 
De ce fait, ils apparaissaient exacerbés en présence de la mutation, amenant ainsi à une 
diminution de la réabsorption de Na
+. Ceci corrobore entièrement l’hyponatrémie 
diagnostiquée. Le rein d’un prématuré étant immature, la quantité de Na+ atteignant la partie 
distale du néphron est plus élevée, du fait que les autres mécanismes de réabsorption en amont 
ne sont probablement pas encore en place. Cette hypothèse est renforcée par l’existence d’un 
frère présentant la même mutation, mais qui, né à terme, ne présentait aucun signe 
d’hyponatrémie.  
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Summary 
 
ASIC1a oligomerization and structure-function of its extracellular vestibule 
Functional characterization of S243PENaC 
Delphine Huser, Department of Pharmacology and Toxicology 
 
The main topic of my thesis is the structure-function relationship of the ENaC/Deg family 
of ion channels, namely the Acid-Sensing Ion Channel ASIC1a and the Epithelial Na Channel 
ENaC. 
The primary part of this research is dedicated to the structure of ASIC1a. Four channel 
crystals have been published, which support a trimeric stoichiometry, although these data 
contradict previous functional experiments on other ENaC/Deg members. We are therefore 
interested in ASIC1a oligomerization and have set up a new assay combining the Substituted-
Cysteine Accessibility Method (SCAM) with bifunctional sulfhydryl reagents (crosslinkers) 
allowing its study. The aim was to first stabilize the channels, then select those that are 
functional and then resolve them according to their size on SDS-PAGE. We demonstrated that 
the stabilized complex has a molecular weight corresponding to a tetrameric stoichiometry. 
In addition to our interest in the oligomerization of the ENaC/Deg family of ion channels, we 
also wanted to investigate the thus far undefined way of permeation for these channels. 
Therefore, taking the advantage of a more electrophysiological approach, we studied the 
accessibility of specific cysteines for methanethiosulfonate reagents (MTS) and were able to 
correlate the MTS association kinetics on cysteine residues with Na
+
 currents. These results 
have given us an insight into ion permeation and our functional evidence indicates that the 
extracellular is larger than that depicted by the crystal structures. 
As a side project, we focused on ENaC, which is made up of three subunits (,  and ) 
and is expressed in various epithelia, especially in the distal nephron of the kidneys. It plays a 
role in Na
+
 homeostasis and is essentially regulated by hormones via aldosterone and 
vasopressin, but also by serine proteases or Na
+
. We have studied the functional impact of the 
S243P mutation, discovered in a premature baby suffering from pseudohypoaldosteronism 
of type 1. This autosomal recessive disease is characterized by hyponatremia, hyperkalemia 
and high aldosterone levels. Firstly, neither biochemical nor electrophysiological experiments 
indicated an expression defect or a strong decrease in activity. However, challenging 
S243PENaC with increased external Na+ concentration showed channel hypersensitivity. 
Indeed, both the “feedback inhibition” and the “Na+ self-inhibition” regulatory mechanisms 
are impaired, leading to a decrease in Na
+
 reabsorption, entirely supports the diagnosis. The 
kidneys in preterm infants are immature and Na

 levels reaching the distal nephron are higher 
than normally observed. We hypothesize that the upstream reabsorption machinery is unlikely 
to be sufficiently matured and this assumption is supported by an asymptomatic sibling 
carrying the same mutation, but born at term. 
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Résumé destiné à un large public 
 
Oligomérisation d’ASIC1a et structure-fonction de son vestibule extracellulaire 
Caractérisation fonctionnelle d’S243P ENaC 
Delphine Huser, Département de Pharmacologie et Toxicologie 
 
La cellule, unité fonctionnelle du corps humain, est délimitée par une membrane 
plasmique servant de barrière biologique entre les milieux intra et extracellulaires. Une 
communication entre cellules est indispensable pour un fonctionnement adéquat. Sa survie 
dépend, entre autres, du maintien de la teneur en ions dans chacun des milieux qui doivent 
pouvoir être réabsorbés, ou sécrétés, selon les besoins. Les protéines insérées dans la 
membrane forment un canal et sont un moyen de communication permettant spécifiquement à 
des ions tel que le sodium (Na
+
) de traverser. Le Na
+
 se trouve dans la plupart des aliments et 
le sel, et est spécifiquement réabsorbé au niveau des reins grâce au canal sodique épithélial 
ENaC. Cette réabsorption se fait de l’urine primaire vers l’intérieur de la cellule, puis est 
transporté vers le sang. Pour maintenir un équilibre, une régulation de ce canal est nécessaire. 
En effet, des dysfonctionnements impliquant la régulation ou l’activité d’ENaC lui-même sont 
à l’origine de maladies telles que la mucoviscidose, l’hypertension ou encore, le 
pseudohypoaldostéronisme (PHA). Cette maladie est caractérisée, notamment, par 
d’importantes pertes de sel dans les urines. Des pédiatres ont diagnostiqué un PHA chez un 
nouveau-né, ce dernier présentant une modification du canal ENaC, nous avons recréé cette 
protéine afin d’étudier l’impact de ce changement sur son activité. Nous avons démontré que 
la régulation d’ENaC était effectivement perturbée, conduisant ainsi à une forte réduction de 
la réabsorption sodique. 
 
Afin de développer des molécules capables de moduler l’activité de protéines. Il est 
nécessaire d’en connaître la structure. Celle du canal sodique sensible à l’acidification ASIC1, 
un canal cousin d’ENaC, est connue. Ces données structurales contredisant cependant les 
analyses fonctionnelles, nous nous sommes penchés une nouvelle fois sur ASIC1. Une 
protéine est une macromolécule biologique composée d'une chaîne d'acides aminés (aa). De 
l’enchaînement d’aa à la protéine fonctionnelle, quatre niveaux de structuration existent. 
Chaque aa donne une indication quant au repliement et plus particulièrement la cystéine. 
Arborant un groupe sulfhydryle (SH) capable de former une liaison spécifique et stable avec 
un autre SH, celle-ci est souvent impliquée dans la structure tridimensionnelle de la protéine. 
Ce type de liaison intervient également dans la stabilisation de la structure quaternaire, qui est 
l’association de plusieurs protéines identiques (homomère), ou pas (hétéromère).  
Dans cette partie, nous avons remplacé des aa par des cystéines à des endroits spécifiques. Le 
but était de stabiliser plusieurs homomères d’ASIC1 ensemble avec des réactifs créant des 
ponts entre deux SH. Ainsi, nous avons pu déterminer le nombre de protéines ASIC1 
participant à la formation d’un canal fonctionnel. Nos résultats corroborent les données 
fonctionnelles soutenant un canal tétramérique. Nous avons également étudié l’accessibilité 
de ces nouvelles cystéines afin d’obtenir des informations supplémentaires sur la structure du 
chemin emprunté par le Na
+
 à travers ASIC1 et plus particulièrement du vestibule 
extracellulaire. 
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Introduction 
Ion channels, as well as aquaporins or the porins, are macromolecular pores inserted in 
the cell membrane. They appeared more than 3 billion years ago with primitive replicating forms 
surrounded by the first lipid envelope (1). While protecting cell from the loss of vital 
components, the envelope also prevents the access of ionized necessary substrates and the loss of 
ionized waste products. Thus, transport mechanisms (membrane proteins) have evolved in 
parallel, each of them with specific transport devices and physiological functions. Their roles are 
to regulate the distribution of ions and water in the intracellular and extracellular compartments. 
The transport can be either passive or active, depending whether molecules cross the membrane 
passively or actively through membrane proteins. In the passive or facilitated transport, 
molecules (such as ions or glucose) cross the transmembrane proteins following their 
electrochemical gradients. Both intra- and extracellular milieus have a heterogenic ionic 
composition influenced by the selective permeability of the membrane for ions. This 
characteristic renders the membrane electrically polarized. The pores (i.e. aquaporins), the 
carriers (i.e. glucose transporters GLUT), as well as the ionic channels, belong to the facilitated 
pathway. Ion channels present diversity and are classified into gene families and subfamilies; 
among them are the voltage-gated, the ligand-gated, the transient-receptor potential TRP or the 
ENaC/Degenerin family of ion channels. 
ENaC/Degenerin family 
The epithelial sodium channel (ENaC)/degenerin (Deg) gene family have been discovered 
lately at the beginning of the 1990s. All members form Na
+
-selective channels sharing a common 
subunit organization characterized by two hydrophobic transmembrane (TM) domains, short N- 
and C- termini, and a large extracellular loop (ECL) containing two to three cysteine-rich 
domains. 
The Figure 1 depicts the phylogenetic relationship of the ENaC/Deg family members 
classified into taxa. Until recently ENaC/Deg channels were found only in Metazoa. Formerly 
restricted to the Bilateria, the identification of new members isolated from the Cnidaria Hydra 
magnipapillata (namely HyNaC1 to 4) moved backwards the first appearance of the ENaC/Deg 
family prior to the Radiata-Bilateria dichotomy. The fact that HyNaC channels are gated by the 
Hydra Arg-Phe-NH2 (RFamide) peptides supports the theory that the peptide-gated ion channels 
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have evolved in organisms bearing a primitive nervous system where transmission occurred 
extensively via neuropeptides (2). Bilateria have another peptide-gated channel subfamily, i.e. the 
FaNaC. Belonging of Protostomia to the subdivision Lophotrochozoa, FaNaC channels have 
been identified from the snail Helix aspersa (Molluska) and are directly gated by the peptide Phe-
Met-Arg-Phe-NH2 (FMRFamide) (3). In the same branch the Ecdysozoa contains the two largest 
subfamilies of ENaC/Deg channels; the Nematoda and the Insecta. The Degenerins of the worm 
Caenorhabditis elegans are composed of 30 members, with DEG-1 and MEC-4 as the first 
discovered via a screening of mutations that caused neurodegeneration (4,5). Expressed in 
mechanoreceptor neurones (MEC, DEG) and muscles (UNC), they are activated by mechanical 
stimuli such as stretch (6). Additionally, C. elegans has distinct members of the degenerins, 
namely FLR, which were isolated through fluoride ion resistant mutants (7). Beside Nematoda, 
Insecta with the Drosophila melanogaster contain no less than 31 related-genes, namely ripped 
pocket (RPK) and pickpocket (PPK) (8). Cell functions and patterns of expression are as various 
as the number of genes, going from a role in mechanosensation to a chemosensory function in 
male courtship behaviors, an implication in salt taste, tracheal liquid clearance or synaptic 
plasticity (9-16). To date, a lot remains to be investigated in order to understand the physiological 
functions of most pickpocket proteins. The final branch of the Metazoa displaying ENaC/Deg 
genes encompasses the vertebrates. We can distinguish two subfamilies; the H
+
-activated ASIC 
and the constitutively open ENaC. Vertebrates also have the brain-liver-intestine Na
+
 channel 
(BLINaC), isolated from the rat brain and the human intestine sodium channel (hINaC). A recent 
study, searching for ENaC/Deg homologs from unicellular eukaryotes to multicellular 
Metazoans, pointed out the existence of homologs in the Naegleria gruberi genome, a eukaryotic 
microbe from the Excavata. Authors raised the question of the ENaC/Deg family presence in the 
N. gruberi and confronted two hypotheses, one supporting a common ancestor and the 
consequent vertical inheritance of the gene family and the other inclining for a lateral gene 
transfer (17). 
Despite a well-conserved topology of the subunits between the ENaC/Deg family 
members, the homology between the subfamilies is quite low, whereas it increases within 
subfamilies. Indeed, within ENaC and Deg subfamilies, the average homology between amino 
acids (aa) sequences reaches 33 and 35 %, respectively, while it attains 38, 43 and 68 % in 
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HyNaC, ASIC and FaNaC, respectively. Regarding PPK members, the sequence homology falls 
to 20 % (see Percent Identity Matrix (Clustal Omega) for detailed values). 
Between subfamilies, conserved motifs exist. The ECL is rich in cysteines and contains seven 
disulfide bridges widely conserved among homologs; the cysteine-rich domains "CRD”. The N-
terminal region contains two residues (His-Gly) highly conserved, this is the “HG motif”. The 
conservation of HG is complete within the ASIC, ENaC, HyNaC, FaNaC and Deg proteins. 
However, it is not within the PPK family. Indeed, 58 % arbor HG, 22 % have a half-conserved 
motif (HN, SG, NG or AG), and 20 % display no conservation or deletion of HG. Then, the 
FPxxTxC sequence following M1 (post-M1, yellow) displays the same kind of conservation than 
HG; F, P, T and C residues display a conservation of 90, 97, 61 and 97 % within the PPK 
members, respectively. The TM domains are a feature fully-conserved throughout the ENaC/Deg 
family. Analyzing the aa identity of the TM1 (respectively TM2) within subfamilies 
demonstrates that the conservation is pretty much higher for the TM2 than the TM1. Indeed, the 
average values are 37 and 71 % for ASIC TM1 versus TM2, 31 and 46 % for ENaC, 28 and 56 % 
concerning HyNaC, as well as 24 and 51 % for Deg proteins.   
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Figure 1 Quartet-puzzling consensus tree for the DEG/ENaC family members. The tree has been constructed from molecular 
sequence data by maximum likelihood, with the program TREE-PUZZLE; branch lengths represent the evolutionary distance. 
Support values below 90% are indicated. The ASIC branch is shown also at higher magnification. Figure modified from 
Golubovic et al. 2007 (2). 
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ENaC 
The existence of an epithelial Na
+
 channel was known prior the cloning thanks to 
experiments of Ussing on frog skin (18). Single-channels recordings on rat kidney performed by 
Palmer and Frindt also confirmed the presence of an epithelial Na
+
 channel (19). ENaC is a 
heteromultimeric membrane protein. To date, four subunits of ENaC have been cloned; ,,  
(20-22) and (23,24). They have been the first members of the ENaC/Deg family expressed 
in a heterologous system. Analyzing the percent of aa sequence homology between them 
indicates an average of 33 %. The highest similarities have been found between  and  (39 %), 
as well as between  and  (36 %) (Figure 2). 
 
Figure 2 Amino acids sequence identity matrix of ASIC channels obtained from basic local alignment of amino acid sequences 
using Clustal Omega (http://www.ebi.ac.uk/Tools/msa/clustalo/). 
To be functional, channels must be composed at least of an  or -like subunit (). 
However, when expressed individually,  or  does not induce an amiloride-sensitive current. 
When co-expressed with  subunit,  and  demonstrate a 3- to 5- fold potentiation of the 
currents. Finally, co-expression of  is required to have a maximal channel activity. This 
maximal current is 25 to 50-fold higher than  or  currents (25). Co-expression of 2 in 
Xenopus laevis oocytes leads to smaller currents than channels made of  subunits. Due to a 
decreased level of expression at the cell surface, it might result from a lower efficiency of 
assembly and/or a trafficking defect (26). 
ENaC is a constitutively open channel characterized by high selectivity for small 
cations such as Li
2+
 and Na
+
 and non-selectivity for larger cations (K
+
 or NH4
+
). Permeability (P) 
is higher for Li
2+
 than Na
+
 which in turn is 20-fold bigger than PK (PLi > PNa >> PK). Patch-clamp 
analyses on rat collecting tubules have demonstrated that the ENaC unitary conductance reaches 
4-5 pS for the Na
+
 and 8 pS for the Li
2+
. Moreover, the Michaelis constant (Km), that is the 
concentration required for half-maximal conductance, indicates that Na
+
 has an apparent binding 
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affinity higher than Li
2+
 with Km of 20-50 mM and 90 mM, respectively. Regarding the gating, 
ENaC is characterized by long spontaneous and closed times (0.5-5 sec at room temperature). 
The duration is shortened to hundreds of millisecond in rat cortical collecting duct (CCD) at 37°C 
(27). Channels made of two subunits ( or ) have functional characteristics slightly different. 
For instance, the magnitude of amiloride-sensitive current has a similar profile between  and 
 channels (Li+ > Na+ >> K+), whereas  has larger Na+ current than Li+. Moreover, single 
channel conductances of  channels (5.1 pS and 4.2 pS for Na+ and Li+, respectively) are 
smaller than for  (6.5 and 10.8 pS for Na+ and Li+, respectively) (28). 
1. ENaC physiology 
ENaC is expressed at the apical side of polarized epithelial cells. ENaC has been 
detected in the kidney and the lung (for details, see next section), as well as in salivary glands 
(29) and taste buds (30,31). Colonic epithelial cells also express ENaC and play a role in Na
+
 
homeostasis (32). In the epidermis, ENaC has also been detected in human primary keratinocytes 
and murine epithelium (33,34). ENaC is the rate-limiting step for Na
+
 transport. The model of the 
Figure 3 illustrates the movement of Na
+
 ions; according to their electrochemical gradient, Na
+
 
ions enter the cell and are then actively extruded through the Na, K-ATPase. This polarized cell 
model is the base of the Na
+
 transport and is found in various epithelia. In the lung ENaC is co-
expressed with the Cl
-
 channel CFTR responsible of the Cl
-
 secretion, whereas in the kidney it is 
with the K
+
 channel ROMK secreting K
+
. 
 
Figure 3 Scheme of the transcellular Na+ transport in a polarized epithelial cell. At the apical membrane, ENaC (in gray) 
transports Na+. Basolaterally, the Na, K-ATPase (in blue) extrudes it from the cell and reabsorbs K+. 
The 1 and 2 subunits expression is, however, not restrained to epithelia. Indeed, these proteins 
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have been detected in non-epithelial tissues as in the CNS (telencephalon) or spermatogenic cells 
(35,36). Surprisingly, neither  nor  ENaC appeared to be co-expressed with . Few works have 
highlighted the presence of  transcripts in epithelia, as for instance in lung tissue (37). However, 
the expression profile of  proteins still remains unknown. 
Several domains have been shown to be important for ENaC structure and function. Some 
of them have been cited before via their conservation throughout the ENaC/Deg family, other 
not. Extracellular cysteines of the “CRD” are involved in disulfide bonds, except the C275. These 
bridges likely play a role in the proper protein folding (38,39). The “HG motif” in the N-terminus 
has been discovered via a human mutation where a serine replaced a glycine in ENaC (G37S). 
This mutation led to an ENaC loss of function due to an opening probability decrease and, 
consequently, to an excessive Na
+
 loss in the urine. (40). 
ENaC channels share common features with ASIC; the degenerin and the amiloride binding sites, 
as well as the selectivity filter. The Deg site has been identified thanks to the mutation of a 
conserved alanine in the pre-M2 region of MEC-4 that led to neuronal cell swelling and 
degeneration in C. Elegans degenerins (5). This mutation leads to the destabilization of the closed 
state that becomes shorter (41). The replacement of the corresponding alanine, serine or glycine 
into ASIC, ENaC, RPK, BLINaC and hINaC by bulkier residues (valine, phenylalanine, 
threonine or lysine) promotes the activation of channel (9,42-45). ENaC and ASIC are inhibited 
by the potassium-sparing diuretic amiloride. The binding site is located in the middle of the TM2. 
ENaC is blocked by nanomolar concentrations, whereas the affinity is 100-fold lower for ASIC. 
Residues involved in the binding have been identified using site-directed mutagenesis; S583, 
G525 and G537 in the rat ENaC (46), G437 in the human ASIC2 (47), and G440 in the human 
ASIC1a (Amiloride dose-response curves Figure 49) (48). Given that these residues are located 
in the conducting pore, more precisely in the middle of the TM2, the amiloride behaves as a plug 
preventing ion permeation (49). This block can be modulated by different factors such as the 
extracellular pH since the amiloride blocks the channel in its positively charged form (50). Thus, 
the more the pH increases the less the amiloride will be protonated. The extracellular Na
+
 
concentration also modifies the block by increasing the association rate constant. This underlines 
a competition between permeating ions and amiloride (51). The amiloride-channel interaction 
depends on the transmembrane voltage too (52). The stretch of residues responsible for the 
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permeability of ENaC/ASIC channels for small cations is called the selectivity filter. This 
preference for small ions shows that the filter constitutes the narrowest part of the pore. It is 
composed of a three amino acid sequence G/SxS, (G587-9 in rat ENaC). Mutation of S589 
allows the passage of larger ions such as K
+
. Bulkier is the mutant residue, the higher will be the 
permeability to large ions. This suggests an enlargement of the permeation pathway and a side 
chain pointing away from the pore (53-56). ENaC subfamily contains the conserved “PY motif” 
(PPPxYxxL) in the C-terminus, which is involved in the regulation of the channel’s cell surface 
expression by the ubiquitin system (ENaC Regulation) (57). 
1.1. ENaC in the lung 
The airway surface liquid (ASL) is composed of the periciliarly layer and the mucus. To 
keep the ASL well-hydrated, the water flow varies according to the osmotic gradients and 
depends on the activity of membrane proteins expressed at the air-liquid interface, which are 
ENaC, the Ca
2+
-activated Cl
-
 channel CaCC and CFTR. Through these proteins, the cells secrete 
Cl
-
 (CFTR, CaCC) and absorb Na
+
 (ENaC) to maintain an appropriate volume. In cystic fibrosis, 
the ASL is dehydrated. That reflects an imbalance between the absorption of and secretion of salt. 
Actually, it is not well known which of the CFTR or the [Cl
-
]i regulates ENaC (Figure 4) (58,59). 
 
Figure 4 Mechanisms of mucus clearance, normal (NL) versus cystic fibrosis (CF) airway surfaces. A, In NL airways, ENaC 
absorbs Na+ and cystic fibrosis transmembrane regulator CFTR secretes Cl- and regulate ENaC. B, In CF, the absence of CFTR 
protein/function leads to unregulated Na+ and water absorption. Bars depict O2 tension in ASL (red and blue for oxygenated and 
hypoxic, respectively). Figure modified from Boucher et al., 2007 (60). 
In the distal lung airway, ENaC is expressed at the air-liquid interface. Loss-of-function 
mutations of ENaC in the salt-losing syndrome named pseudohypoaldosteronism type 1 are often 
associated with neonatal respiratory distress syndrome (see ENaC and pathologies) (61,62). 
Moreover, transgenic mice overexpressing ENaC in the airway epithelia exhibit depleted ASL 
hydration, slowed mucus clearance, mucus adhesion and death prior to weaning, a phenotype 
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similar to cystic fibrosis disease (63). Altogether, these findings suggest a role of ENaC in the 
airways. 
1.2. ENaC in the kidney 
In the kidney, ENaC is expressed in the aldosterone-sensitive distal nephron (ASDN) in 
which it is the rate-limiting step for the Na
+
 uptake allowing the Na
+
 flux out of the primary 
urine. As shown on Figure 5, the Na, K-ATPase, expressed basolaterally, creates the 
electrochemical gradient that is the driving force behind Na
+
 reabsorption through ENaC (64). 
The transepithelial movement of Na
+
 creates osmotic forces that drive the transepithelial 
absorption of water. The K
+
 channel ROMK is responsible of extruding K

 out of the cell. 
 
Figure 5 Transepithelial transport in the principal cells of the cortical collecting duct (CCD). The aldosterone binds to its receptor 
(MR), then the complex translocates into the nucleus where it induces/represses transcription of targeted genes (AIT/ARP). ENaC 
expression, and thus Na+ transport, is increased. 
The mineralocorticoid hormone aldosterone plays a critical role by controlling the Na
+
 
reabsorption and the K
+
 secretion. There are two corticoid receptors (R) in the nephron; the 
glucocorticoid and the mineralocorticoid R (GR and MR). To insure the specificity of 
mineralocorticoids the enzyme 11-hydroxysteroid dehydrogenase type 2 (11-HSD2) converts 
cortisol or corticosterone into an inactive metabolite that prevents the binding of MR by 
glucocorticoids (65,66). The three key players in the fine tuning of Na
+
 reabsorption, that are; 
ENaC, MR and 11-HSD2, are expressed in the ASDN (67). 
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2. ENaC Regulation 
Na
+
 intake varies during the day, thus its reabsorption via ENaC needs constant 
adjustment. Many steps control ENaC expression at the apical membrane of epithelial cells. 
Transcription of ,  and  subunits are under the control of aldosterone. Translation and post-
translational modifications occur through phosphorylation, proteolytic cleavage, ubiquitylation 
and deubiquitylation. This leads to a fast overall turnover of 45 to 60 minutes for each subunit. 
Circadian rhythms also influence the sodium transport independently of blood pressure, body 
water or salt intake (68-70).  
In response to a decrease of the extracellular volume or blood pressure or hyponatremia, an 
increase in plasmatic K
+
 and angiotensin (ANG) II is observed. Both of them induce the 
production of aldosterone and thus an increase in the Na
+
 reabsorption. The renin-angiotensin-
aldosterone cascade (RAAS) is initiated by the angiotensinogen synthesis in the liver. The renin, 
synthetized by granular cells of the juxtaglomerular apparatus in the kidney, then cleaves 
angiotensinogen to ANG I. In a final step, ANG I is cleaved by the angiotensin converting 
enzyme to ANG II. The binding of ANG II on its receptor stimulates the phospholipase C, 
leading to the formation of diacyglycerol and inositol 1,4,5-triphosphate. Subsequent increase in 
[Ca]i depolarizes the plasma membrane of glomerulosa cells and thus induces the production of 
aldosterone (71).  
In vivo, injection of aldosterone in adrenalectomized rats induces an increased ENaC expression 
in the ASDN ( and levels unchanged) and a redistribution of ENaC to the apical membrane 
within two hours (72). These results support previous experiments performed on either NaCl-
restricted or aldosterone-perfused rats. Subsequently, the ENaC cleavage is clearly linked to an 
increase in ENaC-mediated INa+ (73). ENaC current measurements from cortical collecting tubule 
cells of mice expressing -truncated subunit demonstrate that the mineralocorticoid regulation of 
ENaC is still maintained and does not imply the PY motif and hence NEDD4-2 dependent down 
regulation (74). In vitro experiments on ENaC endogenously expressed in a cell line derived from 
Xenopus laevis kidney have highlighted the impact of aldosterone on ENaC. The hormone 
enhances both the transcription and translation of ,  and  subunits by a two- and four-fold 
increase respectively. Consistently, a similar enlargement of the amiloride-sensitive currents is 
observed and unlinked with any change in the Po, the kinetics of single channels or in the rate of 
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degradation of ENaC subunits (75). In vivo and in vitro studies diverge; the former shows an 
overexpression of ENaC only, whereas the latter demonstrates a transcriptional increase of ,  
and ENaC together. 
In the distal nephron, the binding of the antidiuretic hormone arginine vasopressin to its 
basolateral V2-receptor increases the expression of type 2 aquaporins at the apical membrane. 
This leads to an enhancement of water reabsorption. The PKA/cAMP signaling pathway is 
stimulated, inducing the activation of Na
+
 transport via ENaC, and Na, K-ATPase. cAMP 
increases the quantity of ENaC and the Na, K-ATPase at the cell membrane, while PKA activates 
the serum-glucocorticoid kinase (Sgk1), an inhibitor of the ubiquitine-ligase NEDD4-2 (76,77). 
Focusing now on the translational and post-translational modifications, proteolytic 
cleavage and ubiquitylation are known to regulate the Na
+
 transport via ENaC. To date, it has 
been demonstrated that the proteolysis of ENaC is associated with a channel activity increase 
(78-82). Serine proteases (SP) can be classified according to sequence and structure similarities. 
ENaC-activating SPs belong to two subfamilies. The first subfamily contains proteases with His-
Asp-Ser (HDS) as catalytic residues and a primary specificity for Ala, Glu, Phe, Gly, Lys, Gln, 
Arg, Trp and Tyr. A representative member is trypsin. The second subfamily has a catalytic 
domain made of DHS and is specific for Phe, Trp and Tyr residues. TMPRSS (CAP2), elastase, 
prostasine (CAP1) or matriptase, and Furin-like protein convertases are known to activate ENaC 
by four- to seven-fold depending on experimental conditions through an increase in Po and 
without any change in the number (N) of cell surface expressed channels (81). ENaC co-
expression is required for the cleavage and thus the full activation of the channel. Indeed, 
subunits expressed alone in CHO or MDCK epithelial are not cleaved (83). Western blot analysis 
demonstrated that  and  subunits are cleaved, whereas  is not. The absence of  cleavage is 
due to a lack of cleavage site (Figure 6). 
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Figure 6 Linear models of the ENaC subunits. The finger domain contains the cleavage sites by furin for α subunit and by furin, 
prostasin (CAP1), CAP2, elastase, and plasmin for the γ subunit. This alignment also shows that the β subunit lacks the consensus 
motifs for protease recognition but has supplementary sites for glycosylation, as well as an additional Cys pair. Figure from 
Kleyman et al., 2009 (84). 
To exert their function, SPs have to be activated. This activation is tightly controlled, and occurs 
through transcriptional/translational regulation, protease activation and degradation (85), or via 
protease inhibitors (SPIs), such as the protease nexin-1 (86). 
ENaC arbors a motif for degradation called the “PY motif”. It has been shown that the PY motifs 
of  and  subunits are involved and lead to a reduction of ENaC density at the apical cell 
membrane via ubiquitylation (87,88). The ubiquitin (ub) is a polypeptide made of 76 amino 
acids. Through an isopeptide bond, ub is conjugated to the lysine ( amino group). Three kinds of 
proteins are involved in the ubiquitylation cascade: The ub-activating enzyme (E1), the ub-
conjugating enzyme (E2), and the ub-protein ligase (E3). This process is reversible thanks to the 
deubiquitylating enzymes DUBs. It has been described that the E3 Nedd4.2 specifically binds to 
the PY domains of  and  ENaC, thus leading to the ubiquitylation and finally to the endocytosis 
of ENaC (89). Several years later, the DUB USP-45 was shown to be upregulated by aldosterone, 
thus increasing the ENaC content at the apical membrane (90). 
Ions are also involved in the regulation of ENaC. The Na
+
 is a modulator of channel 
activity by two distinct phenomena. The increase intracellular Na
+
 content slowly inhibits ENaC 
currents with a time constant of 10 to 20 min (91); the so-called “feedback inhibition”. The rapid 
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increase of external Na
+
 concentration (0 to 100 mM) induces the fast relaxation of the large INa 
peak to a lower steady-state value (92-94). This mechanism is the “self-inhibition” and, unlike 
the “feedback inhibition”, has a rapid time constant of ~3 seconds and is temperature-dependent 
(95). Self-inhibition is also observed upon fast amiloride removal. 
3. ENaC and pathologies 
ENaC mutations have been found in patients suffering of salt-dependent symptoms, such 
as impaired blood pressure, excessive salt-loss, or pulmonary emphysema. Single point mutations 
are helpful in the understanding of protein function. Mutagenesis studies in vitro have brought 
important progresses in the understanding of protein structure-function relationship. 
Several evidence support the fact that the precise salt handling by the kidneys is very important 
for blood pressure (96). Genetically, animal models, as well as mutations in 18 human genes have 
been associated either with a salt loss (hypotensive) phenotype or a salt retaining (hypertensive) 
phenotype. The major key players that determine blood pressure are Na
+
 and K
+
 transporters in 
the kidney; NKCC2, NCC, ENaC and ROMK. Actually, they are the targets of the clinically 
useful diuretics (67). To date, the hypertension (HT) is the most common disease with over 1 
billion affected individuals worldwide. It is also a risk factor in cardiovascular diseases including 
stroke, myocardial infarction, and heart and kidney failure. It has been shown that ENaC gain of 
function mutations lead to HT, as well as mutations in components of the ENaC regulating 
pathways, for example in the MR or the 11-HSD2 (67). Besides human genetics, experiments 
using rodents have also demonstrated the link between HT and the kidney. For example, a report 
has shown that transplantation of a HT kidney into a normotensive animal leads to HT, indicating 
that something in the kidney is responsible for the high blood pressure (97). Moreover, in the 
early 60’s, the introduction of the diuretic thiazide, a blocker of NCC, has been the first effective 
treatment of HT and is still used (98). 
Furthermore, several transgenic mouse models have been developed to study the roles of 
ENaC in vivo. The phenotypes of these mice demonstrate the importance of each , , or  
subunit for survival and regulation of Na
+
 transport (99). Indeed, the three models of ENaC 
subunit-deficient mice die within two days after birth; ENaC-/- of pulmonary edema (100), 
whereas  and    ENaC-/- of hyperkalemia (101,102).  
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The phenotype of  and ENaC-/- mice is similar to that of humans suffering of 
pseudohypoaldosteronism type 1 (PHA1). This is a monogenic disorder of mineralocorticoid 
resistance characterized, in the first week of life, by severe dehydration, urine salt-wasting, 
hyperkalemia, high aldosterone levels, and failure to thrive (103). An autosomal recessive form 
(AR-PHA1) is caused by loss-of-function mutations in ENaC usually with severe and persisting 
multiorgan symptoms (104), whereas the autosomal dominant form of PHA1 (AD-PHA1) is due 
to mutations in the mineralocorticoid receptor causing milder and transient symptoms restricted 
to the kidney (105). 
Another disease is linked to ENaC mutations, but rather than reducing the Na
+
 
reabsorption, it increases it. This is the Liddle’s syndrome, an autosomal dominant form of salt-
sensitive hypertension with early onset of elevated blood pressure during adolescence. This 
hypertension is associated with hypokalemia, metabolic alkalosis, low plasma aldosterone and 
suppressed plasma renin activity (106). Mutations in the PY motif of  and  subunits have been 
shown to prevent the interaction of NEDD4-2, the subsequent ubiquitylation and endocytosis of 
the channels. Consequently, instead of being decreased, the Na
+
 absorption is maintained 
(57,107). 
4. Pharmacology 
Amiloride, as well as another inhibitor named triamterene, are used as diuretics to treat 
arterial hypertension, whereas benzamil is reserved for laboratory purposes.  
 
Figure 7 Inhibitors of ENaC. From left to right: the amiloride, the triamterene and the benzamil. 
The amiloride has been discovered in the 1960s as a potassium-sparing diuretic able to inhibit the 
transepithelial Na
+
 absorption through the frog skin and the toad blatter (108-111). The cloning of 
ENaC then allowed the target of this compound to be discovered, as well as residues implicated 
in the block (for details, ENaC physiology). 
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Actually, it would be interesting to focus on the ENaC-dependent pulmonary edema. 
Indeed, some PHA1 patients display an excess of airway liquid (112,113). The role of ENaC in 
the transition from liquid-filled to air-filled lung has been supported by ENaC-deficient mice 
(100,114). To get round of this ENaC loss-of function, one possibility is to target the deg site 
which mutation led to an increase open probability or to develop SP-like molecule that would 
increase the activity of the channel. An activator of ENaC has been identified. This molecule 
increases the open probability via an interaction with the ECL of subunit and can reverse the 
loss-of-function phenotype observed in a PHA1 case (G37S) (115). Thus, the activation of 
ENaC function in PHA1 patients could correct dehydration and salt-wasting, or promote lung 
function in neonatal respiratory distress syndrome and pulmonary edema by increasing both the 
Na
+
 and lung fluid ENaC-dependent reabsorption (116). 
ASIC 
As opposed to the epithelial sodium transport mediated by ENaC, the existence of acid-
sensing ion channel was unknown until the cloning of the ASIC genes. Based on its sequence 
homology with DEG and ENaC, ASIC2 (previously known as MDEG for mammalian DEG or 
BNC1 for Brain Na
+
 channel) has been the first ASIC identified from the human brain. It has 
been initially called Brain Na
+
 channel, and then ASIC after the finding that acidification 
activates it (117,118). Furthermore, ASIC1, ASIC3 (formerly DRASIC), and finally ASIC4 
(initially SPASIC for spinal cord) have been cloned (119-121). Finally, the screening of a human 
genomic library with BLINaC as probe leads to the identification of the human intestine Na
+
 
channel hINaC, initially called ASIC5 (43). Actually, both hINaC and BLINaC have been 
classified in another subgroup within the ENaC/Deg family; the BASIC, for bile-acid sensitive 
channels. Regarding the sequence homology, BASIC are closer to ASIC than ENaC. Whereas 
they are not sensitive to protons, the bile is able to activate them in Xenopus laevis oocytes (122). 
Later, new members of ASIC subfamily have been identified from the lamprey, the shark, the 
toadfish and the chicken. It appears that the ASIC from lamprey and shark were insensitive to 
protons implying that different agonists activate ASIC1 in lower vertebrates (123). In mammals, 
seven proteins have been identified; ASIC1a, ASIC1b, ASIC2a, ASIC2b, ASIC3, ASIC4 and 
ASIC5, with 1b and 2b the splicing variants of ASIC1a and 2a. 
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The size of ASIC proteins ranges from 512 to 563 aa. Between human ASIC channels, the 
sequence homology varies, the average being 43 %, as depicted on the Table 1 below. The 
highest homology is found between ASIC1, ASIC2 and ASIC3, whereas ASIC4 and ASIC5 are a 
little bit less conserved; this might explain their insensitivity to protons differentiating them from 
the formers. 
 
Table 1 Amino acids sequence identity matrix of ASIC channels obtained from basic local alignment of amino acid sequences 
using Clustal Omega (http://www.ebi.ac.uk/Tools/msa/clustalo/). 
The left part of the Figure 8 shows typical traces for ASIC channels; a transient peak 
current is induced by a switch from pH 7.4 to pH 6.0, and the channel directly desensitizes. The 
shape of the peak (the time necessary to go from one state to another or the kinetics of activation 
and inactivation) can vary. Different time constants characterize the kinetics;  is the time 
required for the channel to open and D the time necessary for desensitization. Another parameter 
is rec which is the time required between two pH drops to recover the same current amplitude. 
The activity of ASIC channels can be described as being the transition between three states; (1) 
the closed (resting) state at alkaline physiological pH (about 7.4), (2) the transient and open 
conducting state after a fast extracellular pH drop, and (3) the inactivated/desensitized state 
following an extent acidification of the milieu (Figure 8).  
 
Figure 8 Left, scheme of typical ASIC recordings; at pH 7.4 the channel is close, then it opens transiently thanks to a drop of the 
pH (6.0), and desensitized rapidly.  represents the time required for activation (blue), D the time necessary for the channel to 
desensitize (green) and rec the time required between two pH drops to recover the same current amplitude (red). Right, The three 
states of ASIC: closed, open and desensitized. The transition between each state is pH dependent. The pH50 determines the pH 
dependency of the activation whereas the pHin50 the pH dependency of the inactivation (transition from closed to desensitized). 
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The pH dependences of activation and inactivation also varies between ASIC channels. 
The pH0.5 of activation is the pH that induces half of the maximum current (Imax). ASIC1a opens 
upon a fast extracellular pH decrease from pH 7.4 to below 6.9. The current increases until pH 
6.0 and then saturates. The dose-response curve is defined by the Hill equation. The pH 
dependency of half maximal inactivation is described by the pHin0.5, being the pH where one half 
of the channels are closed (and still able to open) and the others are inactivated/desensitized. It is 
obtained by switching from variable conditioning pH solutions slightly acidic to pH 4.0. The Hill 
coefficient (nH) represents the cooperativity of the ligand binding to its receptor. 
ASIC subunits can assemble to form homo- or heteromultimeric channels (124). The 
biophysical properties of ASIC homomers are in the Table 2. ASIC are permeable to monovalent 
ions with a PNa+/PK+ ratio smaller than the Na
+
 permeability of ENaC channels (125). 
Permeabilities and conductances of ASIC channels are summarized in the Table 2. Its 
permeability, even low, for Ca
2+
 and H
+
 distinguishes ASIC1a from the other ASIC. 
Physiologically, this entry of Ca
2+
 being small it should not increase a lot the intracellular Ca
2+
 
concentration. However, it could induce the calcium release of intracellular Ca
2+
 stores (126). 
The PH+ might acidify locally the intracellular milieu and regulate some channels (118,126). 
Structurally, the selectivity filter (GAS motif 444-446 in human ASIC1a) is responsible for this 
ionic specificity (see introduction for details). Strikingly, despite the total conservation of this aa 
stretch, permeability characteristics can change between ASIC channels. This feature is linked to 
the N-terminal part of ASIC. Indeed, mutagenesis studies have shown that residues A22, I33 and 
F34 of ASIC1a (127); I19, F20 and T25 of ASIC2 (128); and T26 of ASIC3 (128), are important 
for selectivity. 
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 ASIC1a ASIC1b ASIC2a ASIC3 
Selectivity 
PNa/PK 5.5-13 
PNa/PK 14 
PNa/PK 10 
PNa/PK 
Ipeak >= 10 
Isustained 1.62 
PNa/PCa 5.5-18.5 
PNa/PH <0.3-0.8 
PNa>>PCa PNa/PCa >100 
 
Conductance (gNa) 14.3 pS ND 10.4-13.4 pS 12.6-15 pS 
  5.8-13.7 9.9 ND <5 
D (s) 0.64 ± 0.09 0.89 ± 0.11 1.4 ± 0.2 0.29 ± 0.02 
rec (s) 5.3-13 4.4-7-7 0.6 0.4-0.6 
pH0.5 5.8-6.8 6.1-6.2 4.5-4.9 
Ipeak 6.4-6.6 
Isustained 3.5 
pH0.5in 7.2-7.4 7.0 6.0 7-7.1 
nH 0.75-4.5 4.8 2.2 1.6 
Table 2 Biophysical properties of ASIC channels. The selectivity of ASIC subtypes is indicated by the ratios of PNa over PK, PCa 
or PH. Conductance of ASIC channels are represented in pS. This table also contains representative range of time constant of 
activation (, inactivation (D) and recovery (rec), and pH50, pHin50 and nH values. ND=not determined (129) (130) (131) (118) 
(132) (133) (126) (134) (135) (124,136-139) (140). 
1. ASIC physiology 
In the central nervous system, ASIC1a and 2a are widely expressed in brain areas such as 
the hippocampus, cingulate cortex, striatum, amygdala, cerebellar cortex and olfactory bulb. 
ASIC2a is found predominantly in dendrites, dendritic spines and synaptosomes (141,142). The 
synaptic vesicles being acidic, the release of neurotransmitters into the synaptic cleft goes along 
with an acidification that could potentially activate acid-sensing ion channels expressed in the 
postsynaptic buttons (143,144). 
Studies on ASIC1a
-
/
-
 mice have demonstrated that ASIC1a was required for long-term 
potentiation and acid-induced inward currents, associated with learning and memory related 
phenotypes or with pain transmission and processing phenotypes. Both of these features were 
decreased in the ASIC1a knockout model, as well as the acid-evoked Ca
2+
 entry at dendritic 
spines and the dendritic spines number in hippocampal slices (145,146). However, another recent 
report suggests that ASIC1a was not necessary for normal long term potentiation and spatial 
memory (147). ASIC1a
-
/
-
 mice also present a fear conditioning deficit as supported by a slower 
freezing response to fear conditioning stimuli (142). 
The reduction of blood flow that accompanies ischemia provokes hypoxia. This deprivation of 
oxygen increases anaerobic metabolism leading to the accumulation of lactic acid. Both the ATP 
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hydrolysis and the increase amount of lactate induce a strong pH decrease to 6.0 (148-150). It is 
known that the tissue acidosis resulting from ischemic stroke induces neuronal injury in the brain. 
The precise mechanism is unclear, but several possibilities exist; the Ca
2+
 toxicity being essential 
for ischemic neuronal injury, an overload induced by GluR was an explanation (151,152). 
However, GluR antagonists having failed to protect the brain, this hypothesis has been ruled out 
(153). The second theory is based on the H
+
-induced Ca
2+
 release induced by ASIC1a. This 
increase of intracellular Ca
2+
 would also provoke neuronal injury (152,154,155). The 
pharmacological block of ASIC1a with psalmotoxin, as well as the ASIC1
-
/
-
 mouse model, 
supports the fact that ASIC1a is a neuroprotective therapeutic target for brain ischemia 
(126,152,156). 
A decrease in the pH also occurs during seizure, intensive neuronal excitation and at the end of 
an epileptic activity (157-159). Thus, the role of ASIC1a has been investigated during these 
events. It results that knockout mouse model have a more pronounced seizure, whereas the 
ASIC1a overexpression decreases it. Moreover, the activation of ASIC1a in inhibitory 
interneurons eases the epileptic activity (160). In these situations, ASIC1a agonists would be 
used to improve seizure. 
The ASIC1a contribution to axonal degeneration in multiple sclerosis is also known. In this 
autoimmune inflammatory disease lesions are accompanied by tissue acidosis. Again, the 
increase Ca
2+
 is the responsible and leads to axonal degeneration. The use of the non-specific 
blocker amiloride gave promising neuroprotective results (161). 
At sensory neuron terminals, H
+
 and other chemicals are thought to activate ASIC 
channels. Two studies on ASIC2
-
/
-
 mouse model support the role of ASIC2 in mechanosensation. 
Firstly, the expression of ASIC2 has been shown adjacently to the hair follicule. While the hair 
movements excite mechanoreceptors in rodent skin, they tested the response of ASIC2
-
/
-
 mice to 
mechanical touch stimuli. They observed a decrease in their sensitivity suggesting a role in 
mechanosensation (162). Another study has figured out that ASIC2 was an important determinant 
of the arterial baroreceptor reflex. Usually, baroreceptor reflex causes a decrease in heart rate 
when there is an increase in blood pressure, and vice versa. Lu et al. first localized ASIC2 in 
aortic baroreceptor neurons in the nodose ganglia, and then demonstrated that ASIC2
-
/
-
 mice 
suffered of hypertension and an impaired baroreceptor reflex (163).  
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Studies on ASIC3 have shown its expression in sensory neurons, in particular in nerve endings 
where mechanical stimuli are converted into electrical signals (121,164). Moreover, ASIC3 is co-
expressed with the calcitonin gene related peptide, an important vasodilator peptide involved in 
pressure-induced vasodilatation (PIV). Thus, Fromy et al. decided to investigate the role of 
ASIC3 in PIV. Using ASIC3
-
/
-
 mouse model and pharmacological block of ASIC3 (APETx2, see 
ASIC pharmacology) they have demonstrated that the deletion of ASIC3 leads to an absence of 
PIV directly linked to a failure of pressure detection. Then, they have carried on experiments with 
stronger and longer pressure. This led to ischemia associated with H
+
 and lactate production that 
can activate ASIC3 and is necessary for reactive hyperemia after compression. They concluded 
that ASIC3 was benefic for the microcirculation and protects against pressure ulcers (165). Taken 
together, these results demonstrate a role of ASIC2 and 3 in mechanosensation. However, unlike 
pH, mechanical stimulation has not been shown to directly gate ASIC, as it does for 
mechanosensitive channels (166), thus there are still debates on the role of ASIC in 
mechanosensation. 
During inflammation, ischemic stroke, infections and cancer, there is a tissue acidosis. In such 
conditions, pH levels can drop near 6 or even lower (167,168). When a tissue is injured, it 
releases mediators of inflammation; substance P, bradykinin, histamin, serotonin, glutamate, 
ATP, interleukin-1, nerve growth factor and H
+
 (169). 
To assess the roles of ASIC in pain, several pharmacological studies have been 
performed. Use of peripheral injections of APETx2 revealed the involvement of ASIC3 in the 
maintenance of primary hyperalgesia (170). Moreover, the role of ASIC1b-containing channels 
has been demonstrated by injection of mambalgins, which induces analgesic effects on acute heat 
pain and inflammatory heat hyperalgesia (171). Recently, Bohlen et al. highlighted the 
involvement of ASIC1 in pain using MiTx injection (172). Moreover, PcTx1 injections 
(intrathecal and intracerebro-ventricular) have demonstrated the role of ASIC1a in the pain 
pathway. Indeed, PcTx1 led to a potent analgesic effect in several models of acute and chronic 
pain (173,174). Knockout mice models additionally delivered new insights into the role of 
ASIC1a in brain function. Formerly, those animals presented an impaired hippocampal long-term 
potentiation and defects in spatial learning and memory (145). Actually, however, those data are 
no longer supported (147) except for the role of ASIC1a in hippocampus through the detection of 
ASIC1a and 2a hippocampal neurons and postsynaptic membranes of the dendritic tree and 
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spines (145,146,175-178). Finally, the use of ASIC1a blockers has also demonstrated the 
implication of ASIC1a in Huntington’s and Parkinson’s diseases (179,180). 
Taken together, these studies show the importance of developing highly specific and 
potent blockers against ASIC1a. Several modulators of ASIC are known and would be described 
in the next chapter. 
2. ASIC pharmacology 
Several endogenous factors are known to modulate ASIC channels. In the class of 
neuropeptides, dynorphins, opioid peptides involved in analgesia, have been shown to limit the 
steady-state desensitization of ASIC1a (133). Normally, steady-state desensitization occurs when 
incremental pH reductions are applied, the channel then desensitizes and activation is prevented 
(181). In a dose-dependent manner, dynorphin A and big dynorphin (EC50 of 32.8±11.5 M and 
26.4±14.8 nM, respectively) inhibit the ASIC1a steady-state desensitization. Indeed, without 
dynorphin, a conditioning pH7.0-solution leads to the desensitization of the channel, which is 
represented by the absence of a pH5.0-induced current. This process is prevented by dynorphins 
[140]. The steady-state desensitization of ASIC2-containing heteromeric channels is influenced 
by big dynorphin in a similar manner. Indeed, conditioning pH of 7.1 and 6.8, usually prevent the 
opening of ASIC1a/2b and 1a/2a at pH 4.5. However, this is disrupted in presence of big 
dynorphin with EC50 of 3.5±1.6 nM and 256.5±76.2 nM, respectively (182). Such slight pH 
decrease occurs during pathophysiological conditions within the acidosis extends over several 
minutes, i.e. ischemia. Dynorphin level being increased under pathological conditions (183), it is 
possible that it enhances neuronal damage following ischemia by preventing the steady-state 
desensitization of ASIC channels. 
FMRFamide is a peptide found in invertebrate nervous system and is able to gate FaNaC 
channels at mM concentrations (3). This tetrapeptide also acts on ASIC channels by potentiating 
H
+
-evoked currents and altering inactivation, thus leading to a sustained current in most cases. 
However, the FMRFamide has not been isolated from mammals. Endogenous mammalian 
RFamide peptides, such as the neuropeptide FF “NPFF”, exist and modulate ASIC but are not as 
potent. Indeed, whereas 50 M FMRFamide induces a sustained current in ASIC1a, 50 M 
NPFF only slightly delays its inactivation (129). Regarding ASIC3, both neuropeptide create a 
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sustained current and postpone the inactivation. However, the kinetics of the peak current are 
different with a D shortened in presence of NPFF and extended with FMRFamide (129,184). 
Belonging to the polyamines, the arginine metabolite agmatine, as well as its analog arcaine, has 
been demonstrated to activate ASIC3 and ASIC3/1b channel, via an extracellular non-proton 
ligand-sensing domain (185). In addition, spermine (0.25 mM) has been shown to induce a two-
fold increase ASIC1a and ASIC1b mediated currents through a 0.2 pH units shift of their steady-
state inactivation curves towards more acidic values (186). Furthermore, various cations can 
inhibit ASIC channels, among them, the Cd
2+
. A 1 mM of Cd
2+
 decreases roughly half of the 
current or rASIC2a and rASIC3, but has no effect on rASIC1a activity (187). The hASIC1a is 
inhibited by Cd
2+
 with an IC50 of 0.37±0.01 mM (127). Another divalent, the Ca
2+
, is known to 
modify the affinity for H
+
; a high Ca
2+
 concentration is reducing the affinity and vice versa (181). 
Extracellular Ca
2+
 has a dual action on ASIC1a; Currents are very small in presence of low 
[Ca
2+
]o, then they increase with augmented [Ca
2+
]o, and finally are reduced with higher [Ca
2+
]o. 
Moreover, depletion of Ca
2+
 leads to an absence of ASIC1a current. Concerning ASIC2a, we 
observe an opposite relation; the currents being decreased with increasing [Ca
2+
]o (138). A study 
on ASIC3 argues that H
+
 and Ca
2+
 compete at a binding site with H
+
 catalyzing the release of 
Ca
2+
 from that site (188). However, disruption of two Ca
2+
 (and H
+
) binding sites on ASIC1a by 
mutation of the negatively charged aa Glu425 and Asp432 relieves the Ca
2+
 block, without 
constitutively opening the channel suggesting the existence of another Ca
2+
/H
+
 binding site (189). 
Inflammatory mediators also modulate the activity of ASIC. The arachidonic acid (ASIC1a and 
ASIC3), the lactate (ASIC1a and ASIC3), the nitric oxide (ASIC1-3), the ATP (ASIC3) or the 
serotonin (ASIC3), are able to increase pH-induced currents (150,190-193). As for synthetic 
molecules, the inhibitory activity of Nonsteroid Anti-Inflammatory Drugs (NSAID), such as 
ibuprofen, aspirin or salicylic acid, influences ASIC. Indeed, the application of NSAID prevents 
the increase mRNA content of ASIC-expressed sensory neurons. Moreover, they directly inhibit 
ASIC currents (194). The diuretic amiloride and its derivatives are also known to reduce the 
currents in ASIC subtypes, whereas ASIC1a is inhibited with an IC50 of 14.6 M, ASIC2a is 
almost insensitive (IC50 72.5 M), ASIC1a/2a represents an intermediate with 36.2 M reducing 
half of the maximal current (138). On ASIC3, the sustained current is unaffected whereas the 
peak current is inhibited with an IC50 of 36.9 M (195). The blocker behaves as a plug binding 
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the middle of the TM2. Residues involved in the block are the G440 in the human ASIC1a 
(Appendix 5, Figure 49 and (48)) and the G437 in the human ASIC2 (47).  
The first ASIC blocker being more potent and specific than amiloride is the compound A-
317567. ASIC currents are inhibited with IC50 of 2.0, 29.1 and 9.5 M in ASIC1- ASIC2- and 
ASIC3-like neurons from adult rat DRG (196). The synthetic compound 2-guanidine-4-
methylquinazoline (GMQ) shifts pH activation of ASIC3 towards alkaline values. This leads to 
the opening of the channel independently of H
+
 at pH 7.4 (197). Diverse effects were observed 
for ASIC1a and 1b with an opposite shift of the pH activation curves towards more acidic pH 
(48). In both cases, however, the steady state inactivation is shifted towards acidic values, 
meaning that the channel inactivation becomes less favorable in term of energy and that the 
recovery is easier. Nafamostat mesilate (NM) has also been tested on ASIC channels thanks to its 
side effect (inhibition of ENaC) in the treatment of pancreatitis (198). For ASIC1a and 3, this 
amidine-guanidine compound seems more potent than amiloride, whereas for ASIC2a it appears 
to be less potent; IC50 are 13.5, 70.6 and 2.5 M for ASIC1a, ASIC2a and ASIC3 (195). 
There are presently no pharmacological blockers for ASIC channels displaying high 
potency, but natural molecules extracted from venoms specifically modulate ASIC channels. The 
peptide Psalmotoxin 1 (PcTx1) in the venom of tarantula (Psalmopoeus cambridgei) selectively 
inhibits the human ASIC1a channels with an IC50 of 13 nM, whereas a higher concentration 
potentiates it (EC50 60 nM) (199,200). Human ASIC1b and chicken ASIC1 currents are enhanced 
by the toxin (EC50 of 100 and 189 nM, respectively) (201,202).  This toxin acts by a binding to 
the extracellular loop at the Cysteine-Rich Domains I/II (201,203). This inhibition is Ca
2+
-
dependent, meaning that an increase of Ca
2+
 leads to a decrease of the PcTX1 inhibition (186). 
Three other toxins extracted from black mamba venom, mambalgins (1 to 3), inhibit currents 
mediated by hASIC1a (IC50 127 nM), rASIC1a (IC50 11-55 nM) and rASIC1b homomers (IC50 
44-192 nM), hASIC1a/2a (IC50 220 nM), rASIC1a/2a (IC50 25-252 nM), rASIC1a/2b (IC50 61 
nM) and rASIC1a/1b (IC50 72 nM) heteromers (171). Mambalgins inhibit all the ASIC-channels 
combinations in the CNS, compared to PcTx1 that inhibits 30 % of these currents. Moreover, 
they inhibit 60 % of ASIC currents in sensory neurons, while PcTx1 about 40 % (171). Only 
ASIC3 and ASIC3-containing channels are not targeted by mambalgins. However, the peptide 
APETx2, isolated from sea anemone Anthopleura elegantissima, inhibits them (IC50 37-63 nM 
for ASIC3, and 2 M, 900 nM and 117 nM for ASIC1a/3, 1b/3 and 2b/3, respectively) (204-206). 
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Studies have also shown the inhibitory activity of APETx2 on Nav1.2, and Nav1.8 channels (IC50 
114 nM and 55 nM to 19 M), and to Nav1.6 (1 M, 17 % inhibition) (207,208). Extracted from 
the venom of Texas coral snake Micrurus tenertener, MitTx is a heteromeric complex 
functioning as a potent, persistent and selective agonist of ASIC, in particular rat ASIC1a and 
ASIC1b (EC50 9 and 23 nM, respectively) channels, and more slightly on rat ASIC3 (EC50 of 830 
nM). Moreover, MitTx does not activate ASIC2a, but strongly potentiates the currents, in vitro, 
by shifting the activation curve towards less acidic pH (172). 
These toxins are a precious tool in the investigations of physiological and pathophysiological 
ASIC roles in vivo especially in pain. Indeed, CNS injections (intrathecal and 
intracerebroventricular) of both PcTx1 and mambalgins in mice induce an analgesic effect in 
acute and inflammatory pain. Furthermore, PcTx1 effects are sensitive to naloxone, whereas 
mambalgins are not. This suggests that ASIC are involved in two different pathways linked to 
pain transmission and/or modulation (171,173,209). Peripheral injections of APETx2, MitTx and 
mambalgins also highlight the role of ASIC in pain and sensory perception. It has been shown 
that the application of APETx2 reduces the mechanical hypersensitivity in a mouse model of 
joint inflammation, as well as in a rat model of cutaneous inflammatory pain (210,211). Then, 
continuous intra-articular APETx2 injection has demonstrated a reduction in pain-related 
behavior and secondary mechanical hyperalgesia in a rat model of ostheoarthritis (212). 
Subcutaneous injections of mambalgins in the mice hindpaw also provide pain relief, as 
demonstrated by the resulting analgesic effect on acute heat pain and inflammatory heat 
hyperalgesia (171). Moreover, peripheral injection of MitTx elicits pain behavior through ASIC1. 
Indeed, ASIC1
-
/
-
 mice spent less time to lick compared to the wt after toxin administration (172).  
Beside their roles in pain, neuroprotective effects of PcTx1 have been shown in various studies, 
to mention but a few; in ischemia, using mouse cultured hippocampal neurons deprivated in 
oxygen and glucose, as well as in extracellular acidosis, using spinal motoneurones (154,213). 
Furthermore, central injection of PcTx1 (or venom) demonstrates a reduction of fear, as well as 
antidepressant and anxiolytic-like effects. Both fear and depression have been linked to ASIC1a 
channels (in ASIC1a
-
/
-
 animal studies), thus their inhibitions are directly responsible of the 
improvement (142,145,214,215).  Anxiolytic-like effects have also been observed after PcTx1 
venom injection, however the mechanism is still unknown (216). 
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3. Structure and function relationship 
ENaC 
The membrane topology of ENaC has been determined by investigating the glycosylation 
of putative glycosylation sites on ENaC. Site-directed mutagenesis has shown that the putative 
residues at both N- and C-termini were not glycosylated. This supports the fact that both N- and 
C-termini are located intracellularly, whereas the large domain between the termini is 
extracellular. Moreover, the use of the truncated ENaC fused with the Na+-K+-ATPase -
subunit (known to be glycosylated) has demonstrated that both transmembrane domains were 
signals for start- and stop-transfer, respectively (217,218). 
Regarding the ENaC stoichiometry, Snyder and colleagues have assessed it taking the 
advantage of ,  and  subunits containing mutations that alter channel inhibition by 
methanethiosulfonate reagents. The use of different ratios of wt versus G536C (*) mutant 
which are, respectively, insensitive and sensitive to MTSET, has permitted to conclude that there 
should be three  subunits. As a second independent test, the MTSEA has been used. MTSEA 
inhibited ENaC, and the mutation of the deg site into cysteine disrupted the inhibitory effect 
(S549C, S520C and S529C). The comparison of channel properties of wt and ratios of single 
mutant, allows concluding, as for the experiments with MTSET that ENaC is made of three  
subunits, as well as three  and three , leading to a nine-subunits stoichiometry. To further 
investigate this arrangement, a sucrose gradient analysis has been used. It confirmed their 
previous results (219). The sucrose gradient sediment technique has also been chosen by Cheng 
and Dijkink, as well as Coscoy to assess ENaC and FaNaC stoichiometries. The former study 
confirmed the nine-subunits oligomerization of Snyder et al., whereas the latter report did not. 
Indeed, the report of Dijkink and colleagues has demonstrated the tetrameric arrangement of 
ENaC (220). Similarly, the study of Coscoy and collaborators has concluded that FaNaC 
molecular weight corresponds to a tetramer and confirmed it with SDS-PAGE analyzing of 
crosslinked channels. For that purpose, the bifunctional crosslinkers NHS-ASA (5.7 Å) and 
SADP (13.9 Å) harboring a photo- and a primary amino-reactive group, or the DSS (11.4 Å) 
interacting with two amine groups have been used (221). A study taking advantage of a 
quantitative analysis of cell surface expressed ENaC has investigated the channel 
oligomerization. The authors have worked with Flag-tagged subunits (F) recognized by an 
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iodinated monoclonal antibody. The binding signal has then been correlated with the measured 
amiloride-sensitive current. The comparison of each tagged subunit co-expressed with increasing 
concentrations of the untagged subunits (F, F, F) led to the observation that the relative 
abundance of ENaC subunits followed the order  >  > suggesting that the channel is made of 
more than three subunits,  being the most abundant. Moreover, looking at concatemers of 
mutants altering the sensitivity to Zn
2+ 
(S583C) or amiloride (S583C, G525C and G537C) 
supported a tetramer with an  organization (222). Another report on the same ENaC mutants 
has assessed the composition of the channel by testing its sensitivity to either MTSEA or 
amiloride. Kosari et al. have concluded that ENaC was made of four subunits, consistent with the 
results of Firsov et al. (223). Another study has investigated the composition of ENaC channel 
with the freeze-fracture electron microscopy. This technique examines cross-sectional area of 
ENaC in the plasma membrane and permits to estimate the number of transmembrane -helices. 
This has suggested the presence of an integral membrane protein complex made of eight or nine 
subunits (224). Given that the stoichiometry remained uncertain with electrophysiology and 
biochemical experiments, Staruschenko and colleagues have taken the advantage of an 
independent biophysical approach; the fluorescence resonance energy transfer FRET. This 
mechanism describes the energy transfer between two chromophores. A donor initially in its 
electronic excited state (cyan fluorescent protein CFP), may transfer energy to an acceptor (YFP), 
if they are close enough (50 % efficiency with a distance of 35 Å (225)). In three independent 
experiments (eCFP_eYFP- or (eCFP_eYFP_ or (eCFP_eYFP_ have been 
expressed. These experiments supported that ENaC was a nonamer made of (226). 
Anantharam and Palmer have looked at individual mutations lining the pore and altering the 
single-channel conductance of ENaC. Wt subunits have been co-expressed with equimolar 
amount of either a S589D (or S592T), G529A, or G534E mutant and the channels 
conductance has been measured. S592D channels (0.5:0.5;1;1) presented an additional 
intermediate conductance different from the small wt and the large mutant conductances (4.2±0.2 
and 7.2±0.2, respectively). This suggested that a channel made of S592D exist. Neither 
G529A, nor G534E displayed this supplementary conductance. Thus, this report 
arrived to the conclusion that ENaC is made of (227). Later, two studies have investigated 
again the structure of ENaC. As Cl
-
 ions of unknown function are present on the ASIC crystal 
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structure (coordination via Arg310, Glu314 and Lys212 (228)), Collier et al. have decided to 
work on the equivalent Cl
-
 binding sites on ENaC. Based on their sequence, homologous residues 
have been identified; Met321, Asn288 and Met299. Whereas  and  mutants decreased the 
inhibitory effect of Cl
-
,  did not lead to any significant difference compared to the wt. Cl- being 
coordinated by more than one residue, the pairing of palm and thumb domains according to either 
an  or an  orientation has been examined.Asn288 paired with His418 on a  model, 
whereas it paired with His396 on . Given that only Asn288-His418 had an effect on Cl- 
inhibition, the  model is supported. Reduction of the Cl- inhibitory effect of Met299-
Arg388 further confirmed this model (229). Stewart et al. have then developed a method based 
on AFM imaging in order to determine the stoichiometry and arrangement of ENaC. To start, 
each subunit has been tagged; V5 or FLAG, V5 or His6 and V5. Then, FLAGHis6V5 has 
been purified via the FLAG tag and used for AFM. The use of anti-His6 antibodies and anti-V5 
Fab fragments has allowed the subunit differentiation and the calculation of angles. Altogether, 
these results supported a trimeric organization (230). 
These studies have been made on ENaC, mainly because this channel is made of three 
distinct subunits. Indeed ,  and  can be distinguished from the others through individual 
mutations. These mutations modify the channel affinity for inhibitors (amiloride, Cd
2+
) or MTS 
reagents. Experiments that correlate the channel function to the structure are more relevant. 
Indeed, if we focus only on a structural analysis of the channel subunit composition, how to be 
sure that our results are relevant for the functional channel. From my point of view, 
electrophysiological experiments analyzing the effect of ,  or  mutations on the single channel 
conductance and on their affinity for ligands are of primary interest (219,222,223,227). However, 
these reports do not support the same ENaC stoichiometry and lead the question about the 
number of subunits that compose ENaC/Deg channels still open. 
ASIC 
Gao et al., working with heteromers made of ASIC1a and ASIC2b, took advantage of the 
inability of ASIC2b to form homomeric channels. Similarly to Staruschenko et al., they have 
created distinct constructs and co-expressed them. Each condition led to a positive FRET signal, 
in details; (2a+1a_CFP+1a_YFP) and (1a+2a_CFP+2a_YFP) have a FRET efficiency of 34 and 
22 %, indicating that channels are made of at least two ASIC1a and two ASIC2a. Furthermore, 
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(1a_CFP+1a_YFP+2b) 44 %, (1a+2b_CFP+2b_YFP) 39 %, (2a_CFP+2a_YFP+2b) 21 % and 
(2a+2b_CFP+2b_YFP) 31% mean that in heteromeric channels, there are at least two copies of 
the different subunit types, thus at least four subunits form an ASIC channel (231). Subsequent 
studies addressing ASIC oligomerization have concluded to a trimeric organization, in agreement 
with the crystal structure. Carnally and colleagues have developed a method based on atomic 
force microscopy (AFM) imaging, in order to directly determine the arrangement of subunits. 
The distribution of measured molecular volumes has allowed them to find ASIC1a stoichiometry 
(232). A crosslinking approach has highlighted the importance of the four C-terminal cysteines 
(C464, C469, C495 and C526) of mASIC1a. Using H2O2 as oxidizing agent, they have pointed 
out that these four cysteines were involved in the stabilization of high molecular weight 
complexes via intersubunit disulfide bonds on SDS-PAGE and western blots. The presence of 
high molecular weight complexes has been confirmed by crosslinking experiments with sulfo-
EGS and sulfo-DSP, two amino-reactive crosslinkers of 12 Å. Authors have observed four bands 
on their blots referring to them as ASIC1 monomer, two disulfide-linked ASIC1a subunits, trimer 
and higher ASIC1a disulfide-linked subunits. They concluded that ASIC1a was present under a 
trimeric organization, arguing that higher complexes were either, an inter-trimer complex or, 
ASIC1a crosslinked with another protein (233). 
Crystal structures 
To date, four X-ray crystal structures of ASIC have been published. The first one has been 
obtained from the chicken ASIC1 overexpressed in Sf9 cells with deletion in the N- and C- 
termini (26 to 463 amino acids instead of 527) (228). This led to a non-functional channel. 
Biochemical experiments combining glutaraldehyde crosslinking with SDS-PAGE gel and Light 
Scattering analyses revealed a channel molecular weight of 165 kDa, consistent with a trimeric 
stoichiometry. Looking into details, this 1.9 Å resolution structure gave a nice depiction of the 
ECL. The figure 9 shows the ECL domains rearrangement that resembles an upright forearm and 
clenched hand. Within the hand, the main piece is the palm made of seven-strand sheet that 
connect directly the extracellular part to both transmembrane domains. Above the palm stands the 
knuckle domain and close-by the finger. The tip of the finger is in contact with the thumb domain 
rich in disulfide-bonds. The palm, the finger and the thumb encircle the 5-strand--ball domain. 
This hand is rich in conserved cysteines involved in disulfide bridges (“CRD” discussed in the 
chapter about the ENaC/Degenerin family). Likely, the integrity provided by these bonds 
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facilitates the transmission of conformational changes to the transmembrane domains leading to 
the pore opening. In the extracellular region resides the putative H
+
 binding site, which is not 
clearly established yet. The Cl
-
 also has a binding site there; however its physiological relevance 
remains unknown. 
 
Figure 9 Overview of a cASIC1 subunit. It looks like a hand holding a ball (-ball domain) with the palm, the knuckle, the finger 
and the thumb highlighted in light pink, green, orange and brown, respectively. 
Another crystal structure has been obtained by overexpressing a C-terminus truncated cASIC1 
into Sf9 cells. Actually, this protein is longer (N terminus included and C terminus stopped at 
residue 466) and led to a functional channel in CHO cells while the function has not been 
assessed in Sf9 cells (234). This crystallization provides a clear picture of the role of the TM2 as 
a pore lining structure. The orientation of the TM2 with respect to the ion permeation pathway is 
consistent with previous functional studies. For instance, both the degenerin (G432 and S576) 
and the amiloride (G439 and S583) binding sites have been described as being accessible for 
MTS reagents, Zn
2+
, and the pore blocker amiloride (41,222,223,235,236), whereas the residue 
S589 of the ion selectivity filter is not accessible for MTSEA (Figure 10) (53,54). In addition, 
the side chain of S589 has been proposed to point towards the subunit-subunit interface 
(237).These accessibility studies have been made using the substituted-cysteine accessibility 
method (SCAM). Residues are first mutated into cysteine and their accessibility then tested using 
thiol reactive reagents such as the Cd
2+
 or methanethiosulfonate reagents (MTSEA or MTSET).
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Figure 10 Comparison of the cASIC1 (pdb 3HGC) and the αENaC TM2. The cylinder depicts the TM domains of a channel with 
the pore in its middle surrounded by TM segments of the cASIC1 on the left (blue residues) and of the rENaC on the right 
(green residues). The side chains of the degenerin site (DEG, cGly432 and Ser 576), the amiloride binding site (cGly439, 
Ser583) and the selectivity filter (cSer445, Ser589).  
Despite the good correlation between the TM domains of this second crystal structure and the 
functional studies, there is still a problem. Indeed, due to a crossing of the TM2, this structure 
does not allow the flow of Na
+
 ions through the pore, nor the binding of the amiloride. More 
generally, the available ASIC crystal structures do not identify a clear ion permeation pathway 
for permeant cations. 
The surface of the ASIC1 structure based on the electrostatic potential (Figure 11) shows that the 
only access to the pore is across the lateral fenestrations, and no continuous pathway is possible 
through the extracellular loop. 
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Figure 11 Left, Vestibules and possible ion permeation pathways. An electrostatic potential surface and cartoon representation of 
the mfc cASIC1 cutted along the 3-fold axis of symmetry. Colors from red to blue depict the electrostatic potential from −50 kT 
to +30 kT. White is 0 kT. Right, Radius of the putative permeation pathways along the 3-fold axis. This was generated with 
HOLE, a program allowing the analysis and the visualization of the pore dimensions (red < 1.4 Å < green < 2.3 Å < purple). 
Figure taken from Gonzales et al., 2009 (234). 
These two structures of ASIC1 show an ion channel non-conducting for permeant ions (228,234). 
Two interpretations can be formulated; the first proposed by the authors is that the crystal has 
been made at an acidic pH of 6.5 and represents a desensitized channel. According to them, ions 
might reach the extracellular vestibule through lateral fenestrations. The second proposed that 
since the protein was crystallized from Sf9 cells in which the function was not assessed, it is 
possible that this structure does not correspond to the functional channel. The lipid composition 
of insect cells is different from mammalian cell lines (lower cholesterol to phospholipid ratio) 
and can account for a less active or even an inactive membrane protein (238,239). 
More recently the complex made of psalmotoxin and cASIC1 has been crystallized 
(201,203). The idea behind the use of PcTx1 was to stabilize the open state of the channel. 
Indeed, contrary to human or rat ASIC1a, cASIC1 is activated by PcTx1 (240). The toxin 
potentiates the cASIC1 (EC50 189 nM) (202) and leads to the partial desensitization of the 
channel (201). Both articles confirm a previous functional study highlighting the binding of the 
toxin to the acidic pocket of ASIC1. As shown on the schematic view below, PcTx1 binds the 
interface between two subunits, namely the H
+
-sensitive pocket (241). 
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Figure 12 Schematic representations of two ASIC subunits. Red arrows indicate the domains proposed to be involved in channel 
gating by coupling the extracellular domain with the TM1 and TM2, the acidic pocket is depicted with the red circle, palm in 
yellow and thumb in green. Figure from Baron et al., 2013 (242). 
In the first paper published by Dawson et al., a 3.0 Å resolution crystal structure at pH 5.5 has 
been obtained. Given that the study is based on the truncated construct (26-463) used in 2007 for 
the first crystallization, this led to disturbed transmembrane domains making difficult the 
decision of whatever the pore in an open or closed conformation was. However, this study 
allowed the characterization of the PcTx1-binding site and its molecular interaction with the 
channel. Three PcTx1 molecules were bound per trimeric channel in the H
+
-sensitive pocket. 
This pocket is between the thumb and the palm domains of the adjacent subunit (Figure 12). 
In the second report, Baconguis and Gouaux have used a longer and functional construct (14-
463). Crystals of the PcTx1-cASIC1 complex have been obtained at two different pH. At pH 7.25 
with a 3.3 Å resolution, the channel presents a large pore (10 Å) lined by TM2 and TM1 residues 
and not selective for Na
+
. At pH 5.5, the structure (2.8 Å) displayed a 3.2 to 5.2 Å pore, large 
enough to selectively accommodate a hydrated Na
+
 ion. The toxin binding site is identical in the 
two studies with a few discrepancies concerning the molecular interactions. 
To date, none of the crystals displays trapped Na
+
 ions in the putative permeation pathway 
neither in the desensitized, closed nor open conformation. This would be the evidence of an open 
and conducting channel state. Nevertheless, Baconguis and Gouaux found that the toxin 
prevented the complete desensitization of the channel leading to a small steady-state current at 
both pH 5.5 and 7.25 with some channels being open, while other are closed. In the present study, 
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both crystals are in an open conformation, pH 7.25 being unselective, whereas pH 5.5 specifically 
conducts Na
+
 with a PNa+/PK+ of ~10. Strikingly, this Na
+
 selective pore is asymmetric and 
exposes one of its TM1 to the lumen as depicted on the mapping of the solvent accessible 
pathway of figure 13. 
 
Figure 13 Mapping of solvent-accessible pathway along the three-fold axis. Left, High-pH structure (7.25) with a large pore. 
Right, Low-pH structure (5.5) with the opposite arrows depicting the constriction. Maps were generated using the HOLE software 
(243) (red < 1.4 Å < green < 2.3 Å < purple) Figure from Baconguis et al., 2012 (201). 
Regarding the ECL, movements are the same between the desensitized structure and both pH 
7.25 and 5.5 crystals. There is an enlargement of the ECV with Val75 going from 7 Å to 11 and 
12 Å in the selective and unselective states. The distance between Asn357 (thumb) and Arg85 
(palm) also increases from 8 to 11 Å, as well as the peptide bond separating Thr84 and Arg85 
flips by ~180°. Motions have also been observed in the 11-12 linker near to 1-2, confirming 
the crucial role of these linkers for desensitization (244,245). 
In conclusion, stoichiometric studies (crosslinking, AFM and FRET) support a channel 
made of three or four subunits and all of the four crystal structures highlight a trimeric 
organization of ASIC1. However there are still open questions regarding these structures: what is 
the access pathway taken by the ion to cross the ASIC1 channel (central axis or lateral 
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fenestrations)? Why are they no permeant ion trapped in the open pore? Do these structures 
reflect the functional ASIC1 channel? 
To answer these questions, it would be necessary to combine functional and structural 
investigations. Thus, we have decided to study the structure-function relationship of ASIC1a 
channels. Two parts compose this project: the stoichiometric analysis of the functional pool of 
ASIC1a channels expressed at the cell surface, and the functional study of the extracellular 
vestibule structure. 
  
35 
 
Material and Methods 
1. Xenopus laevis oocytes 
The biological expression model used in this work is the Xenopus laevis oocyte. By 
surgery, we remove stage V to VI oocytes from the ovarian tissues of animals anesthetized by 
immersion in MS-222 (2 g/l; Sandoz, Basel, Switzerland). Oocytes are then defolliculated and 
used for experiments. Oocytes are kept in an incubator at 19°C in a solution containing in mM: 
10 NaCl, 2 KCl, 0.82 MgSO4, 0.41 CaCl2, 0.33 Ca(NO3)2, 80 NMDG and 5 HEPES. 
2. Site-directed mutagenesis 
We clone the coding sequence of hASIC1a in pSDEasy vector and introduce an 
octahistidine coding sequence (H8) into the multiple cloning site using XhoI and SalI restriction 
sites. H8-hASIC1a-C466A-C471A-C497A-C528Stop (ΔCCt) is used as template for mutagenesis. 
C49A, C59V, C61S, C59V-C61S, V74C, Y426C, G430C, G433C, N368A, N395A, and N368A-
N395A point mutations are introduced in H8_hASIC1a and ΔCCt cDNA by Site-Directed 
Mutagenesis (Stratagene's QuickChange). Mutations have been verified by sequencing 
(Synergene Biotech, Zurich, Switzerland). Primers list is in the appendix (Primer sequences). 
For experiments on human ENaC, the template for mutagenesis is pbluescript(+)-hENaC. 
3. In vitro transcription 
The linearized and purified cDNA is transcript in vitro using the SP6 RNA polymerase 
(Promega, Dübendorf, Switzerland). After digestion of the template with an RNAse-free DNAse, 
RNA is purified with the Nucleospin RNA clean-up kit from MACHEREY-NAGEL.10 ng of 
RNA are pressure-injected per oocyte. 
4. ASIC and ENaC expression in oocytes 
ASIC-injected oocytes are kept in a Medium Barth Saline solution (MBS) containing in 
mM: 85 NaCl, 1 KCl, 2.4 NaHCO3, 0.82 MgSO4, 0.41 CaCl2, 0.33 Ca(NO3)2, 10 HEPES and 
4.08 NaOH at pH 7.2.Whereas ENaC-injected oocytes are maintained in a solution with low Na
+
, 
in mM: 10 NaCl, 2 KCl, 0.82 MgSO4, 0.41 CaCl2, 0.33 Ca(NO3)2, 80 NMDG, 5 HEPES. 
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5. Electrophysiological measurements 
5.1. Labeling with MTS reagents 
 
To assess the kinetics of MTS accessibility, we incubate oocytes in the control solution 
(pH 7.8) supplemented with x M MTS. After varying time, we quench the MTS with 100 M 
cysteine and directly crosslink the unoccupied cysteines of the protein with 2 mM BMOE. After 
three washing steps, we measure the currents using the Two-Electrodes Voltage Clamp (TEVC). 
Then, currents are normalized over the maximum current (INa+/INa+ max) and plotted in function 
of time. We apply the following equation for one phase association; 
 Y = Y0 + (Plateau – Y0)*(1 – e
(-k*X)
), 
with X the time and k the rate constant. The association constant k2 is determined by dividing k 
by the concentration of MTS, and its unit is M
-1 
* s
-1
. k2 constants are calculated for each oocyte. 
Oocytes with aberrant or undefined k2 are excluded from the analysis. 
5.2. Crosslinking in situ 
To crosslink proteins in situ, we incubate intact oocytes in the incubation solution 
supplemented with 2 mM of BMOE (or 10 mM NaTT) at 19°C. After varying time (5 or 120 
min), we wash the cells three times and proceed with the electrophysiological measurements 
and/or the biochemistry. 
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5.3. Two-electrodes voltage Clamp (TEVC) 
 
Figure 14 Setup of TEVC. The oocyte is impaled with two electrodes; one measuring the current (i) and the other the voltage (v). 
Figure from http://www.ionchannel.ku.dk/research/electrophysiology/ 
Electrophysiological measurements are made 24-48 hours after injection. Sodium currents 
are recorded using the TEVC technique (model TEV-200; Dagan Corp.). Measurements are 
carried out by placing the oocyte in a bath, perfused with different solutions, and impaled with 
two electrodes. One electrode measures the membrane potential (Vm) and the second one injects 
the current necessary to maintain the desired potential that would otherwise be modified by the 
channel activity. The two electrodes are realized using micropipettes containing a 1 M KCl 
solution. All electrophysiological experiments were performed at room temperature (22-25 °C). 
For hASIC1a sodium currents, we used an holding potential at -80 mV. The control solution at 
physiological pH contains in mM: 120 NaCl, 2 MgCl2, 10 HEPES°H
+
, adjusted at pH 7.4 or 7.8 
with N-Methyl-D-Glucosamine (NMDG). The acidic solution for the activation of hA1a contains 
in mM: 120 NaCl, 2 MgCl2, 10 MES and pH 6.0 is adjusted with NMDG. For each oocyte, three 
to four activations are performed at 40 seconds intervals. For ENaC recordings, the composition 
of the perfusion solution is in mM: 120 NaCl, 2.5 KCl, 1.8 CaCl2-2H2O, and 10 HEPES-H
+
 for 
the Na
+
 solution; NaCl is replaced by 120 mM NMDG-HEPES or KCl for the perfusion solutions 
devoid of Na
+
. To determine amiloride-sensitive currents, we add amiloride (Sigma, 10 µM) in a 
separated fraction of each test solution. Inward Na
+ 
current is generated by switching from a 
solution without Na
+
 (NMDG or KCl) to a perfusion solution containing 120 mM of Na
+
. In the 
experiment with proteases, the oocytes are exposed to 5 µg/ml trypsin (Sigma-Aldrich Chemie) 
in the 120 mM NaCl-perfusion solution. 
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5.3.1. pH activation curves 
Measurements are made by switching solutions from pH 7.8 to pH 7.4, 7.2, 7.0, 6.8, 6.5, 
6.0, 5.5 and 5. Oocytes are stimulated twice at each pH solution. Currents are then normalized 
regarding the maximum INa that is pH 5.0. Points are then fitted with the equation: 
Y=1/(1+(10^-pH/10^-x)^n) ; 
With, pH = pH of half activation and n = Hill coefficient 
5.3.2. pH inactivation curves 
Measurements are made by switching solutions from pH 7.8, 7.4, 7.2, 7.0, 6.8 to pH 5.0. 
Oocytes are stimulated twice at each pH solution. Currents are then normalized regarding the 
maximum INa that is after incubation at pH 7.8. Points are then fitted with the equation: 
Y=z+((1-z)/(1+(10^-x/10^-pH)^n)) ; 
With pH = half max pH for inactivation, n = Hill coefficient and z = baseline 
5.4. Cut-open technique 
 
Figure 15 Setup of Cut-open 
The cut-open technique allows the recording of macroscopic currents while both the 
inside and the outside of the oocyte are continuously perfused. Xenopus laevis oocytes are placed 
in an experimental holder divided in three chambers. The superior pole of the oocyte is in contact 
with the upper chamber and perfused with the extracellular solution. The lower pole is impaled 
by a microperfusion pipette used as well as microelectrode. The guard compartment isolates 
electrically the external (upper) and the internal (lower) compartments. The voltage clamp is 
performed using a Dagan cut-open oocyte voltage clamp apparatus (Dagan Corporation, 
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Minneapolis, MN; model CA-1 high performance oocyte clamp). 24-48 hours after RNA 
injection, oocytes are perfused intracellularly with either a control, 1 mM MTS or an acidic 
solution, and the sodium current is measured. In crosslinking experiments, oocytes are perfused 
either with BMOE or NaTT. To test if the MTSEA-biotin-mediated biotinylation specifically 
involved cysteines modification, some experiments are performed with oocytes perfused with a 
solution containing 1 mM MTSEA-biotin with or without 5 mM free cysteines (L-Cysteine*HCl, 
pH 7.35 with NMDG, Fluka). 
6. Biochemistry 
6.1. Pull-down on nickel-NTA-agarose beads 
Oocytes are lysed with a lysis buffer (LB) containing 1% (v/v) Triton and, in mM: 100 
NaCl, 20 Tris-HCl at pH 7.5, 10 N-Ethylmaleimide (NEM), 1 PMSF and 10 g/ml each of 
Leupeptin, Pepstatin and Aprotinin (20 l LB/oocyte). After 10 min centrifugation at ~15,000g 
(4°C), the intermediate phase comprising the solubilized protein fraction is recovered and 
subjected to batch affinity chromatography on nickel-NTA-Agarose beads (Qiagen, 
Hombrechtikon, Switzerland), incubating 2 h at 4°C in the presence of 20 mM imidazole to 
reduce non-specific binding. 
After 2 min centrifugation at 2,000 rpm, the beads are washed 3 times with LB. 40 l of 
sample buffer (25 mM DTT, final concentration) are added to the pellet containing the drained 
beads and heated at 95°C for 5 min. Bound proteins are then recovered by centrifuging through 
Evergreen mini-filters (EVE-208). 
6.2. Biotinylation of the cell-surface expressed ASIC  
48h hours after cRNA injection, 30 oocytes/condition are labeled by 15 min incubation on 
ice in 1 ml of biotinylation buffer (in mM: 10 Triethanolamine, 150 NaCl and 2 CaCl2) 
supplemented with 1 mg/ml of EZ-link sulfo-NHS-SS-biotin (Pierce, #21331). After aspiration of 
the bathing solution, oocytes are incubated for 5 min in 1 ml of quenching buffer (in mM: 192 
Glycine, 25 Tris-HCl at pH 7.5, in MBS solution) and subsequently washed 3 times with MBS 
solution. Oocytes are finally lysed with a Streptavidin binding buffer (SBB, 20 l LB/oocyte) 
containing 1% (v/v) Triton and, in mM: 5 EDTA, 100 NaCl, 40 Tris-HCl (pH 7.5), 1 PMSF and 
10 µg/ml of each Pepstatin, Aprotinin and Leupeptin. After 10 min centrifugation at ~15,000g, 
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biotinylated proteins are isolated from the intermediate phase by a pull down assay. After 
incubation with 50l of streptavidin-agarose (1h at RT, Immunopure immobilized streptavidin 
gel from Pierce #20349), beads are washed three times in SBB and bound proteins are then eluted 
as described above. Pilot studies using lysates from non-biotinylated oocytes are carried out to 
assess the absence of non-specific binding of His-tagged hASIC1a to streptavidin (not shown). 
For in situ crosslinking studies, we supplement the SBB with 10 mM NEM to avoid crosslinking 
of free cysteines. 
6.3. Blue native technique and Oligomer Characterization by Addition of Mass 
CHO cells stably transfected with the His8_sGFP_TCS_hASIC1a or 
His8_sGFP_TCS_cASIC1 are used and treated as described in the paper of Gandhi, Walton and 
Rees (246). Proteins are then resolved on a blue native polyacrylamide gel electrophoresis (BN-
PAGE) according to the modified protocol of H. Schägger used by Swamy et al. (247). 
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Results 
This section will be separated in two parts. The main part deals with the structure-
function of ASIC: oligomerization and functional investigation of the apparent size of the 
extracellular vestibule. The other part is a side project on ENaC. It is the functional 
characterization of an ENaC mutation (S243P) found in a patient diagnosed with a PHA1. 
ASIC 
1. Oligomerization of ASIC 
Previous experiments on the stoichiometry of ENaC/Deg channels remain controversial. 
Moreover, the oligomerization of the functional ASIC channels in situ has never been addressed 
so far. Thus, we have investigated the subunit composition of the functional human ASIC1a 
channel using a crosslinking approach. 
1.1. Preliminary crosslinking experiments with sodium tetrathionate 
When Jasti et al. published the crystal structure, we were already working on the 
crosslinking of human ASIC1a (hASIC1a). We assessed the effect of the oxidizing agent sodium 
tetrathionate (NaTT) on His8_hASIC1a, either after the incubation of total lysates with the 
reagent, or after the NaTT injection into Xenopus laevis oocytes. SDS-PAGE and western blot 
analyses of crosslinked hASIC1a purified on nickel-beads led to the detection of three bands at 
66±4, 147±13 and 304±33 kDa (mean±SD, n=4) (Figure 16). The distribution of these molecular 
weights follows a linear regression with a slope of 79.2±0.4 (R
2
=1). Using a construct lacking the 
four cysteines of the C-terminus, we have noticed a disappearance of the highest band (304 kDa), 
a decrease of the intermediate (147 kDa) and an increase of the band at 66 kDa. Looking at the 
control condition without NaTT does not allow us to conclude that the NaTT crosslinking works. 
Indeed, the NaTT is an oxidizing agent that induces the disulfide bond formation. In order to see 
the effect of NaTT, we have to avoid the use of reducing agents (DTT) in the SDS-PAGE gels. 
Thus, it is impossible to distinguish disulfide bonds induced by NaTT from disulfide bridges 
already formed before the crosslinking treatment. However, this experiment shows the role of the 
C-terminal cysteines in the stabilization of high molecular weight complexes. 
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Figure 16 Analysis of the NaTT-crosslinked H8hASIC1a. Stabilized ASIC1a wt is compared with CCt (construct lacking the 
four cysteines in the C-terminus). On a 5-15 % SDS-PAGE gel (non-reducing conditions (–DTT)), three bands are detected with 
the anti-His antibody (1/1000) at 66±4, 147±13 and 304±33 kDa (n=4). ni=non-injected oocytes. 
Experiments performed by Jasti and colleagues on cASIC1 showed that glutaraldehyde 
stabilized a trimeric complex of ~165 kDa (monomer ~50 kDa) (228), whereas under our 
conditions, the NaTT stabilized a complex of 303±33 kDa closer to a tetramer (monomer 66±4 
kDa). However, these experiments have been performed on total lysates and thus, do not make 
the distinction between functional cell surface expressed channels and cytosolic proteins. 
Moreover, the impact of the crosslinking on the channel activity was unknown. Thus we decided 
to assess the NaTT effect on channel function using the cut-open technique. As depicted on 
Figure 17, the crosslinker did not affect the hASIC1a activity of neither the wt nor the CCt 
(black circle and green squares, respectively, n=12 per condition). Then, proteins from the 
perfused oocytes have been separated on a non-reducing SDS-PAGE gel. This led to a migration 
pattern similar than for NaTT-injected oocytes (n=1, data not shown). 
 
Figure 17 Analysis of the activity of hASIC1a perfused with 20 mM NaTT using the cut-open technique. hASIC1a wt is 
represented by the black circles and hASIC1a without the four cysteines of the C-terminus (CCt) by the green squares 
(n=12/condition). 
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To summarize, on non-reducing SDS-PAGE gels, hASIC1a migrate under three 
molecular weight forms; 66±4, 147±13 and 303±33 kDa. The presence of the high molecular 
weight band is dependent of the C-terminal cysteines stabilizing high molecular weight 
complexes through intersubunit disulfide bonds formation. 
1.2. Crosslinking experiments with bismaleimidoethane 
The bismaleimidoethane (BMOE) is an 8 Å crosslinker for covalent and irreversible 
conjugation between thiol groups. Results are explained in the article “A crosslinking study of 
the human ASIC1a: evidence of 4 distinct oligomeric states at the cell surface” (Appendix). 
In this article, we have developed a crosslinking approach to stabilize ASIC1a directly at the cell 
surface of Xenopus laevis oocytes. Similarly to NaTT, we have analyzed the effect of BMOE on 
the function of ASIC1a (wt and CCt) using the cut-open technique (Figure 18 A). The BMOE 
does not change the ASIC1a activity. Moreover, SDS-PAGE gels (reducing condition) and 
western blot analyses of perfused oocytes confirm the BMOE-dependent crosslinking with three 
bands migrating at 72±2, 156±7 and 329±19 kDa (mean±SD, n=7) and their absence without 
BMOE treatment, as well as without the four cysteines in the C-terminus (Figure 18 B). 
 
Figure 18 Effects of intracellularly applied BMOE on hASIC1a activity and oligomerization. A, Cut-open oocytes expressing 
either ASIC1a wild type (solid circles, n=18) or ASIC1a-ΔCCt (open circles, n=17) were intracellularly perfused with 2 mM 
BMOE; time 0 corresponds to the onset of perfusion with BMOE; currents (m±SD), elicited at pH 6.0 were normalized to the 
peak current at time zero in the absence of BMOE. B, Oligomerization of ASIC1a identified by an anti-ASIC1 western blot from 
oocytes, not injected (n.i.), or expressing ASIC1a or ASIC1a-ΔCCt lacking cysteines in the C-terminus, that were either untreated 
(ctrl), internally perfused (perf.), or intracellularly injected (inj.) with 2 mM BMOE. Numbers I to IV identify bands that are 
specific for ASIC1a and represent by Mw multiples of band I. 
Given that C-terminal cysteines are able to form disulfide bridges between subunits (233), we 
cannot rule out that the 329 kDa-band is the result of the interaction of ASIC with an adjacent 
protein. Thus, we have engineered new cysteine mutants in a background where the four 
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cysteines of the C-terminus have been mutated (CCt background). We have chosen these 
residues based on two criteria; their accessibility for MTS-reagents and the orientation of their 
side chains towards the pore lumen. These mutants are V74C and Y426C in the ECV (upper and 
bottom parts, respectively), as well as G430C and G433C in the TM2. They are functional and 
display an increased sensitivity for Cd
2+
. Furthermore, BMOE treatment leads to a current 
inhibition for Y426C and G430C. Both results indicate that the residues are on the permeation 
way.  
SDS-PAGE and western blot analyses of in situ crosslinked and cell surface purified channels 
allow the detection of four distinct bands. The distribution of their molecular weights follows a 
linear regression with a slope of 72±4 kDa consistent with a subunit mass (Figure 19). 
 
Figure 19 ASIC1 oligomeric states revealed by SDS-PAGE separation after crosslinking of cysteines in the ECV. A, Anti-His-tag 
western blot of the biotinylated fractions of surface proteins from non-injected oocytes (n.i.), from oocytes expressing either the 
His8-tagged forms ASIC1a/ΔCCt (ΔCCt) lacking cysteines in the C-terminus, or the substitution mutants V74C/ΔCCt, Y426C/ΔCCt, 
G430C/ΔCCt, and G433C/ΔCCt. The crosslinking with 2 mM BMOE was performed at the cell surface; the biotinylated surface 
proteins were affinity-purified on streptavidin beads. Numbers I to IV, as in figure 18. B, Apparent Mw values of the ASIC1 
oligomers (kDa, mean ±SD) estimated for each of the four main bands (I to IV) resolved by SDS-PAGE (see Methods) for the 
different constructs, as in A. C, Relative intensities (mean, vertical bars ±SD) of the four distinct bands I-IV identified in A: 
horizontal bars represent SD for the apparent Mw value for each band. 
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The engineered cysteine accounts only for two bands, while the others involve native cysteines of 
the TM1, in particular C59 and C61, as depicted on the Figure 20. 
 
Figure 20 Contribution of the cysteines in the first transmembrane helix (TM1) to the subunit crosslinking by BMOE. A, ASIC1a 
oligomeric states identified by anti-His-tag western blot (using the same experimental procedure as in figure 3A) of the His8-
tagged forms of ASIC1a-ΔCCt (ΔCCt), and the cysteine substitution mutant G433C-ΔCCt associated or not with the C59V or 
C59V/C61S substitutions (G433C/C59V/ΔCCt or G433C/C59V/C61S/ΔCCt). Numbers I to IV have the same meaning as in figure 
1. B, Relative intensities (arbitrary units, mean ±SD, n=4) of the bands identified on SDS-PAGE estimated for ASIC1a-ΔCCt, 
G433C/ΔCCt, G433C/C59V/ΔCCt, and G433C/C59V/C61S/ΔCCt. Horizontal bars represent ±SD of apparent molecular weight 
sizes. 
Do these four bands reflect a diversity of ASIC1a oligomers at the cell surface or are they 
dissociated subunits coming from one unique oligomer? A way to discriminate between them is 
to optimize our crosslinking protocol (time, concentration, available cysteines). We have chosen 
to focus on the G433C mutant, mainly because it is not inhibited by BMOE, meaning that even 
after its stabilization we are still working on a functional channel. While the optimized conditions 
do not lead up to an enhancement of the crosslinking into Xenopus oocytes, they do in CHO cells. 
Indeed, as shown on Figure 21, the crosslinked ASIC1a wt is translated into four bands of 75±2, 
160±13, 224±20 and 304±22 kDa (mean±SD, n=9). The engineered G433C increases the amount 
of high molecular weight complexes (224 and 304 kDa, 26 and 59 % of the total pool, 
respectively), whereas the 75 and 160 kDa bands have disappeared. 
On the Figure 21, a doublet is present for the highest molecular weight complex. We hypothesize 
that the two bands represent two complexes made of four subunits that have been stabilized in 
two distinct conformations, i.e. a closed ring versus a linear configuration (248). 
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Figure 21 Stabilization of the ASIC1a channel complex at the cell surface of transfected CHO cells. A, Anti-His-tag western blot 
showing ASIC1a oligomeric states obtained from cell surface fractions of proteins expressed by CHO cells and transiently 
transfected with an empty vector (n.t.), or His8-tagged forms of ASIC1a wt, ASIC1a-G433C/ΔCCt, or ASIC1a-G433C mutants, 
and treated with 2 mM BMOE or vehicle. Surface proteins were biotinylated, purified on streptavidin beads and analyzed by 
western blot.. Numbers I to IV have the same meaning as in figure 19. B, Relative intensities (mean ±SEM) measured of the 
different bands detected for the different constructs without (open circles) or with 2mM BMOE (filled circles). Horizontal bars 
represent apparent Mw values (±SEM) estimated for each band. Significant (** = p<0.01) difference in intensity between bands 
III and IV for each protein was determined by a paired, two-tailed t-test. 
An increased number of cysteines available for crosslinking does not lead to an unique oligomer. 
We hypothesize that this could be a limitation of the BMOE itself. Indeed the number of free 
accessible and well-distanced cysteines might be too low. Thus we switch to the formaldehyde, a 
2-3 Å amino crosslinker. The reaction of the formaldehyde with proteins is composed of three 
steps. Frist, a methylol adduct on amino groups is formed. This adduct is then partially 
dehydrated. This yields a labile Schiff-base that can crosslink with several aa residues. Arginine 
and tyrosine are the main residues, but asparagine, glutamine, histidine and tryptophan can also 
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be crosslinked (249). Consequently, no more difference is observed between ASIC1a wt and 
G433C mutant, because the number of formaldehyde-reactive residues is the same between both 
wt and cysteine mutant constructs. Furthermore, formaldehyde crosslinking is dose-dependent 
and leads finally to the stabilization of the 313±22 kDa oligomer representing between 70 and 80 
% of all oligomeric states (Figure 22).  
 
Figure 22 ASIC1a channel complex at the cell surface of CHO cells after crosslinking with formaldehyde. A, Anti-His-tag 
western blot of the biotinylated fractions of surface proteins in CHO cells transiently transfected either with empty vector (ctrl), or 
with His8-tagged ASIC1a, or ASIC1a-G433C mutant (G433C). Cells were treated either with vehicle (DMSO), or BMOE (2 
mM), or with 1 or 4% formaldehyde (1F, 4F, respectively). Surface proteins were biotinylated, purified on streptavidin beads 
before western blot analysis. Numbers I to IV have the same meaning as in figure 18. 
In conclusion, stabilization of the functional hASIC1a expressed at the cell surface adds 
supplementary evidence in favor of a tetrameric ASIC1a channel, independently of the 
crosslinker, the expression system and the cysteine mutant. 
2. Functional characterization of the extracellular vestibule size 
In this part, we combine molecular, functional and biochemical approaches with 
bioinformatics to gain information on structural aspects of the extracellular vestibule (ECV). The 
aim was to evaluate functionally the size of the ECV. This has been done by testing the 
accessibility of specific residues, mutated in cysteines, for ligands of different molecular weight 
and shape. This technique is called SCAM for Substituted-Cysteine Accessibility Method. 
Based on the crystal, we have identified pore-lining residues in the ECV. They are the E63, Y68, 
H73, V74, K423, A425, Y426, and G430 (Figure 23). 
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Figure 23 A, View of cASIC1 crystal with cysteines mutated residues in the extracellular vestibule (ECV). B, Inlet shows an 
enlarged representation of the ECV. Lining residues are H63, Y68, H73, V74, K423, A425, Y426, and G430, labeled in cyan, 
pink, green, yellow, orange, black, purple and blue. 
2.1. Functional characteristics of the extracellular vestibule mutants 
We have investigated by functional electrophysiological techniques the accessibility of 
E63C, Y68C, H73C, V74C, K423C, A425C, Y426C, and G430C ASIC mutants in the 
background of C-terminal deleted cysteines. Y68C, V74C and A425C show a lack or a strong 
reduction of current. V74C recovers its full activity after a reducing treatment (10 mM DTT), 
suggesting that disulfide bonds might be responsible of the loss of function (Table 3). No current 
was recovered after DTT treatment of Y68C and A425C. Thus, we further investigate the 
functional cysteine substitutions of E63, H73, V74, K423, Y426, and G430. 
2.2. Electrophysiological analyses of the accessibility 
2.2.1. Effect of Cd2+ on Na+ currents 
In order to assess the accessibility of these engineered cysteines, we use the Cd
2+
. Having 
approximately the same size than the Na
+
 ion, it is an indicator that a cysteine is along the 
permeation pathway. While the Cd
2+
 inhibits ASIC1a wt with an IC50 of 1.2±0.1 mM, V74C is 
irreversibly blocked, and Y426C as well as G430C display an increased affinity (IC50 
0.032±0.002 and 0.010±0.001 mM, respectively), other mutants (E63C, H73C and K423C) do 
not present any change. This absence of modification in Cd
2+
 affinity suggests that these 
cysteines are not accessible. Thus we do not continue our investigations on them. 
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This first screen shows the accessibility of V74C, Y426C, and G430C for a small ligand like 
Cd
2+
, and their subsequent inhibition (Table 3). This inhibition can result either from a pore 
occlusion or from the channel inability to open due to a crosslinking being two cysteines. 
2.2.2. Effect of NaTT on Na+ currents 
NaTT is an oxidizing agent that induces the formation of disulfide bonds between two 
cysteines that are close, in the range of a S-S, about 2 Å. We wonder if this treatment would lead 
to an inhibition, as observed for the Cd
2+
. Neither the wt, the V74C, the Y426C nor the G430C 
displays a current significantly different after 10 min of incubation with 10 mM NaTT. This may 
indicate that two cysteines are not sufficiently close to form disulfide bridges, or that the S-S 
bond does not inhibit the current. As SDS-PAGE gel analysis has not been performed on these 
oocytes we are not able to distinguish between these two possibilities. 
2.2.3. Effect of BMOE on Na+ currents 
To further investigate the accessibility of these residues, we tested the effect of the 
homobifunctional disulfide crosslinker BMOE. Oocytes were incubated in 2 mM BMOE and 
then the currents recorded with TEVC. The BMOE drastically inhibits Y426C and G430C 
mutants compared to the ΔCCt wt channel, whereas V74C is not blocked (Table 3), the residual 
currents are 6.4±02, 9.5±0.2 and 115±24 %, respectively. The V74C inhibition is likely prevented 
by disulfide bridges as demonstrated by the absence of INa+ of this mutant recovered after a 
reducing treatment with DTT. On SDS-PAGE analysis, the BMOE is able to crosslink V74C, 
Y426C and G430C resulting in the appearance of high molecular weight complexes (see the 
aforementioned article “A crosslinking study of the human ASIC1a: evidence of 4 distinct 
oligomeric states at the cell surface”). 
Thus, Y426C and G430C are accessible to Cd
2+
 and BMOE. The inhibition seems to be related 
with the crosslinking activity of BMOE as shown by the stabilization of dimers on SDS-Page (for 
details, see chapter: Crosslinking experiments with bismaleimidoethane, Figure 19). 
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hASIC1a INa peak 
+ BMOE 
Relative INa 
(% of control) 
Cd
2+
 
(IC50 mM) 
INa peak + DTT 
ΔCCt  45.06 ± 20.6  90.2 ± 10.0 1.16 ± 0.095 38.04 ± 15.24 
V74C- ΔCCt 2.9 ± 2.4
** 
115.7 ± 24 Irreversible block 25.84 ± 15.72
** 
Y426C- ΔCCt 22.65 ± 14.22 6.4 ± 0.18
** 
0.032 ± 0.0016
* 
29.92 ± 16.8 
G430C- ΔCCt 22.75 ± 14.73 9.5 ± 0.17
** 
0.010 ± 0.0008
* 
26.29 ± 19.37 
Table 3 ASIC1a currents (μA) were elicited at pH 6.0 for the cysteine mutants in the C-terminal deleted cysteines background 
(ΔCCt). Effects of extracellular BMOE (2 mM), Cd
2+ and DTT (10 mM). Data are means ± SD. ** denotes p<0.01 and * p<0.05 
(Student T-test). 
We do not know whether the current inhibition is due to the upholding of the channel in a closed 
conformation or to a steric hindrance that prevents the Na
+
 flux. To gain information about the 
process of inhibition, we turn on ligand with one reactive group; the methanethiosulfonate 
reagents (MTS). 
2.2.4. Effect of methanethiosulfonate reagents on Na+ currents 
In a search for evidence that MTS-reagents can access the ECV and cysteines in the ion 
permeation pathway, we have first tested the effects of MTSET, MTS-PTrEA, MTS-TBAE or 
MTSEA coupled to biotin or fluorescein (MTSEA-biotin, MTSEA-fluorescein) on ASIC 
currents. MTS-reagents only have one reactive group, thus, they should occlude the vestibule 
without freezing it in an inactive conformation. The structure of the MTS, as well as the scheme 
of the reaction is depicted in the appendix 3. MTSET, MTS-PTrEA and -TBAE are positively 
charged MTS. MSTET with its 5.8 Å head group is the smallest, whereas -PTrEA and -TBAE are 
bulkier analogues. The neutral MTSEA-biotin has a head group of 12 Å. Its longer analogue is 
the -biotinCap with an extent linker separating the reactive from the head group. MTSEA-
fluorescein is the biggest MTS we have used.  
We have incubated the oocytes with MTS and then measured the ASIC activity. Due to disulfide 
bridges between V74C residues, the accessibility of this cysteine to MTS-reagents cannot be 
tested directly. A pre-treatment with DTT is necessary for V74C to become free. The 
accessibility of V74C for MTS-reagents still has to be performed. Both Y426C and G430C have 
increased peak currents after incubation in MTS (details in the next chapter). Moreover, 
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incubation of Y426C and G430C with MTSEA-biotin induces a partial desensitization of the 
channel leading to a sustained current (Figure 24). 
 
Figure 24 Representative traces of hASIC1a wt, Y426C and G430C with or without MTSEA-biotin (in blue and black, 
respectively). Currents are obtained by switching from a solution at pH 7.8 to pH 6.0. 
2.2.4.1. The peak current 
The Figure 25 summarizes the peak current in the presence of MTS-reagents. It shows 
that the peak current (Ipeak) of G430C (25.33±4.40 A) is significantly increased after incubation 
in MTSEA-biotin (58.95±28.73 A) and MTS-TBAE (46.17±7.64 A), whereas both MTSET 
(25.85±4.05 A) and MTS-PTrEA (27.49±7.88 A) did not affect it. The Ipeak of Y426C 
(19.81±3.21 A) is significantly increased after incubation in MTSEA-biotin (36.38±5.12 A), 
whereas MTS-PTrEA, MTSET and MTS-TBAE (27.39±6.93, 22.64±4.07 and±1.5 A, 
respectively) did not affect it. The incubation in MTS-TBAE has been made another day. The 
corresponding control (unmodified Y426C) had less current (8.03±1.45 A, n=27). Thus, the 
difference in current between Y426C treated or not with MTS-TBAE is non-significant. 
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Figure 25 Effect of MTS on the peak currents. A, Y426C without MTS (black, n=16). Y426C modified with MTSEA-biotin (1 
mM, gray, n=19), MTS-PTrEA (1 mM, orange, n=7), MTSET (1 mM, blue, n=12) and MTS-TBAE (1 mM, red, n=29). B, G430C 
without MTS pre-treatment (black, n=15) and G430C modified with MTSEA-biotin (1 mM, gray, n=11), MTS-PTrEA (1 mM, 
orange, n=10), MTSET (1 mM, blue, n=12) or MTS-TBAE (1 mM, red, n=7). MTS incubations last 10 min. Unpaired Student T-
test: * and ** stand for P values smaller than 0.05 and 0.001, respectively. Errors are SD. 
Then, we wonder if the pH dependence of activation was changed for the MTS-modified 
channels. Starting at pH 7.8, each oocyte is stimulated with different pH-solutions (pH 7.4, 7.2, 
7.0, 6.8, 6.5, 6.0, 5.5 and 5.0). Currents are then normalized regarding the maximum peak 
current.  
First, we look at the effect of the cysteine mutation on the pH0.5 values. The V74C mutation shifts 
the pH0.5 towards more alkaline values compared to the wt, (6.34±0.02, n=31 for the wt and 
6.52±0.02, n=35, for V74C, pH0.5±SE, P<0.0001). Y426C behaves similarly with a pH0.5 of 
6.50±0.02 (n=10, P=0.001). G430C has a pH of half activation unchanged compared to the wt 
(6.37±0.02, n=4). The effect of MTS-incubations on the pH0.5 values is shown on the Figure 26; 
MTSEA-biotin, MTSET, MTS-TBAE and -PTrEA shift pH activation curve of Y426C 
(pH0.5±SE is 6.50±0.02) towards more alkaline values (6.90±0.01, 7.08±0.02, 6.58±0.01, and 
7.18±0.03, respectively). MTSEA-fluorescein, however, does not modify the affinity for H
+
 
(6.40±0.03). This is similar for G430C channels with pH0.5 (±SE) without MTS or with MTSEA-
biotin, -TBAE, -fluorescein and MTS-PTrEA of 6.37±0.02, 6.84±0.04, 6.60±0.02, 6.32±0.03, 
and 7.03±0.02, respectively. The amplitude of the shift is not dependent of the MTS size. Indeed, 
the shift induces by the MTS-PTrEA is larger than with MTSET, which in turn is larger than in 
presence of MTSEA-biotin.  
The pH dependence of inactivation is unchanged for V74C compared to the wt (7.21±0.03, n=10 
and 7.15±0.02, n=10, respectively (pH0.5in±SE)), as well as for G430C (7.05±0.05, n=4). Y426C 
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as a pH inactivation curve shifted towards more alkaline values compared to the wt (7.11±0.01, 
n=11, and 7.02±0.01, n=5, P=0.0001).The binding of MTSEA-biotin slightly modifies the pH 
dependency of inactivation for the Y426C (7.16±0.02, n=11, P=0.03). The pH0.5in of G430C is 
shifted towards more alkaline values in presence of MTSEA-biotin (7.23±0.01, n=10, P=0.015) 
(Figure 27). 
 
Figure 26 pH dependence of activation of Y426C and G430C. A, Y426C without MTS pre-treatment (black circle, n=10). Y426C 
modified with MTSEA-biotin (1 mM, gray, n=5), MTS-PTrEA (1 mM, orange, n=13), MTSEA-fluorescein (0.1 mM, green, n=6), 
MTSET (1 mM, blue, n=13) or MTS-TBAE (1 mM, red, n=13). B, G430C without MTS pre-treatment (black circle, n=4) and 
G430C modified with MTSEA-biotin (0.1 mM, gray, n=17), MTS-PTrEA (1 mM, orange, n=13), MTSEA-fluorescein (0.1 mM, 
green, n=6), MTSET (1 mM, blue, n=13) or MTS-TBAE (1 mM, red, n=15). MTS incubation last 10 min, except for MTSEA-
fluorescein that lasts 15 min. C-D, pH0.5 of activation values, colors are described in A and B. Unpaired Student T-test: **, *** 
and **** stand for P values smaller than 0.01, 0.001 and 0.0001, respectively. 
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Figure 27 pH dependence of inactivation of Y426C and G430C. A, Y426C without MTS pre-treatment (black, n=11). Y426C 
modified with MTSEA-biotin (green, n=11). ASIC wt (blue, n=5) without MTS pre-treatment. B, G430C without MTS pre-
treatment (black, n=4) and G430C modified with MTSEA-biotin (green, n=10). ASIC wt (blue, n=5) without MTS pre-treatment. 
To summarize, the MTS-reagents (except MTSEA-fluorescein) shift the pH activation of Y426C 
and G430C mutants. Indeed, a pH-drop to 6.0 would open almost all the MTS-labeled channels 
(100% of them, except Y426C labeled with MTS-TBAE (97 %)), whereas 92 and 86 % of the 
unlabeled-Y426C and G430C channels. The amplitude of the shift explains partially the amount 
of increased Ipeak. Indeed, the shift is not correlated with the amount of Ipeak; whereas the MTS-
PTrEA leads to the largest pH0.5 shift for both Y426C and G430C mutants, it only increases by 
two-fold the Ipeak of Y426C and does not change the Ipeak of G430C. MTSEA-biotin induces the 
largest Ipeak increases for both Y426C (4.7-fold) and G430C (2.3-fold). 
2.2.4.2. The sustained current 
Beside the increased peak current, the binding of MTS also leads to a change in the 
kinetic of the current with a partial desensitization leading to a sustained component as 
previously shown on Figure 24. For G430C, this current represents 28.6±3.3 %of the Ipeak with 
MTSEA-biotin, 25.0±5.0 % with MTSET, 37.9±3.2% with MTS-PTrEA, and 8.9±1.2 % with 
MTS-TBAE (mean±SD). For Y426C, this current represents 14.1±3.2 %of the Ipeak with 
MTSEA-biotin, 23.7±12.3 % with MTSET, and 2.9±0.4% with MTS-PTrEA. MTS-TBAE does 
not induce a sustained Y426C current. Results are depicted on the Figure 28. 
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Figure 28 MTS-induced sustained currents. A, Y426C without MTS (black, n=16). Y426C modified with MTSEA-biotin (1 mM, 
gray, n=19), MTS-PTrEA (1 mM, orange, n=7), and MTSET (1 mM, blue, n=12). B, G430C without MTS pre-treatment (black, 
n=15) and G430C modified with MTSEA-biotin (1 mM, gray, n=11), MTS-PTrEA (1 mM, orange, n=10), MTSET (1 mM, blue, 
n=12) or MTS-TBAE (1 mM, red, n=7). MTS incubations last 10 min. Unpaired Student T-test: *, *** and **** stand for P 
values smaller than 0.05, 0.001 and 0.0001, respectively. Errors are SD. 
2.2.5. Competitive interaction between MTS and Cd2+ for cysteines in the vestibule 
To confirm that the effect of MTS-binding occurs via the same residue that coordinates 
Cd
2+
, we have set up a competitive interaction for cysteine mutants between Cd
2+
 and MTS. 
Given that both Y426C and G430C are more sensitive to Cd
2+
, we hypothesize that this enhanced 
affinity for Cd
2+
 should be reversed by a pre-incubation in MTS. Cd
2+
 dose-response curves of 
both Y426C and G430C mutants are shifted towards the left, as consequence of a higher 
sensitivity (Figure 29, red curves). This shift occurs independently of the incubation solution pH 
(either at pH 7.5 or 6.5), whenever the channel in a closed or desensitized state is. Concerning 
Y426C, MTEST and MTSEA-biotin are able to reverse this effect. On the other hand, MTSEA-
biotin or –biotinCap totally reverses this phenomenon for G430C (blue and purple curves), 
whereas the MTSET does not (orange). This suggests that Cd
2+
 and MTS compete for the same 
binding site. MTSET does not shift the Cd
2+
 dose-response curve of G430C. This could be due to 
the non-binding of MTSET to G430C. 
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Figure 29 Cd2+ dose-response curves. A, hASIC1a wt is depicted in black and Y426C mutant in red (n=12 for each condition). 
Cd2+ dose-response curves of wt and Y426C mutant incubated either in MTSET or MTSEA-biotin are represented in grey and 
green and, orange and blue respectively (n=14, 17, 16 and 10). B, hASIC1a wt is depicted in black and G430C mutant in red (n=9 
and 11). Cd2+ dose-response curves of G430C mutant incubated either in MTSET, MTSEA-biotin or –biotinCap are represented 
in orange, blue and purple respectively (n=4, 10 and 6). 
2.2.6. Competitive interaction for G430C between MTSET and BMOE 
To confirm the MTSET absence of binding to G430C, we have made another competitive 
interaction for this cysteine between the MTSET and BMOE. Previously, we have shown that 
BMOE inhibited G430C mutant channels. Thus, we have pre-incubated oocytes into MTS and, 
again challenge the channels for BMOE block. On the Figure 30, we have compared the ability of 
MTSET to prevent the BMOE block for the wt (in gray) and the G430C (in blue). Although there 
is an important variability for the relative currents of oocytes incubated with MTSET and BMOE, 
results suggest that the BMOE block (0.20±0.04 A, n=5, mean±SD) is prevented by the pre-
incubation of G430C in MTSET (2.21±0.45, n=5).  
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Figure 30 Competitive interaction for G430C between MTSET and BMOE. CCt and G430C are depicted in grey and blue, 
respectively. We compare INa+ from MTSET- and BMOE-untreated (circle), BMOE-treated (square) and MTSET- and BMOE-
treated oocytes (triangle). n=4-11 oocytes/condition, 2 batches. Student T-test: * and ** for P values smaller than 0.5 and 0.01, 
respectively. Results are mean±SD. 
Under this condition, the MTSET is able to prevent the BMOE block of G430C mutants, 
demonstrating a competition for the same residue. These experiments confirm the effective 
binding of MTSET to G430C. 
2.2.7. Kinetics of accessibility of the MTS 
Our data show that the MTS-reagents bind Y426C and G430C residues. We would like to 
investigate the kinetics of the binding reaction of the MTS-reagents to the cysteines. This would 
give you an indication of how easy/difficult it would be for a MTS to reach its binding site. We 
have set up an assay in which oocytes are incubated in a control solution at pH 7.8 supplemented 
with a constant concentration of MTS. The reaction is quenched with free cysteines at different 
time points. Then, oocytes are incubated in BMOE and ASIC activity recorded. With this 
protocol we measure the current recovery of the MTS-modified channels. 
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Figure 31 Kinetics of accessibility of MTS to C426. A, MTSEA-biotin at 10 and 100 M, in black (n=7) and red (n=7), 
respectively. B, MTS-PTrEA at 10 and 100 M, in red (n=8) and black (n=8), respectively. C, MTSEA-fluorescein at 100 M 
(n=6). D, MTSET at 10 M (n=6). D, MTS-TBAE at 10 M (n=5). INa+ are normalized on the maximum INa+ that is the condition 
without MTS and without BMOE. Symbols are mean ± SEM. 
The graphs on the Figure 31 represent the current recovery from the BMOE block of Y426C 
(INa+/INa+ max) in function of the MTS incubation time. Looking at the condition with 10 M 
MTSEA-biotin (panel A, black curve): At time zero, BMOE inhibits Y426C currents. After 30 s 
of incubation in MTSEA-biotin, 45 % of the current is recovered. This indicates that BMOE is 
still able to block 55 % of the current, whereas the MTS-binding prevents the block of the 
remaining 45 %. After 300 and 600 s of MTS-incubation the curve saturates. The current 
recovery reaches is maximum (INa+/INa+ max equal to 1.0) with the absence of BMOE block, 
meaning no more cysteine available for crosslinking. With 100 M of MTSEA-biotin, the current 
recovery is faster, with a saturation reached after 60 s of MTS-incubation. The current recovery 
in presence of MTS-PTrEA (panel B) is similar than MTSEA-biotin. However, the MTS-PTrEA 
does not lead to a complete current recovery. Indeed, 20 % of the current remains sensitive to 
BMOE. This suggests that MTS-PTrEA does not occupy all the available Y426C that are still 
crosslinked by BMOE. MTSEA-fluorescein also leads to the complete current recovery (panel 
C). The difference with the MTSEA-biotin is that the saturation is reached after a longer time 
(800 s). Increasing MTSET incubation time leads to the recovery of 50 % of the current (panel 
D). The small size of this MTS might explain its difficulty to find and interact with a residue that 
is located in a large vestibule. The MTS-TBAE is not able to prevent the BMOE block as shown 
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by the straight line connecting the points (panel E). It indicates that there is no current recovery 
after MTS-TBAE suggesting an absence of binding to Y426C. 
 
Figure 32 Kinetics of accessibility of MTS to G430C. A, MTSEA-biotin at 10 M (n=10). B, MTSEA-biotinCAP at 10 M 
(n=9). C, MTS-PTrEA at 10 M (n= 9) and 100 M (n=4), in black and red, respectively. D, MTSEA-fluorescein at 100 M 
(n=17). E, MTSET at 1, 5 and 10 M, black circle (n=3), black square (n=11), and red (n=4), respectively. F, MTS-TBAE at 10 
M (n=10). INa+ are normalized on the maximum INa+ that is the condition without MTS and without BMOE. Symbols are mean ± 
SEM. 
The panels of Figure 32 represent the current recovery from the BMOE block of G430C after 
increasing MTS incubation times. In presence of MTSEA-biotin, MTSEA-biotinCap, as well as 
MTS-PTrEA, the current recovery is complete after 300 s (panels A to C). Incubation into 
MTSEA-fluorescein allows the recovery of 60 % of the current. 40% of the channels are still 
available for a block by BMOE after 1200 s. (panel D). 5 and 10 M of MTSET lead to the 
complete current recovery after 300 s, whereas 1 M recovers 50 % of the current from the 
BMOE block (panel E). MTS-TBAE leaves 20 % of current unrecovered (panel F). 
Second order constants are then calculated (for details, refer at the section: Labeling with MTS 
reagents). k2 values are similar for Y426C and G430C mutants ranging from ~1000 to ~7300   
[M
-1
*s
-1
] and thus supporting a free access to both residues. The k2 of MTSEA-fluorescein is 
smaller ~60 [M
-1
*s
-1
], indicating that the largest MTS has more difficulties to reach C426 and 
C430. However, looking more into details the Figure 31 and Figure 32 shows that neither 
MTSET nor MTS-TBAE is able to completely recover the current from the BMOE block of 
C426. Indeed, MTSET leads to a 50 % current recovery and MTS-TBAE 25 %. 
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Figure 33 Association rate constants (k2) of MTS for Y426C and G430C. A, Mean values for MTSEA-biotin, -PTrEA, -
fluorescein, MTSET and MTS-TBAE are 938 ± 212 (n=14), 1193 ± 463 (n=16), 61 ± 16 (n=6), 1497 ± 463 (n=6) and 4937 ± 
1864 (n=5) [M-1*s-1], respectively. B, Mean values for MTSEA-biotin, -biotinCap, -PTrEA, -fluorescein, MTSET and MTS-
TBAE are 2516 ± 1174 (n=10), 4694 ± 625 (n=9), 2033 ± 475 (n=13), 66 ± 15 (n=17), 7066 ± 1617 (n=18) and 7344 ± 1387 
(n=10) [M-1*s-1], respectively. Results are mean ± SE. 
These competitive experiments for the binding of MTS to Y426C and G430C indicate that the 
extracellular vestibule can accommodate MTS-reagents as bulky as the MTSEA-fluorescein. This 
binding prevents the BMOE current block without interfering with the Na
+
 flux. The association 
rate constants of the MTS to Y426C and G430C are equivalent and do not support a correlation 
between the MTS-shape and the localization of the residue. In most cases, this binding modifies 
the pH dependency of the activation leading to a channel that opens at less acidic pH. The pH 
dependency of the inactivation is also changed but in a less extent. 
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2.3. Biochemical evidence of methanethiosulfonate reagents binding 
These observations support that large ligands are able to coordinate C426 or C430 
residues into the vestibule. This is further supported by biochemical experiments using a pull-
down assay of MTSEA-biotin-modified ASIC on streptavidin beads. 
 
Figure 34 SDS-PAGE and western blot analysis of the streptavidin-bound fractions from NHS-SS-biotin or MTSEA-biotin 
labeled hASIC1a wt and mutants oocytes. n=40 oocytes/condition (2 batches), ni = non-injected oocytes. n=5 independent 
experiments. Anti-His and anti-actin antibodies are diluted 1/1000 before use. 
 
 
Figure 35 Quantification of the pull-down with MTSEA-biotin. The MTSEA-biotin labeled proteins are expressed in function of 
the surface expressed channels (MTSEA-biotin/NHS-SS-biotin). Then, to compare binding efficacy between mutants, we 
normalize regarding to G430C binding signal plotted as equal to 1. n=5 (n=2 for G433C). Unpaired Student T-test: * stands for P 
= 0.456, ns for P = 0.1026 and **** for P = 0.0001. Results are mean ± SD. 
We compare the binding of MTSEA-biotin on residue V74C, Y426C, G430C or G433C to the 
wt. MTSEA-biotin binds most efficiently to G430C, with almost the same signal for cell surface 
expressed channels and MTSEA-biotin labeled channels. Therefore, we use it for normalization. 
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Next, we catch significantly more V74C (20%) than the wt. Regarding Y426C, there is only a 
tendency but the absence of significance is likely due to the high variability between experiments. 
Functionally, MTSEA-biotin is able to recover 100% of the Y426C BMOE block (Figure 31). 
However, the pull-down assay shows that only ~30% of Y426C channels expressed at the cell 
surface are caught by the streptavidin beads. There are two possibilities to explain this value; 
first, not all the channels are modified. And second, the streptavidin is less efficient to interact 
with MTSEA-biotin-modified Y426C than with MTSEA-biotin-modified G430C. Given that the 
MTSEA-biotin recovers 100% of the Y426C BMOE inhibition, I would support the second 
hypothesis. 
2.4. Amiloride block of MTSEA-biotin-modified channels 
Because MTS-reagents bind in the ECV without blocking the Na
+
 flux, we wonder if the 
pore blocker amiloride would still reach its binding site in the middle of the TM2 (S583, G537 
and G525 on ENaC). In our laboratory, we have observed that mutation of the corresponding 
glycine into alanine on hASIC1a (G440A) completely disrupts the inhibition (see Appendix, 
Amiloride dose-response curves). To assess whether the MTS impaired the access to G440, we 
have performed dose-response analyses of G430C mutant channels, pre-treated either with, 
MTSEA-biotin, MTS-TBAE, or MTSEA-fluorescein (Figure 36). 
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Figure 36 Amiloride dose-response curves. A, hASIC1a with or without MTSEA-biotin (1 mM, 5 min) in grey (n=4) and black 
(n=4), respectively. B, G430C treated with MTSEA-biotin (1 mM, 5 min) or MTSEA-biotin + BMOE are in dark (n=23) and light 
blue (n=6), respectively. C, G430C treated with MTS-TBAE (1 mM, 10 min) or MTS-TBAE + BMOE are in red (n=6) and brick 
(n=5), respectively. D, G430C treated with MTSEA-fluorescein (10 mM, 5 min) or MTSEA-fluorescein + BMOE are in light 
(n=6) and dark green (n=6), respectively. B-D, BMOE-treated oocytes are represented in black (2 mM, 5 min, n=12). Non-treated 
G430C expressing oocytes are depicted in purple (n=20). 
The presence of MTS does not impair the amiloride block. Indeed, the blocker is still able to 
reach its binding site in the transmembrane domain. Statistical analysis shows a significant 
difference between the amiloride affinity of the G430C mutant and the wt (IC50 of 59.07±10.99 
and 132.40±11.84 M, respectively, P<0.0001). These values support that the engineered 
cysteine 430 increases the affinity of the amiloride for ASIC. To assess the impact of MTS 
binding on the block efficacy, we compare untreated to MTS- and BMOE-treated oocytes. While 
unmodified channels are blocked, we only take notice of the MTS-modified channels being still 
functional. In this way, we point out that neither MTSEA-biotin (11.90±1.05 M), MTS-TBAE 
(15.97±2.36 M) nor MTSEA-fluorescein (41.45±6.69 M) decrease the amiloride affinity for 
G430C mutant channels. The sensitivity of G430C is even increased after modification with 
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MTSEA-biotin, MTS-TBAE and MTSEA-fluorescein (P=0.0011, P<0.0001 and P=0.0011, 
respectively). 
In conclusion, these experiments indicate that thiol modifying reagents of different shape 
and size are able to modify cysteines introduces at positions Y426 and G430. The increased 
affinity of Y426C and G430C for Cd
2+
 indicates that these residues are accessible for a cation of 
similar size than Na
+
. This observation supports that both of these cysteines line the ion 
permeation pathway. The current block by BMOE shows that Y426C and G430C are accessible 
to a bifunctional crosslinker of 8 Å-length. The binding of BMOE induces an inhibition of the 
current, suggesting that the modified channel is blocked in a closed conformation. Accessibility 
experiments with MTS-reagents of different shape show the MTS-binding into the ECV. These 
bindings prevent neither the Na
+
 nor the amiloride to flow through the pore. The interaction of 
most tested-MTS with Y426C and G430C even increases the Ipeak and shifts the pH dependences 
of activation and inactivation towards more alkaline pH, and leads to a partial desensitization. 
Furthermore, MTS-reagents increase the affinity of G430C channels for the pore blocker 
amiloride. 
3. Contributions 
I have generated the ASIC constructs, as well as I have transcript and expressed them into 
Xenopus laevis oocytes. I have done the whole biochemistry experiments and the 
electrophysiological analyses with the help of Ivan Gautschi. I have made the size exclusion 
chromatography and the blue native gels. Miguel van Bemmelen has done the experiments with 
CHO cells. Concerning the bioinformatics section, Dr. Simon Bernèche and Dr. Justyna 
Iwaszkiewicz (Molecular Modeling Group, Swiss Institute of Bioinformatics, Lausanne) have 
provided us with the trimeric structure of cASIC1 and done the MTS docking. 
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ENaC 
The side project focuses on the description of a novel Ser243Pro mutation in the αENaC 
subunit associated with a transient AR-PHA1. 
At birth, a premature boy (32 weeks of gestation) was hypotonic and had feeding problems. 16 
days after birth, he suffered from severe hyponatremia, hyperkalemia as well as mild metabolic 
acidosis, and both his plasma renin activity and his aldosterone level were high. Moreover, his 
urinary ratio Na
+
/K
+
 was four-fold too high. The boy did not present any respiratory distress nor 
any excess of Cl- in the sweat. Thanks to NaCl supplementation and cation-exchange resins, the 
patient improved (normal levels of Na
+
 in the serum and normal Na
+
 excretion) and the treatment 
stopped at 6 months of age. Altogether these symptoms supported a severe salt-losing syndrome 
and suggested a pseudohypoaldosteronism of type 1 (PHA1). The symptoms being restricted to 
the kidneys, clinicians opted for an AD-PHA1 and sequenced the mineralocorticoid receptor 
(MR) gene. The absence of mutation made them investigate the trail of ENaC genes and the AR-
PHA1 even if the symptoms were not multi-systemics. Thus they discovered a missense mutation 
in the in the ENaC subunit leading to the replacement of the Serine 243 by a Proline. 
We have performed the characterization of Ser243Pro channel function, in vitro, by 
expressing it in Xenopus laevis oocytes, the results are reported in the paper named: “A 
homozigous missense mutation in SCNN1A is responsible for a transient neonatal form of 
pseudohypoaldosteronism type 1” (Appendix, A homozygous missense mutations in SCNN1A is 
responsible for a transient neonatal form of pseudohypoaldosteronism type 1). 
Traces of ENaC-mediated Na
+
 current (INa+) are obtained by rapidly changing the perfusion 
solution from a Na
+
-depleted to a 120 mM Na
+
 containing solution. This leads to a INa+ 
characterized by a large peak (Ipeak) followed by a relaxation and then a steady state current (Iss). 
The relaxation is a physiological inhibitory response of the channel to extracellular Na
+
 ions, 
known as self-inhibition (for details, see ENaC Regulation). Qualitatively, both wt and mutant 
channel display similar INa+. However the quantity is different; currents are decreased in the 
S243P ENaC by 30 % compared to wt channels (Figure 37, A and B) and an impaired cell 
surface expression does not account for this lower activity (Figure 38). 
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Figure 37 ENaC mediated Na+ currents in oocytes expressing ENaC wild type (WT) and ENaC S243P mutant. A and B. 
Representative recordings of amiloride-sensitive Na+ current in oocytes expressing ENaC wild type (WT αβγ) and ENaC 
αS243Pβγ mutant. 
 
Figure 38 Surface expression of ENaC wild type (WT) and αS243P mutant. A. Western blot using anti-α ENaC and anti-actin 
antibodies of the unbound fraction to streptavidin beads (non biotinylated fraction) of total proteins from oocytes expressing 
ENaC wild type or the αS243P mutant. B. Similar Western blot of the biotinylated fraction of total proteins bound to streptavidin 
beads representing the surface expression of αENaC wild type and mutant. 
In the introduction, I mentioned that the Na
+
 ion regulated ENaC function. Thus, we challenged 
the channel with different concentration of extracellular Na
+
. We compare currents of oocytes 
incubated either in a low (10 mM) or in a high Na
+
 medium (85 mM). ENaC being constitutively 
open, both extracellular and intracellular contents of Na
+
 will be the same. In response to an 
increase in intracellular Na
+
 load, INa+ decreases in order to prevent an excessive accumulation of 
Na
+
 that would be toxic for the cell. It appears that the response of S243Pis exacerbated 
compared to the wt channels with an 80 % stronger diminution of the Iss (Figure 39, C and D). 
This supports an impaired “feedback inhibition”. 
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Figure 39 ENaC mediated Na+ currents in oocytes expressing ENaC wild type (WT) and ENaC S243P mutant. C. Absolute 
amiloride-sensitive steady state Na+ currents measured in oocytes incubated for 24 hours (see methods section of the article in the 
Appendix) in a low Na+ containing solution (filled bars, n=12 experiments) and in a high Na+ solution (open bars, n=8 
experiments). Oocytes expressed either αβγ wild type or αS243Pβγ mutant. ** denotes P<0.01, *** denotes P<0.001. D. Relative 
changes in the ENaC mediated amiloride-sensitive current in oocytes expressing the αS243Pβγ mutant relative those expressing 
ENaC  WT, after incubation in a low Na+ containing solution (filled bars) and in a high Na+ solution (open bars). *** denotes 
P<0.001. 
A second mechanism involving the Na
+
 and known to modify ENaC activity is the “self-
inhibition”. To measure it, we calculate the ratios Iss/Ipeak of wt and mutant channels. We observe 
that it is apparently slightly stronger for the S243PFigure 40). 
 
Figure 40 ENaC self-inhibition of the wild type (WT) channel and the S243P mutant. Channel self-inhibition was defined as the 
ratio of the steady-state current (Iss) measured after 20 seconds over the peak current (Ipeak) (see Fig. 2A and 2B). Filled and 
open bars denote respectively low and high Na+ incubation conditions. Iss/Ipeak ratio was for the S243P and the WT 0.57 ± 
0.04 and 0.70 ± 0.03 respectively (P<0.05, Student’s T-test, n=12), and 0.51 ± 0.04 versus 0.65 ± 0.04 (P<0.01, Student’s T-test, 
n=8). 
The parents being heterozygotes, we compared the INa+ of , with S243P 
and S243P channels. We observed that the magnitude of the S243P current was 
intermediate (40 % decrease) to that of the wt and the mutant channels. The parents being 
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heterozygotes and asymptomatic, this suggests that a reduction of 40 % is tolerated and without 
any consequence for the maintenance of Na
+
 homeostasis.  
Finally, we wondered if the decreased INa+ could be due to an impaired regulation by serine 
proteases. To assess it, we applied trypsin externally and measured the change in INa+. For both 
wt and mutant channels, independently of the low or high Na
+
 load, the trypsin increased by two-
fold the currents, indicating that this mechanism of regulation was retained. 
To summarize our results, the mechanisms of regulation implying Na
+
 are impaired in this 
premature boy; namely, the “feedback inhibition” and the “Na+ self-inhibition”, leading to 
decreased ENaC activity and thus a severe salt-losing syndrome. Neither the expression of the 
channel nor its regulation by serine proteases is affected. Interestingly his brother, born at term 
and carrying the same mutation did not lose salt. This could be explained thanks to studies on 
newborn rabbits. Indeed, rabbits being born with immature kidneys they are representative for 
human kidneys of preterm babies. The immature kidneys do not have any significant Na
+
 
transport and no conducting ENaC channels (250,251). It is known that not only ENaC reabsorbs 
Na
+
, but also other transporters located upstream; the Na
+
,K
+
,Cl
-
 co-transporter (NKCC2) and the 
thiazide-sensitive NaCl transporter (NCC). Salt-losing diseases distinct from PHA1 involve these 
transporters, namely the Barter and the Gitelman syndromes, respectively (67). We can 
hypothesize that NCC and/or NKCC2 are immature in the preterm kidney, leading to a too 
elevated Na
+
 concentration in the distal part of the nephron where ENaC is expressed. 
1. Contributions 
For this project, I have created the S243P ENaC mutant using site-directed mutagenesis. 
I have done the in vitro transcription of ,  and  ENaC cDNA, injected them into Xenopus 
laevis oocytes and performed all the electrophysiological, as well as the biochemical analyses. 
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Discussion/Conclusion 
ASIC 
1. Stoichiometry 
We have demonstrated that the crosslinking of cysteines located in the C-terminal 
domain, the first transmembrane domain, and the extracellular vestibule of ASIC1a allows the 
covalent stabilization of ASIC1a subunit interactions and the subsequent identification of four 
distinct ASIC1a oligomeric states. These complexes weigh ~75, ~160, ~224 and ~304 kDa as 
determined by SDS-PAGE under reducing conditions and correspond to multiples of one ASIC1a 
oligomer (~75 kDa). 
Independent from the ASIC1a construct used (native or engineered cysteines), the expression cell 
system (Xenopus laevis oocytes or CHO cells) and the crosslinker (NaTT, BMOE or 
formaldehyde), the estimated molecular weight of these complexes was highly reproducible. 
Moreover, optimizing the experimental conditions using an increased number of accessible 
cysteines or the amino-reactive crosslinker formaldehyde, led to the identification of the 
predominant ASIC1a oligomer expressed at the cell surface, which weighed ~310 kDa and 
corresponded to the expected mass of a homotetrameric ASIC1a channel. In the sections below, I 
present evidence that supports our theory that ASIC1a has indeed a tetrameric assembly and that 
the tetrameric structure we identify is not just a result of the crosslinking to a neighboring 
protein. 
1.1. Crosslinked oligomers are homomultimers of ASIC1a subunits 
Several observations from this research indicate that crosslinking leads to the stabilization 
of homomultimers of ASIC1a subunits rather than between two ASIC1a channels. 
- The differences in mass between the four identified stabilized complexes correspond to 
the size of one subunit. 
- The stabilization of the high molecular weight complexes depends upon the interaction of 
G433C with native cysteines of the TM1 (C59 and C61). 
- The length of the BMOE ranges from 6 to 11 Å and given that G430C and G433C 
residues are located in the TM2, it is very unlikely that they form inter-channel 
crosslinking. 
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- The calculated masses of the four stabilized complexes were comparable from both 
solubilized and membrane bound ASIC1a, with clusters of channels unlikely to form from 
the solubilized form. 
Thus, under our experimental conditions, we conclude that crosslinking only occurs between 
cysteines within the same homomultimeric channel complex expressed at the cell surface. 
1.2. Stabilization of a predominant ASIC1a complex at the cell surface 
We have shown that cysteines in the TM1, as well as in the C-terminal, are important for 
the stabilization of high molecular weight complexes. Using an ASIC1a channel with its native 
TM1 and C-terminal cysteines along with an engineered cysteine, increases the possibility of 
BMOE to stabilize a high molecular weight complex, allowing the stabilization of the 
predominantly homotetrameric complex observed for ASIC1a. The stabilization of the 
homotetrameric ASIC1a is further confirmed by the use of the formaldehyde. With both 
crosslinkers, the amount of tetrameric complexes identified by SDS-PAGE, increases while the 
quantity of smaller molecular weight complexes decreases, i.e. monomers, dimers and trimers. 
1.3. The homotetramer and the literature 
1.3.1. Crosslinking studies 
Our results, which show the stabilization of a predominantly homotetrameric ASIC1a 
complex are in accordance with two previously published crosslinking studies. Zha et al., showed 
that the formation of a disulfide-bond with the oxidizing agent H2O2 and the crosslinking with 
sulfo-EGS allowed the stabilization of ASIC1a complexes expressed at the cell surface. By SDS-
PAGE, they observed a migration pattern composed of monomers, dimers, trimers and higher-
order ASIC1a oligomers that they interpreted as inter-channel complexes (233). Their identified 
oligomers migrated at sizes equivalent to ours, yet we have excluded the hypothesis of inter-
channel crosslinking. Supporting the possibility of a four-subunit stoichiometry for ASIC1a, 
Coscoy et al., identified a tetrameric stoichiometry for another member of the ENaC/Deg family; 
the FMRFamide Na
+
 channel (FaNaCh). Using photo-inducible and amino-reactive crosslinkers 
they obtained a similar pattern of migration on SDS-PAGE gels with four distinct oligomeric 
states corresponding to monomeric (74-82 kDa), dimeric (151-164 kDa), trimeric (205-230 kDa) 
and tetrameric forms (305-327 kDa) (221). 
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An additional study into ASIC1, based on the use of double cysteine mutants, demonstrated the 
presence of a disulfide bond between Y426C and G430C residues of adjacent subunits (252). On 
non-reducing SDS-PAGE, these disulfide bonds led to the stabilization of one single high-order 
molecular weight band of 190 kDa, which was  reported as being a homotrimer based on the 
monomer size of ~60 kDa (252). This is different from the other crosslinking studies presented 
above, which revealed the presence of distinct oligomers, i.e. four different complexes (221) 
(233), In our experimental conditions, using single cysteine mutants and thiol reactive 
crosslinkers, we were unable to stabilize one single oligomer. This incomplete crosslinking could 
be perceived as a limitation of the technique, but on the other hand, it did enable us to count the 
number of subunits and estimate the molecular weight separating each complex. 
1.3.2. Other biochemical and functional studies 
In addition to the above described crosslinking studies, other methods have been 
employed to elucidate the stoichiometry of other members of the ENaC/Deg ion channels family. 
For ENaC, for example, methods have included the use of concatemers, the channels affinity for 
pore blockers, mutant constructs or biochemistry and most of these studies have supported the 
tetrameric oligomerization of ENaC made of 2, 1 and 1subunits (220,222,223,227). 
1.3.3. Crystal structures 
The crystal structures of the C-terminal truncated chicken ASIC1 (cASIC1) revealed a 
trimeric organization of the channel (201,203,228,234). These structures challenge previous 
studies, as well as our own, which support a tetrameric stoichiometry of ENaC/Deg members. 
These discrepancies could be due to a number of structural aspects of these crystal structures. 
First of all, the construct used for crystallization was C-terminal truncated. As demonstrated in 
our study, as well as in the report by Zha et al. (233), cysteines found in this C-terminal region 
are crucial for subunit-subunit interactions and aid to prevent the dissociation of high molecular 
weight oligomers. Moreover, there is no distinction between cytosolic and cell surface expressed 
proteins with the crystallized cASIC1. Therefore, it would have been difficult to separate the 
functional from non-functional channels, the latter of which might have been incompletely 
assembled. For this reason, we stabilized and purified exclusively the cell surface functional full-
length ASIC1a channels. 
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1.3.4. Alternative approaches 
We have used alternative approaches to investigate the molecular weight of non-
denatured hASIC1a complexes. Such an example is size exclusion chromatography, which 
estimates the size of a native complex, by measuring the time required for a protein to go through 
a column filled of porous polymer beads. Smaller proteins will have a longer path length and a 
subsequent longer retention time. This technique is generally used for the purification of a high 
volume of protein such as those required for structural studies; for instance, the purification of the 
beta-adrenergic receptor prior to its crystallization (253). The molecular weight of the beta-
adrenergic receptor obtained by size exclusion chromatography was 120 kDa, whereas its 
theoretical predicted size was 46 kDa (253). The difference is attributed to the detergent, which 
can have a variable impact on molecular weight determination depending both upon the type of 
detergent used and the membrane protein. Thus, it is difficult to differentiate between complexes 
made of three or four subunits using this technique. 
Another additional approach is the use of blue native gels, which allows the separation of 
native proteins with blue native polyacrylamide gel electrophoresis. Coomassie blue is a 
negatively charged dye that binds to protein, and therefore, the proteins electrophoretic mobility 
is determined both by the interaction with the dye and by the size and the shape of the protein 
(254). We have used this technique to investigate the oligomerization of the chicken ASIC1 
channel construct used for the second cASIC1 crystal structure (234). For our research, the 
minimal functional construct (mfc) was kindly provided by Eric Gouaux (Vollum Institute, 
Oregon Health and Science University), which is a truncated chicken ASIC1 (cASIC1Δmfc) 
fused to a His8_sGFP with a Thrombin cleavage site present in the sequence of the linker. We 
have used this blue native technique for two main reasons. Firstly, the channel stays under its 
native state. Secondly, proteins are detected because of the Coomassie blue, overcoming the 
unavailability of a chicken ASIC1 antibody. However, as this technique requires a higher amount 
of protein than SDS-PAGE, we decided to switch from Xenopus laevis oocytes to CHO cells, 
where we could obtain these higher volumes. Expressed in CHO cells, H8_GFP_cASIC1mfc 
produces functional ASIC1 channels. After purification on Ni
2+
-beads the ASIC1 complex was 
treated with or without thrombin and run on a blue native gel. The cleaved cASIC1mfc complex 
migrated at a molecular weight higher than 240 kDa (n=1), but it was difficult to distinguish a 
trimer from a tetramer, with insufficient resolution between bands corresponding to 242 and 480 
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kDa. Thus, we turned to another protocol, the Oligomerization Characterization by Addition of 
Mass (OCAM). The principle of this is to expose the native H8_GFP_TCS_cASIC1mfc 
complex to thrombin, and depending of the time of exposure, different cASIC1 complexes would 
be observed on the gel, i.e. those having none, one, two, three or more added His8_sGFP. 
 
Figure 41 Scheme of the OCAM. 
As cleaved His8_sGFP has a fixed mass of 27 kDa, the cleaved complexes would have, 
depending on digestion time, different weights, which should easily be separable on a gel. In 
theory, the number of subunits constituting the channel would be deducible and thus the number 
of homologous subunits that constitutes the ASIC1 channel complex could be directly 
determined. In practice, however, we could not obtain the required resolution to distinguish 
between cleaved complexes. This could be due to the degradation of the protein leading to 
smeary bands, or to the insufficient quality of our home made gradient gels. Either way, we 
stopped our OCAM investigations to pursue more reliable techniques. 
2. Functional characterization of the extracellular vestibule size 
To functionally evaluate the size of the ECV, we tested the accessibility to specific 
residues mutated in cysteines (V74C, Y426C and G430C) for ligands of different shapes and 
sizes. The binding of a bulky ligand to one of these cysteines would suggest a large extracellular 
vestibule, whereas an absence of binding would indicate that there is not enough space to 
accommodate such a reagent. Starting with Cd
2+
 and BMOE, we then investigated the binding of 
methanethiosulfonate reagents into the vestibule. Both Cd
2+
 and BMOE have an inhibitory effect 
on ASIC1a mutants, whereas MTS activates them. Detailed results regarding these 
aformentioned ligands are discussed below. 
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2.1. Accessibility for Cd2+ 
The small ligand Cd
2+
 has a similar radius to the permeate Na
+
 ion, and is therefore a 
useful indicator to study ASIC1a permeation. Cd
2+
 can be coordinated by sulfhydryl groups, as 
well as negative residues, such as glutamate or aspartate. V74C channels are irreversibly blocked 
by the Cd
2+
, whereas Y426C and G430C channels show an increased sensitivity to Cd
2+
. In the 
three cases, our results support that the Cd
2+
 is able to access and modify the cysteine residues.  
Baconguis et al., have shown that V74C residues move between two conformational states, from 
7 Å at an acidic pH, to 12 Å at pH 7.25 (201). In our experiments, we have shown that a disulfide 
bond between two V74C residues makes the V74C mutant channel non-functional. This loss of 
function supports the requirement of an increased distance between two V74C residues for 
opening. Indeed, the full activity of V74C channel is restored upon extracellular reducing 
treatment with DTT. Therefore, a dynamic constraint on V74C channels (either with the 
coordination of Cd
2+
 or with a disulfide bond) might interfere with the activity of the channel and 
thus maintain it in a closed conformation. 
In collaboration with the Swiss Institute of Bioinformatics (SIB, Lausanne), we have simulated 
the docking of Cd
2+
 in the extracellular vestibule of the V74C channel. As depicted in Figure 42, 
distances from the thiol group to Cd
2+
 are about 3.5 Å. The analysis of high-resolution PDB files 
with Cd
2+
 coordination has shown that distances range from 2 to 2.6 Å between the sulfhydryl 
atom and the Cd
2+
. Taking into account that the resolution of the crystal structure is about 3 Å, 
the coordinated distances are plausible. 
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Figure 42 Cd2+ docking on V74C. Side chains of the V74C residues are depicted with the sticks and balls, ribbons are in yellow. 
We can rule out that the increased Cd
2+ 
affinity to Y426C and G430C is due to coordination by 
two Y426C or two G430C as pairing residues 10 and 15 Å apart with Cd
2+
 is impossible. Thus, 
the observed increased affinity could be attributed to coordination between the engineered 
cysteine and a nearby negative residue. D434 and E427 being at 6 and 4.7 Å from G430C, 
respectively, are the closest putative candidates. It is difficult to explain the Cd
2+
 coordination on 
the desensitized crystal structure. Indeed, Y426 and G430 are too far apart and the distance does 
not decrease in the open state. Indeed, the two open state crystal structures of PcTx1-cASIC1 
(Baconguis (pH5.5) and Dawson) pointed out that the distance between the side chains of V74 
(V75 in the cASIC1) increases from 7 to ~11 Å, as well as the increase in distances observed 
between Y426C or G430C residues (201,203). 
In conclusion, Cd
2+ 
coordination requires a channel where candidate residues of distinct subunits 
(Y426C, E427, G430C and D434) become closer to each other. This might be possible by adding 
a fourth subunit. 
2.2. Accessibility for BMOE 
As previously shown (Crosslinking experiments with bismaleimidoethane), BMOE 
irreversibly decreases the activity of both the Y426C and G430C mutants but not of the V74C 
mutant. According to the distributor, BMOE has an 8 Å spacer length (Thermo scientific 
#22323). However, this can vary substantially, as has been demonstrated by a method based on 
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stochastic dynamic simulations, which gives new quantitative data on widely used crosslinkers. 
Briefly, this technique simulates the effect of a solvent on the conformation of molecules, and 
indicates that  BMOE is able to crosslink residues separated by 6.3 to 10.5 Å (255). Desensitized 
structure analysis shows that there are 15 and 10 Å between two C426 and two C430 residues, 
respectively. As the resolution of this crystal is about 3 Å, a BMOE crosslinking between C426 
(or C430) residues is conceivable. In the open-state structure of Baconguis, the measured 
distances between two Y426C or two G430C increases to ~18 and 12-15 Å. Thus, it is possible 
that BMOE prevents the enlargement of the extracellular vestibule. The lack of effect that BMOE 
has on V74C could be explained by the pre-existing disulfide bond. 
2.3. Mechanism of block by crosslinking reagents 
Together with the biochemical analysis (SDS-PAGE analysis of the crosslinked 
complexes), these functional (electrophysiological) experiments indicate that V74C, Y426C and 
G430C residues are accessible to an extracellularly-applied thiol ligand or reagent and that V74C 
forms spontaneous disulfide bonds in the extracellular vestibule of the functional channel. Cd
2+
 
reacts with a cysteine and a negative amino acid, while BMOE reacts with two cysteines, both of 
which maintains the connected residues in a constrained distance impairing either the opening of 
the channel or the flux of ions. 
2.4. Accessibility for methanethiosulfonate reagents 
We do not know if BMOE blocks the ASIC1 channel by maintaining it in an inactive 
conformation or if because the size of the reagent physically prevents ions from passing. To test 
the possibility that ligand binding at Y426C and G430C inhibits ASIC1a by interfering with the 
flux, we used methanethiosulfonate reagents (MTS) such as MTSET, MTS-PTrEA, MTS-TBAE 
or MTSEA coupled to biotin or fluorescein. Given that MTS reagents have one reactive group, 
they will not constrain the channel in a non-conducting conformation. However, due to their size 
and shape, the reagents would still prevent ions to go through the channel. 
We did not observed any block in the activity of the cysteine mutant channels, but there were 
several indications that MTS does bind the ECV: 
- An increase in the peak currents was observed after incubation with MTS-reagents. 
- There was a shift in the pH activation curves towards more alkaline values. 
- MTS was responsible for the partial desensitization of Y426C and G430C. 
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- The observed competitive interaction of MTS with Cd
2+
 (and BMOE) for Y426C and 
G430C supports the specificity of the MTS-binding. 
- Using a pull-down assay with streptavidin beads, we isolated MTSEA-biotin-labeled 
Y426C and G430C channels.  
Because the ion flux is not decreased or inhibited by MTS, it indicates that Cd
2+
 and BMOE 
interfere with the conformational rearrangement occurring at channel opening as opposed to 
interference of the ion flux. 
2.4.1. Shift in the pH0.5 of activation 
Upon MTS binding we observed a shift in the pH activation curve leading to a channel 
that opens at more alkaline value. Each of the above mentioned MTS have different 
characteristics, such as size and shape. The extent of the shift in the pH activation curves varies 
according to the reagent. The size order of the reagents is as follows: MTSEA-fluorescein < 
MTS-TBAE < MTSEA-biotin < MTSET < MTS-PTrEA, but there was no correlation between 
the size and the shift for either of the mutants. 
A study investigating pore opening mechanisms on Y426C and G430C residues of mouse ASIC1 
(252) also demonstrated that G430C was accessible to a positively charged MTS, such as 
MTSET, and that its binding induced a shift in the pH of activation curve, which is in line with 
our work. Moreover in this study carried out by Tolino et al., MTSET promoted the sustained 
opening of the channel when perfused at pH 7.0. They also showed the induction of MTSET-
dependent sustained currents for Y426C mutant channels, but we were never able to observe this 
in our study. We did observe a sustained current following the Ipeak when we opened the channel 
by switching from pH 7.8 to 5.5, but, not with pH 7.0 solution supplemented with MTSET as 
they did. Tolino et al. argue that the opening of the modified channel occurs via a steric repulsion 
between the G430C-MTS and the side chain of Y426 initiating thus a conformational 
rearrangement of the TM2 and pore gating (252). 
Another report by Li et al. described the accessibility of TM2 residues in the lamprey ASIC1 
(256). MTSEA was perfused either from the extracellular or the intracellular side, in both the 
open and the closed conformations. Accessibility of residues varies according to the state and the 
perfusion site enables them to show the movement of the TM2 from an open to a closed state. 
They demonstrated that in both conformations there was a narrowing of the pore. In the open 
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conformation, the narrowing is located midway of the TM2, whereas in the closed state it is at the 
external end of the pore. In accordance with our results, the G430C residue was accessible 
independently of the channel state (256). 
In addition, the accessibility of Y426C for MTSET under both closed and desensitized states has 
also been confirmed (257). Similarly, we have shown a shift in the pH activation curve of Y426C 
in presence of MTSET supporting its binding. 
Finally, investigations into the degenerin site of ASIC2 (G430 corresponding to G433 in the 
hASIC1a) have highlighted the accessibility of this residue for MTS reagents in the open state 
and its subsequent non-inactivating current. MTSET, as well as the bulky MTS-4-fluorescein 
reaches the middle of the TM2. These authors suggest that the modified residue would sterically 
hinder the rotation of the TM required to close the channel (258). We have tried, unsuccessfully, 
to modify hASIC1a G433C with MTSET in both conformational states. The reason may arise 
from the difference in ASIC subtype. Indeed, we are currently working on the ASIC1a, whereas 
they have used the ASIC2 subtype. 
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2.5. Docking of methanethiosulfonate reagents 
To visualize the binding of MTS-reagents to C426 or C430 residues, we have performed 
docking analyses in collaboration with the SIB using AutoDock Vina (259) and SwissDock 
(260). We added two constraints: the reactive part of the MTS has to point towards the free SH 
group of the cysteine and a disulfide bond ranging from 2.5 and 3.5 Å. We only included results 
with a reasonable distance between each reactive part (the SH of the cysteine and the reactive 
part of the MTS). With these parameters, Justyna Iwaskievicz (SIB) docked each MTS into the 
extracellular vestibule of both Y426C and G430C mutants. Below are the closest distances 
obtained between the reactive part of the MTS and the free cysteine. Given that docking distances 
of Y426C and G430C display similar results, illustrations and discussions presented below are on 
for the G430C mutant. 
 
 
 
 
Table 4 Distances between engineered cysteines and MTS-reagents. Distances are expressed in Å. 
The docking of MTSEA-biotin on the crystal structure is depicted in the Figure 43. The 
whole view of the channel highlights one of the putative entrances for MTS (red arrow) (228). To 
assess the size of these lateral fenestrations, we used the program ghecom (261), which takes 
advantage of a pocket detection algorithm covering the proteins with a 3D grid and indicating 
empty grid points defined as pocket if they satisfy a number of energetic and geometric 
conditions (261). This program indicated that the size of a lateral fenestration is about 7 to 10 Å. 
The sliced view below, illustrates that this compound fills the extracellular vestibule close to 
residue 430. Indeed, the MTSEA-biotin (blue) is located in the middle of the vestibule as a plug 
that hides the pore. 
 Y426C G430C 
MTSEA-Biotin 4.18 Å 3.93 Å 
MTSEA-BiotinCap 4.83 Å 3.74 Å 
MTS-PTrEA 3.89 Å 3.44 Å 
MTSET 4.30 Å 3.40 Å 
MTS-TBAE 3.87 Å 3.56 Å 
MTSEA-Fluorescein 4.99 Å 5.30 Å 
80 
 
 
Figure 43 Docking of MTSEA-biotin on the desensitized cASIC1 crystal structure. A, Whole view of cASIC1. B, Sliced view. 
The dotted arrow indicates where the channel is sliced. MTSEA-biotin is in blue, G430C in purple and lateral fenestrations are 
highlighted by the red arrows. 
Docking of MTSEA-biotinCap, MTS-PTrEA, MTSET and MTS-TBAE have shown that the 
extracellular vestibule can accommodate MTS of different shapes and sizes (Figure 44). In 
addition to the extracellular vestibule, the -biotinCap (in purple) also fills one of the lateral 
fenestration with its long tail (A). MTS-PTrEA and –TBAE are restricted to the vestibule, in 
orange (B) and red (D), respectively. The smallest reagent, MTSET, in blue, does not fill the 
whole vestibule (C). MTSEA-fluorescein is too large to pass through the fenestration and to be 
accommodated in the vestibule. 
We have compared the binding of MTSEA-biotin to Y426C at both alkaline and acidic pH and it 
appears to be unchanged. This means that even under a desensitized conformation MTSEA-biotin 
is able to go through the lateral fenestration and reach its binding site. 
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Figure 44 A-D, Clipped views of the MTSEA-biotinCap in pink, MTS-PTrEA in orange, MTSET in blue and MTS-TBAE in red, 
dock on the desensitized cASIC1 crystal structure. G430C is depicted in violet. 
In conclusion, these docking experiments illustrate that MTSEA-biotinCap, MTS-PTrEA, 
MTSET and MTS-TBAE can be accommodated by the ECV. Given that the MTS reagents fill 
the vestibule, it is difficult to conceive that this binding does not prevent the Na
+
 flux. 
2.6. Association rate constants 
As we have clear indications that MTS-reagents do bind the channel, we estimated the 
association rate constants of these MTS with Y426C and G430C. Specifically, we investigated 
the accessibility kinetics of MTS to the engineered cysteines of the ECV. Association rate 
constants range from ~1,000 to ~7,000 [M
-1
*s
-1
] independently of the mutant and without any 
significant difference between compounds, excluding the bulky MTSEA-fluorescein, which 
displays a lower constant (60 [M
-1
*s
-1
]). Two main factors can influence this value: The 
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ionization of the sulfhydryl side chain and the steric hindrance (i.e., how difficult it is for the 
MTS to physically approach and bind the sulfhydryl group). Under our experimental conditions 
the ionization of Y426C and G430C are not expected to change, so, the parameter modifying the 
constant is the steric hindrance. It indicates that the bulky MTSEA-fluorescein has more 
difficulties to bind to Y426C or G430C compared to the smaller MTS-reagents. This suggests 
that the vestibule can accommodate the MTSEA-fluorescein but that there are some steric 
hindrances that increase the time required for modifying the cysteine. 
Wagner et al. studied the GABA binding pocket for the MTSEA-biotin. They showed that a 
residue located at the mouth of the binding pocket presents a k2 of ~250,000 [M
-1
*s
-1
], whereas 
another one in the deepest part of the pocket has a slower k2 of ~120 [M
-1
*s
-1
] (262). The 
association rate constants that we have observed for the accessibility of MTS-reagents to Y426C 
and G430C are far from either of these extreme values. However, they are closer to the slower 
values (~120 [M
-1
*s
-1
]). This indicates that Y426C and G430C are localized in a somehow 
confined part of the channel, i.e. the extracellular vestibule. 
2.7. Amiloride block of MTS-bound channels 
MTS is docking onto Y426C or G430C, does not appear to perturb amiloride binding 
affinity. However, it is hardly to believe that an amiloride molecule of ~10 x 5 Å is able to weave 
past the MTS until its binding site located in the middle of the TM2 (G440). As we have been 
working with the desensitized cASIC1 crystal structure, we cannot rule out that the opening of 
the extracellular vestibule occurs during the activation of the channel, which would allow for the 
amiloride binding. To date, the conformation of ASIC1 during its natural open state is not known. 
Indeed, in the above-mentioned study by Baconguis and Dawson the open-state of ASIC1 is 
somewhat forced, by the binding of PcTx1, which may not be representative of the open 
conformation induced by protons. Moreover, PcTx1 binding leads either to a non-selective 10 Å 
pore at pH 7.25, or to a twisted pore as observed for the first non-functional N- and C-truncated 
crystal structure (201). Finally, the non-selective channel crystallized at pH 7.25 has almost fully 
lost its sensitivity for the amiloride. This absence of block further supports the fact that this open-
state is not representative of the open ASIC1 conformation. 
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2.8. Ion permeation pathway of the crystal structures 
Several vestibules and cavities are present along the 3-fold axis of symmetry of the 
extracellular loop within each of the four ASIC1 crystal structures. At the level of the TM 
domains, the pathway seems close off. However, the presence of cations in each of the two 
PcTx1-cASIC1 structures is supported by two observations: firstly, there is an anomalous density 
feature with a cation trapped in the central vestibule (203) and secondly, there is an ion-binding 
site at the extracellular end of the TM1, near a lateral fenestration (201). Despite this, however, 
none of the crystal structures present an electron density feature consistent with the presence of 
cations in the pore. This goes against observations for other ion channel structures, which clearly 
show permeant ions and their interaction with pore lining residues. Examples of this include the 
KcsA K
+
, the prokaryotic Cl
-
, the Ca
2+
 Orai, or the ligand-gated GLIC channels obtained from 
soaked crystals in solutions (263-266). 
The crystal structure models have been valuable for the interpretation of results obtained in the 
study of the biophysical properties of ASIC1, such as its activation and the desensitization. As 
mentioned before, Tolino et al., using double mutant analysis, have demonstrated that the tilting 
of the TM is necessary for ASIC opening (252). Furthermore, through accessibility screening of 
the TM domains, Li et al. have proposed that a narrowing in the external end of the pore is 
present in the closed state, whereas this narrowing moves further up the pore in the open 
conformation (256). Moreover, Adams et al. have further confirmed that the non-inactivation of 
deg site bulkier mutant was due to steric hindrance, which blocks the channel in an open 
conformation (258). None of these studies, however, are able to address the question of ASIC 
stoichiometry, or the structure-function analysis of the ECV, which requires a biochemical 
approach and cannot be studied using the crystal structure. 
3. Summary 
In our study, we have focused on the structure-function of the extracellular vestibule of 
ASIC, by investigating the accessibility of the residues Y426C and G430C. We have shown that 
both residues line the ion permeation pathway (Cd
2+
 experiments) and have identified that larger 
crosslinkers (BMOE) are able to connect two Y426C (or G430C). This has been confirmed 
biochemically, by the stabilization of high molecular weight complexes corresponding to 
tetramers, and functionally, by the inhibition of channel activity. In addition, competitive 
experiments using MTS-reagents and crosslinkers have supported the binding of MTS to Y426C 
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and G430C. These MTS-bindings do not prevent the Na
+
 flux or the amiloride block, which 
indicates that the ECV is able to accommodate large reagents without blocking the activity of the 
channel. 
Our biochemical approach using crosslinking analysis of hASIC1a supports a homotetrameric 
organization of the channel. Moreover, our study into the structure-function of the extracellular 
vestibule suggests that an enlargement in this cavity occurs to allow for amiloride binding despite 
the presence of bulky MTS, which fills the whole vestibule. The addition of a supplementary 
subunit might increase the size of the extracellular vestibule, as well as the entire permeation 
pathway. 
Previous studies into the stoichiometry of ENaC/Deg family members have employed either 
biochemical or electrophysiological techniques, but not a combination of the two, making our 
study innovative as it makes the link between the structure and function of ASIC1a channels. 
- The crosslinking approach we have used focuses on functional ASIC1a expressed at the 
cell surface. The stabilization of the G433C mutant does not block channel activity and 
we specifically separate cell surface ASIC from that expressed in the cytosol. 
- In the structure-function analysis of the extracellular vestibule, we have tested the 
accessibility of Y426C and G430C residues for MTS. Competitive interaction between 
MTS and BMOE allows us to distinguish MTS-labeled from unlabeled channels. Once 
labeled with MTS, Y426C and G430C are no longer blocked by BMOE. Thus we are 
certain that the recorded function represents the activity of MTS-modified channels. 
We have then tried to interpret our results in function of the crystal structures. It appears that 
these structures can explain neither the high molecular weight complexes supported by the 
crosslinking approach, nor the docking of MTSEA-fluorescein in the extracellular vestibule, nor 
that the amiloride block is not prevented by the binding of the large MTS into the vestibule. 
This study adds further evidence that the ion permeation pathway of this crystal channel might be 
constricted and suggests that: 
- subunits have to be closer in order to explain the crosslinking data 
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- the extracellular vestibule has to be larger to accommodate the MTS-reagents without 
interfering with the Na
+
 flux or amiloride block. 
The addition of a supplementary subunit might explain how the tetrameric complex stabilized at 
the cell surface and our data on the structure-function of the extracellular vestibule. 
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ENaC 
In our published case report, we have functionally characterized the mutation S243P 
discovered in the SCNN1A gene of a PHA1 patient. Our study demonstrated that S243 is involved 
in Na
+
 sensing, with both feedback inhibition and Na
+
 self-inhibition impaired in the S243P 
ENaC channel. This leads to a channel with an exacerbated response to a high Na
+
 load. 
1. Self-inhibition 
Several studies have aimed at localizing residues involved in self-inhibition. Vincent Bize 
demonstrated that both  and  subunits were required (complementary results of (267) and 
published in his thesis), with both  and  lacking self-inhibition, but not  or . 
Furthermore, Babini et al., cloned a new ENaC subunit from Xenopus leavis.  channels are 
functional but display a slower self-inhibition that . Using a chimeric  construct, they 
identified that the proximal part of the ECL controlled the speed of self-inhibition (268). 
Moreover, two specific histidines in the ECL of  and subunits (mouse H282 and H239 
corresponding to human H255 and H233) have been implicated, with the mutation of these 
sites leading to a potentiation of, and a suppression of self-inhibition, respectively (269). 
Localization of these residues on the homology model of ENaC, which is based on the first 
cASIC1 crystal structure, demonstrates that both histidines are exposed to the environment. 
Moreover, the residue S243, which once mutated into proline leads to PHA1, is in the proximity 
of H255 (Figure 45). Its replacement by a proline, a residue characterized by an increased 
conformational rigidity given by the cyclic structure of its side chain, might disrupt the structure 
of this entire region changing the orientation of the H255 side chain and impairing the self-
inhibition mechanism.  
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Figure 45 Extracellular loop of ENaC. Homology model of ENaC based on the first cASIC1 crystal structure. S243 (red) 
and H255 (green) are both located on the  subunit. H233 (green) is the corresponding H255 of the ENaC subunit. 
2. High Na+ load in the kidneys of a preterm neonate 
In the kidney of a baby born at term, the amount of Na
+
 reaching ENaC is controlled by 
other transporters located upstream of the channel. Salt-losing diseases such as the Barter or 
Gitelman syndromes have highlighted the importance of these transporters in Na
+
 handling; 
NKCC2 and NCC (67). In addition, Satlin & Palmer have demonstrated that there is no Na
+
 
transport in the CCD of immature rabbit kidneys (250,251). It has also been shown that the 
transition between foetal and neonatal life correlates with a strong reduction in urinary excreted 
Na
+
 (270).  Together, these reports could explain the elevated amount of Na
+
 to which ENaC is 
exposed to in the kidney of this preterm boy. As the S243P channel is hypersensitive to high 
Na
+ 
load, it responds in an exacerbated way by decreasing its Na
+
 current and thus Na
+
 
reabsorption. 
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Perspectives 
1. ASIC 
It is not be the first time that the use of different methodologies has led to the 
identification of various stoichiometries for the same channel. For example, the large-
conductance mechanosensitive channel MscL, has been identified as having a hexameric, a 
homopentameric and a homotetrameric organization depending on the methodology used (271-
274). The challenge is to find the most reliable technique in order to unveil the correct 
stoichiometry, of, in our case, the human ASIC1a channel. In my opinion, one of the best 
techniques to use would be to crystallize ASIC1a in its 2D form. Studies have been performed to 
compare the accuracy of the 3D versus the 2D crystal structures and as the native protein is 
embedded in a lipid bilayer, 2D crystals are likely to be more representative (275). 
To find an explanation for the discrepancy between our results (homotetramer) and the trimeric 
stoichiometry of the crystallized chicken ASIC1, it would be interesting to overexpress the 
human ASIC1a construct into Sf9 cells and then compare the oligomerization pattern of Sf9 with 
CHO and Xenopus laevis cells. Indeed, the difference in the lipid composition between insect and 
mammalian cells might account for a different oligomerization. 
We would like to investigate the physiological roles of ASIC channels. This could be done by 
screening compounds present in the nervous system and testing if they are able to activate the 
hASIC1a channel at a physiological pH as with MTS. Potential candidates would be amino acids, 
serotonin, histamine, acetylcholine, adenosine, or dopamine, to name a few. Alternatively, the 
knock-down of ASIC-like proteins in vivo, in Drosophila melanogaster for example, could also 
determine ASIC functions. Indeed, we have already started this project and using the GAL4/UAS 
system, we have generated ~30 complete knock-downs (276), among which, 9 gave a lethal 
phenotype. Limiting the expression of GAL4 to the nervous system leads to a similar phenotype 
for 6 out of 9 RNAi knock-downs, which share unexpanded wings and a cuticular sclerotization 
defect. This phenotype is characteristic by a dysfunction occurring at the time of eclosion and 
involving the neuropeptide Bursicon (277). Now the aim is to look deeper into this pathway in 
order to determine where these ASIC-like proteins are expressed and what physiological role they 
may have. 
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2. ENaC 
Given that self-inhibition is exacerbated in the S243P ENaC mutant channel, it would 
be of interest to test a molecule known to increase the open probability of the channel by 
specifically inhibiting an exacerbated self-inhibition, such as S3969, shown in the Figure 46 
(115). This would further confirm our data and maybe even be a useful treatment in case of new 
PHA1 linked to S243P. 
 
Figure 46 Structure of S3969 (N-(2-hydrosyethyl)-4-methyl-2-(4-methyl-1H-indol-3-ylthio)pentanamide. Modified from Lu et 
al., 2008 (115). 
Currently, we are working on a novel mutation of the SCNN1G gene discovered in a new PHA1 
patient. This mutation leads to the replacement of threonine 353 by a proline (T353P) on the  
subunit of ENaC. We have created this mutation and started to investigate its effect on ENaC 
function, in vitro, using Xenopus laevis oocytes. 
Our preliminary experiments confirm that ENaC loss of function correlates with PHA1 diagnosis. 
Protein expression analysis via SDS-PAGE shows a cleavage defect of the  complex, which 
could be responsible for this loss of function. More specifically the post-translational cleavage of 
the  subunit, normally present when ENaC is expressed at the cell surface is absent (n=2). 
Moreover, pull down experiments on total lysates, demonstrate that mutated  is co-purified with 
 and  subunits but it seems that the efficiency of the pull down is decreased with T353P (n=3). 
This would support an assembly defect of the T353P channel. These pull down experiments 
also show an absence of  cleavage in T353P channels and confirm the previously 
demonstrated impaired  cleavage. 
Bioinformatical analysis excludes the localization of the T353P mutation in a cleavage consensus 
sequence or near  or  cleavage sites. This indicates that there is not a direct effect of the 
mutation on the cleavability of ENaC. Structural analysis of T353P supports our preliminary 
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results, showing ENaC loss of function, as the substitution of a threonine for a proline is 
destructive in terms of structural channel stability. This amino acid has a particular 
conformational rigidity given by the cyclic structure of its side chain. Thus, adding a proline into 
a -helix or a -sheet would disturb the protein’s secondary structure. It is difficult to predict 
what exactly is happening in the patient, the loss of ENaC function could be due to a complete or 
partial folding defect or the degradation of the mutant channel. However, it is clear that there is a 
structural problem. Indeed, FoldX studies show that the stability of T353P is lowered by ~2.5 
kcal/mol compared to the wild-type channel (278). 
Homologous mutations in the  and  subunits do not lead to a similar phenotype. Phenotype 
conservation would have indicated that T353P is part of a conserved region important in the 
promotion of ENaC cleavage. In this case, it suggests that T353 is not part of a region directly 
involved in the ENaC cleavage. 
As preliminary experiments have been done on total lysates with a rat ENaC His-tagged 
construct co-expressed with human  and  subunits, we next have to construct the human ,  
and  His-tagged subunits and then repeat the pull-down experiments on the cell surface 
expressed pool of channels. The idea is to specifically look at the functional pool of ENaC 
involved in the transport of Na
+
, and to avoid a mixture of immature and mature channels. 
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Appendix 
1. Primer sequences 
 
Mutant Forward primer Reverse primer 
C59V gtgctgctggttgtatgcacggagcgtgt acacgctccgtgcatacaaccagcagcac 
C59V_C61S gtgctgctggttgtgtccacggagcctgt acaggctccgtggacacaaccagcagcac 
V74C ccactaccaccattgcaccaagctcgacg cgtcgagcttggtgcaatggtggtagtgg 
Y426C gagaccattgaacagaagaaagcctgtgagattgcagggct
cctg 
caggagccctgcaatctcacaggctttcttctgttcaatggtctc 
G430C ggcctatgagattgcatgtctcctgggtgacatcg cgatgtcacccaggagacatgcaatctcataggcc 
G433C gcagggctcctgtgtgacatcgggg ccccgatgtcacacaggagccctgc 
C466A ggagctatttgactacgcctacgaggtcattaagcacaagctg
gcccgacgaggaaaatg 
cattttcctcgtcgggccagcttgtgcttaatgacctcgtaggcgtagt
caaatagctcc 
C471A gctatttgactacgcctacgaggtcattaagcacaagctgtgc
cgacgaggaaaagcccagaaggag 
ctccttctgggcttttcctcgtcggcacagcttgtgcttaatgacctcgt
aggcgtagtcaaatagc 
C497A ggacgacgtcaaaagacacaacccggccgagagccttcg cgaaggctctcggccgggttgtgtcttttgacgtcgtcc 
C528Stop cacgttcgaggactttacctgatgagccccgcagg cctgcggggctcatcaggtaaagtcctcgaacgtg 
Supplemental Table 1.Sequences of the primers used for the PCR mutagenesis. 
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2. Percent Identity Matrix (Clustal Omega) 
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Abstract 
The chicken acid-sensing ion channel ASIC1 was crystallized as a homotrimer. 
Previous functional studies on the epithelial sodium channel ENaC, a close member of 
the same ion channel family, have however provided evidence for a tetrameric channel 
made of homologous subunits. The oligomeric state of the functional ASIC1 at the cell 
surface has not been specifically addressed so far. 
We have developed a crosslinking approach using the sulfhydryl crosslinker BMOE 
and engineered cysteines in the extracellular vestibule of the human ASIC1a channel 
pore to stabilize the functional multimeric complex expressed at the surface of Xenopus 
laevis oocytes or CHO cells. Under reducing conditions, we could identify by western blot 
four distinct oligomeric states that correspond by mass to multiples of a single ASIC1a 
subunit. We could show that these oligomeric states identified on SDS-gel are oligomers 
made of ASIC1a subunits. By optimizing the intersubunit crosslinking between cysteines 
in the extracellular vestibule, in the first transmembrane helix and in the C-terminus of 
ASIC1a subunits, we could isolate from the cell surface a major channel complex, which 
by mass corresponds to four ASIC1a subunits. Similar results were obtained with 
formaldehyde, a less specific amino-group crosslinking agent. We conclude that the 
major ASIC1a channel complex expressed at the cell surface has a mass corresponding 
to a tetramer suggesting that the functional ASIC1 channel has a subunit stoichiometry 
different from the cASIC1 multimeric structure revealed by crystallography. 
 
 
 
  
 3
Introduction 
Acid-sensing ion channels (ASICs) are proton-gated cation channels that belong to the 
degenerin/epithelial, non-voltage-gated, sodium channel family. Four orthologs of ASICs 
have been identified in vertebrates. At the subcellular level, ASICs are localized in cell 
bodies, in dendrites and in post-synaptic dendritic spines, suggesting a role in synaptic 
transmission. ASIC1 knockout mice have decreased acid-induced inward currents and a 
reduced long-term potentiation associated either with fear-related behaviors, altered 
learning and memory processes, or pain sensation (1). 
ASIC channels open upon acidification of the extracellular milieu to a pH below 7.0. 
ASIC channels show a selectivity for Na+ over K+, and a slight permeability to Ca2+ ions 
(2). The chicken ASIC1 (cASIC1) was crystalized as a homotrimer (3, 4).  Each subunit 
comprises a large extracellular domain between 2 transmembrane α helices (TM1 and 
TM2) arranged pseudosymmetrically around a non-conducting pore, a channel 
conformation that was interpreted as the desensitized state of the channel. The TM2 of 
each subunit is located close to the three-fold axis, lining the putative ion channel pore, 
while the TM1 helices lie at the periphery, making most of the contact with the lipid 
bilayer. The crossing of the TM2 helices identifies an extended physical gate in the 
transmembrane domain that precludes the flow of ions between the extracellular and 
the intracellular milieus.  
The peptide Psalmotoxin 1 (PcTx1) in the venom of the tarantula Psalmopoeus 
cambridgei inhibits homomeric ASIC1a channels at nanomolar concentrations (5). A 
crystal structure of ASIC1 bound to psalmotoxin-1 obtained at two different proton 
concentrations shows a rearrangement both of the inter-subunit interactions at the 
extracellular domain and of the transmembrane α helices (6). This results in the 
expansion of the extracellular vestibule and the enlargement of the diameter of the 
transmembrane channel pore, with little changes in the extracellular domain. These 
structural features were interpreted as reflecting an open channel conformation, 
although no permeant ions could be identified in the pore of either of these two ASIC1 
structures. 
Since the crystallization of ASIC1, the field seems to have settled that ASIC and ENaC 
channels are trimers made of three homologous subunits. Two recent studies using the 
atomic force microscopy imaging of solubilized ENaC and ASIC complexes tagged with 
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antibodies agreed as well with a trimeric subunit assembly of these channels (7, 8). The 
cASIC1 crystal structures contradict however previous functional and biochemical 
studies on ENaC that supported a heterotetrameric organization of this channel, made of 
homologous α, β, and γ subunits (9-12). Additional studies have been performed on 
ENaC subunit stoichiometry including a fluorescence microscopy study that concluded 
to an equal number of each subunit in the ENaC channel complex, a model consistent 
with a previously reported 9 subunit stoichiometry (13, 14). 
Taken together, these observations raise intriguing questions about the 
oligomerization state of ASIC and ENaC channels. A variability in the stoichiometry 
among members of the ENaC/ASIC/degenerin ion channel family remains conceivable, 
similarly to what has been reported for ion channels members of the MscL family. 
Indeed, the early model for the Escherichia coli MscL (EcMscL) stoichiometry based on 
crosslinking and electron microscopy studies was a hexamer (15, 16). The subsequent 
elucidation of the crystal structure of the Mycobacterium tuberculosis (MtMscL) revealed 
a pentameric oligomerization (17). Finally, the crystal structure of Staphylococcus 
aureus MscL (SaMscL) truncated at the C-terminus was shown to be a tetramer (18). 
Thus far, the subunit stoichiometry of a functional ASIC1 as it is expressed at the cell 
surface has not been specifically addressed. In this report, we have used an intersubunit 
crosslinking approach to identify the oligomeric state of the human ASIC1a channel at 
the cell surface. Our results reveal the presence of a functional oligomeric ASIC1a 
complex at the cell surface made of more than three homologous subunits. 
 
Results 
It has been recently reported that intracellular cysteine residues at the C-terminus of 
ASIC1a participate in the formation of intersubunit disulfide bonds in the presence of 
hydrogen peroxide (19). In a first set of experiments, we assessed the oligomerization 
state of wild type ASIC1a and of a mutant lacking the cysteines in the C-terminus 
(ASIC1a-ΔCCt), at the cell surface of Xenopus laevis oocytes, and after in situ crosslinking 
using the homobifunctional disulfide crosslinker bismaleimidoethane BMOE. BMOE is a 
short-arm (8 Å) crosslinker for covalent, irreversible conjugation between sulfhydryl 
groups. Since the formation of intersubunit disulfide bonds in the C-terminus has been 
reported to affect ASIC1 activity (19), we tested the effect of BMOE (2 mM) applied 
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intracellularly in oocytes expressing either ASIC1a or ASIC1a-ΔCCt. As shown in figure 
1A, the current magnitudes mediated by ASIC1a or the ASIC1a-ΔCCt mutant were 
maintained unchanged during the time of the intracellular perfusion with BMOE. The 
ASIC1a subunit crosslinking was investigated in the same oocytes perfused 
intracellularly with BMOE, or alternatively, in those injected with the crosslinker, 60 to 
180 minutes before current measurements. The Triton-X100-soluble fractions of these 
oocytes were collected and analyzed by western blot after SDS-PAGE under reducing 
conditions. The blot in figure 1B shows side by side the ASIC1a and ASIC1a-ΔCCt bands 
obtained after either perfusion or injection with vehicle or BMOE. In the absence of 
intracellular BMOE, both forms of ASIC1a migrate as a predominant band at ~70 kDa, 
size expected for an ASIC1a monomer; a discrete band could be detected around 150 
kDa for ASIC1a, which was absent in the case of ASIC1a-ΔCCt. Upon intracellular 
application of BMOE, the intensity of the 150 kDa band increased for both constructs. In 
addition, a specific band could be detected for ASIC1a, at an apparent molecular weight 
higher than 250 kDa. The estimated mass of the oligomers identified as distinct bands 
on SDS-PAGE for both constructs, with or without BMOE were (mean±SD, n=7) 72±2, 
156±7, and 329±19 kDa for ASIC1a and 73±2 and 164±6 kDa for ASIC1a-ΔCCt. A band 
corresponding to the molecular mass expected for a trimeric channel could not be 
consistently detected. Furthermore, ASIC1a complexes migrating as bands higher than 
the 330 kDa were not detected under these experimental conditions. The 329 kDa 
molecular weight band could represent by mass the crosslinking of either four ASIC1a 
subunits, of two ASIC1a dimers or alternatively, the crosslinking of an ASIC1a trimer 
with another protein. The differences in the band profile observed between ASIC1a and 
ASIC1a-ΔCCt indicate that the C-terminal cysteines participate in the formation of the 
BMOE-mediated intersubunit bonds that stabilize the different ASIC1a oligomeric forms. 
These results are consistent with the results obtained by Zha et al. under similar 
experimental conditions (19). 
To further investigate the subunit composition of the ASIC1a multimeric complex, we 
developed an intersubunit disulfide crosslinking strategy using cysteine residues 
engineered at positions exposed to the ion permeation pathway at the extracellular 
entrance of the channel pore and therefore not expected to participate in crosslinking 
with residues at contiguous channel units (figure 2). A recent study using modifications 
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by thiol-specific reagents of cysteines introduced in the transmembrane helices of 
Lamprey ASIC1 allowed to functionally assess the orientation of the TM1 and TM2 with 
respect to the channel pore in the open and closed conformations; this functional 
evidence showed that the external end of TM1 and a well-defined side of the TM2 are 
exposed to the channel pore (20).  
Based on these data, we have introduced cysteines at positions G430 and G433, in the 
TM2 α helix of ASIC1a that correspond to the side of the helix exposed to the channel 
pore (figure 2B). Two additional cysteine substitutions were performed at position V74 
in the prolongation of the external end of the TM1 and at position Y426 in the short loop 
preceding the TM2, which presumably faces the external vestibule of the ASIC1 pore. 
Finally, the V74C, Y426C, G433C, and G430C substitutions were generated in the ΔCCt 
background of ASIC1a lacking the C-terminal cysteines to avoid a potential crosslinking 
of the channel subunits with adjacent membrane or cytosolic proteins. 
As shown in Table 1, all the cysteine mutants were functional: the V74C and G433C 
mutants show a decreased current, but full activity of V74C could be restored upon 
extracellular treatment of oocytes with DTT. All these mutants show an increased 
sensitivity to block by extracellular Cd2+; BMOE drastically and irreversibly decreased 
the activity of both the Y426C and G430C mutants but not of the V74C and G433C forms. 
Together, these functional experiments indicate that different thiol ligands or reagents 
applied from the extracellular side bind to V74C, Y426C, G430C and G433C and that this 
interaction interferes with the ASIC1a activity. These results are consistent with a 
location of these residues in the ion permeation pathway.   
The oligomeric states of ASIC1a, and of the cysteine mutants in the ΔCCt background 
(V74C/ΔCCt, Y426C/ΔCCt, G430C/ΔCCt and G433C/ΔCCt) were assessed by anti-His-tag 
western blot analysis under reducing conditions. Crosslinking with BMOE was 
performed at the cell surface of oocytes and was followed by cell-surface biotinylation 
and purification on streptavidin beads. The western blot in figure 3A shows that, after 
crosslinking with BMOE, ASIC1a-ΔCCt runs as a major band corresponding to the mass of 
a monomer, and as a weaker, ~160 kDa band consistent with an ASIC1a dimer. In 
contrast, each of the BMOE-treated cysteine mutants, V74C/ΔCCt, Y426C/ΔCCt, 
G430C/ΔCCt or G433C/ΔCCt, run as ladders of four distinct bands on SDS-PAGE, with 
similar migration patterns. As for the experiments in figure 1B, we never observed any 
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additional bands at higher molecular weights (Mw) than those shown in this blot. 
Figure 3B summarizes the migration patterns on SDS-PAGE gels of the ASIC1a-ΔCCt, 
V74C/ΔCCt, Y426C/ΔCCt, G430C/ΔCCt, and G433C/ΔCCt mutants expressed at the cell 
surface after crosslinking with BMOE. In this graph, each point represents the average 
molecular weight estimated for each band (bands I to IV), in a series of four independent 
experiments. This analysis shows the linearity of the distribution of the apparent sizes of 
the four bands detected for each mutant. Regression analysis of the estimated molecular 
weights for the four bands of each ASIC1a mutant yielded an average slope of 72±4 kDa, 
consistent with the mass of a single subunit. The relative intensities of each of the four 
bands obtained for the ASIC1a-ΔCCt constructs shown in figure 3B are illustrated in 
figure 3C. Except for ASIC1a-ΔCCt, and for V74C/ΔCCt that are predominantly in either a 
monomeric or in a high Mw form, respectively, none of the four bands detected for the 
other cysteine-substitution mutants is predominant. These experiments identify for 
each of the mutants and independently of the position of the cysteine substitution, four 
distinct oligomeric states corresponding by mass to multiples of a single ASIC1a subunit. 
Since this pattern of four oligomeric states was highly reproducible among the ASIC1a 
mutants in terms of the apparent mass of each oligomeric state, the next set of 
experiments were carried out exclusively on the G433C mutant. 
If the cysteine residues available for crosslinking were only those engineered in the 
extracellular vestibule, the homo-bifunctional BMOE would stabilize exclusively dimers 
of ASIC1a but not trimers or tetramers. The stabilization of oligomers of higher order 
than dimers requires therefore the participation of additional native cysteines in the 
intersubunit crosslinking. Candidates are the native cysteine residues C59 and C61 in 
the TM1 close to G433C in the transmembrane domain (see figure 2B). Figure 4A 
displays the oligomerization patterns on SDS-PAGE gels of ASIC1a-ΔCCt, G433C/ΔCCt, 
G433C/C59V/ΔCCt, and G433C/C59V/C61S/ΔCCt, after crosslink with BMOE at the cell 
surface. All these ASIC1a mutants were functional (data not shown). Similarly to what is 
shown in figures 1B and 3A, cell surface crosslinking with BMOE yields a major 80 kDa 
band and a faint 170 kDa band for ASIC1a-ΔCCt, and four distinct bands for the 
G433C/ΔCCt. The two high molecular bands of G433C/ΔCCt (234±8 and 303±17 kDa, 
n=4) become less accentuated for the mutants carrying either the C59V or the double 
C59V/C61S substitutions. The bands detected for the G433C/C59V/C61S/ΔCCt mutant 
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closely resemble those obtained for ASIC1a-ΔCCt. The relative intensities of the four 
bands migrating by mass at 80±10, 160±6, 230±9 and 300±19 kDa (Mw±SD) for the 
ASIC1a-ΔCCt, G433C/ΔCCt, G433C/C59V/ΔCCt, and G433C/C59V/C61S/ΔCCt constructs, 
are represented in figure 4B (n=4 experiments). The two highest molecular weight 
oligomers that represent respectively 24±4% and 10±6% of the total immunostaining in 
the case of the G433C/ΔCCt form, are virtually absent in the mutants lacking both the 
C59 and C61 in the TM1 (0±1% for both oligomers), as is the case for ASIC1a-ΔCCt 
(0±1% for both oligomers). Thus, the substitution of both the C59 and C61 cysteines in 
the TM1 nearly completely reverses the effect of G433C in stabilizing the two high 
molecular weight ASIC1a channel complexes (234±8 and 303±17 kDa), indicating that 
these two ASIC1a oligomers result from the crosslink between cysteines in the 
extracellular vestibule and those in the TM1.  The comparison of ASIC1a-ΔCCt and 
G433C/C59V/C61S/ΔCCt shows that crosslinking by BMOE of two G433C residues 
enhances the stabilization of a complex that by mass corresponds to a dimer. Altogether, 
our results identify a network of BMOE-mediated cysteine crosslinks that involve G433C 
in the extracellular vestibule and C59/C61 cysteines in the TM1 that are essential for the 
stabilization of the high molecular weight ASIC1a channel complexes. Therefore these 
high molecular weight oligomers of ASIC1a are likely made of homologous ASIC1a 
subunits and do not represent heteromultimeric complexes with other cell surface 
proteins. 
The identification of four distinct oligomers of ASIC1a on SDS-PAGE gels provides 
evidence for the existence at the cell surface of a ASIC1a channel complex of a higher 
oligomeric order than a homotrimer. The other identified ASIC1a oligomers may 
originate from a unique multimeric ASIC1a complex at the cell surface from which some 
of the ASIC1a subunits dissociate during SDS-PAGE, due to a limited efficiency of BMOE 
to crosslink and stabilize all the subunits of the native channel. Alternatively, ASIC1a 
channels could be present in various oligomeric states at the cell surface, as reported for 
the MscL channels (21, 22). To differentiate between these two possibilities, we 
searched for the presence of a predominant ASIC1a oligomeric state at the cell surface 
by optimizing the efficiency of the crosslinking. Because the C-terminal cysteines 
participate in intersubunit interactions in the presence of BMOE (see figure 1B), we 
investigated whether these cysteine further stabilize the multimeric ASIC1a channel 
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complex at the cell surface. We used CHO cells as an alternative expression system 
because of its wide use as cell system for functional expression of ASIC1a (6, 23, 24); we 
compared the crosslinking patterns of the ASIC1a and of ASIC1a-G433C mutant, both in 
the wt and the ΔCCt background. The functional integrity of these ASIC1a constructs in 
CHO cells was verified by patch-clamp (data not shown). After incubation of transiently 
transfected CHO cells in the presence of 2 mM BMOE or vehicle, we analyzed by SDS-
PAGE the relative abundance of each of the four stabilized oligomeric states of ASIC1a, 
ASIC1a-G433C and ASIC1a-G433C/ΔCCt constructs in cell-surface biotinylated protein 
fractions. A representative western blot carried out under reducing conditions is 
displayed in figure 5A. In the absence of BMOE, the three constructs are detected 
mainly as a single band (75±2.4 kDa, n=9), corresponding to that expected for the 
ASIC1a monomer; under conditions where the monomer is abundant, a fast migrating 
band of unclear origin and associated with the monomer could be detected, in particular 
with the ASIC1a-G433C/ΔCCt, mutant. After BMOE treatment of the intact cells 
expressing ASIC1a, four well defined bands of similar intensity were observed with 
estimated molecular weights of 75±2, 160±13, 224±20 and 304±22 kDa (Mw±SD), 
based on the migration of 2 different standard markers (See supplementary figure 1). 
Introduction of the G433C mutation in the absence of the C-terminal cysteines (ASIC1a-
G433C/ΔCCt) improves the crosslinking efficiency with the bands at 224 and 304 kDa 
becoming the main oligomeric forms detected. As for the monomer, a fast migrating 
band was associated with the tetramer at 270±25 kDa.  The presence of the native C-
terminal cysteines further increases the levels of the 304 kDa band of the ASIC1a-G433C 
construct, concomitant with a decrease in the intensity of all the other fast migrating 
bands with molecular weights below 250 kDa. The quantification of the relative 
intensities of the bands detected by western blotting is shown in figure 5B, for each 
ASIC1a construct on separate panels, with their apparent molecular weight. All the 
constructs were found as monomers in the absence of BMOE. After BMOE treatment, 
none of the multimeric forms of the wild type ASIC1a complex expressed at the cell 
surface represented more than 20% of the total amount of ASIC1a detected in the blot 
(figure 5B, left panel). For the G433C/ΔCCt (figure 5B, middle panel), the two most 
abundant multimeric forms are the ~224 and ~304 kDa oligomers representing each up 
to 40% of the total amount of protein. By contrast, the ASIC1a-G433C expressed at the 
cell surface and crosslinked with BMOE is detected in WB as a major ~304 kDa band 
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accounting for 59% of the total amount of the channel complex compared to 26 % for 
the ~224 kDa band (figure 5B right panel). For all the constructs, the abundance of the 
intermediate 270 kDa band was minor compared to that of the ~224 and ~304 kDa 
bands. Finally, to exclude the potential crosslinking by BMOE of two adjacent ASIC1a 
channel complexes at the cell membrane, treatment with the crosslinker was also 
performed on the streptavidin-bound fraction of the ASIC1a channel complex obtained 
after protein solubilization. Under these conditions, the migration profile of the ASIC1a 
complex on SDS-PAGE remained qualitatively similar to that obtained when BMOE was 
directly applied to the cells (see supplementary figure S2A).  
All the crosslinking experiments performed so far revealed four highly reproducible 
ASIC1a oligomeric states in oocytes and in CHO cells; they involve crosslinking of 
specific cysteines at the C-terminus, the extracellular vestibule of the pore and the 
transmembrane helices of ASIC1 subunits. To finally exclude the possibility that the 
identified ASIC1a oligomeric states are dependent on the type of crosslinking, we 
compared the migration band pattern of ASIC1a and the ASIC1a-G433C mutant in cell-
surface biotinylated fractions from cells treated with either 2 mM BMOE or 
formaldehyde (1 or 4%), a less specific, amino group-selective, crosslinking agent. 
Figure 6A shows the ASIC1a oligomeric states detected by western blot for the ASIC1a 
and ASIC1a-G433C using either type of crosslinker. In the absence of crosslinker the 
band corresponding by mass to a monomer is predominant, although three faint bands 
of higher Mw corresponding to dimers, trimers or tetramers could be detected. In the 
presence of the crosslinkers, the high molecular bands corresponding by mass to 
trimers and tetramers are the most intense. BMOE and formaldehyde yield qualitatively 
comparable band patterns; however, in contrast to BMOE where the accumulation of the 
highest Mw band was predominant only for the ASIC1a-G433C construct, the respective 
intensities of the 222±16 kDa and 313±22 kDa (Mw±SD, n=3) bands in the ASIC1a and 
ASIC1a-G433C samples were very similar (figure 6B), as expected for a less specific 
crosslinking agent. In addition, the stabilization of the 313±22 kDa by formaldehyde was 
dose-dependent (figure 6A), and represented between 70% and 80% of the sum of all 
oligomeric states identified by western blot (figure 6B). This further supports the 
presence of a main ASIC1a oligomeric state at the cell surface that corresponds by mass 
to a homotetrameric channel. In addition, our data favor the hypothesis that the other 
three lower molecular weight oligomers detected on SDS-PAGE result from the 
 11
dissociation of non-covalently linked ASIC1a subunits from the native tetrameric ASIC1a 
channel complex expressed at the cell surface. 
Discussion 
Our experiments show that the crosslinking of cysteines located in the extracellular 
vestibule, in the C-terminal domain, and in the first transmembrane domain of ASIC1a 
allows a covalent stabilization of ASIC subunit-subunit interactions and the 
identification of four distinct oligomeric states by SDS-PAGE under reducing conditions. 
These oligomeric states correspond by mass to multiples of the ASIC1a monomer 
detected as a 75-80 kDa band. The estimated molecular mass of these four oligomeric 
states was highly reproducible among different ASIC1a constructs with native or 
engineered cysteines, using two different crosslinkers BMOE and formaldehyde, and in 
different cell systems expressing functional ASIC1a channels. Improving the 
intersubunit crosslinking efficiency by increasing the number of available cysteines for 
BMOE or by using a less specific crosslinker, formaldehyde, allowed us to identify at the 
cell surface a predominant ASIC1a oligomer with a molecular weight ~310 kDa, 
corresponding to that expected for a homotetrameric channel.  
Several observations support the notion that the ASIC1a oligomers crosslinked by 
BMOE and detected by SDS-PAGE/WB under reducing conditions are homomultimers of 
ASIC1a subunits. First, the apparent Mw of the four different oligomers represent 
multiples of the mass of a single subunit. Second, we identified the cysteine pairs in the 
extracellular vestibule (G433C) and in the TM1 (C59V and C61S) that are necessary and 
sufficient for the stabilization by BMOE of both of the higher molecular weight ASIC1a 
oligomers with sizes corresponding to trimers and tetramers. Third, since the 
homobifunctional crosslinker BMOE can bridge S-S distances in the range of 6 to 11 Å 
(25),  it is unlikely that the crosslinking of cysteines engineered in the TM2 
transmembrane domain and exposed to the pore (G430C, G433C) stabilizes a multi-
channel ASIC1a complex.. Finally, the migration profile was qualitatively similar when 
the crosslinking was performed directly on the native cells or on solubilized and affinity 
purified fractions bound to streptavidin beads. It can be expected that this latter 
procedure minimizes the chances of crosslinking ASIC1a subunits with adjacent surface 
proteins that could form clusters at the cell membrane. Taken together, these 
observations support the fact that, under our experimental conditions, cysteine 
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crosslinking with BMOE occurs exclusively between ASIC1a subunits to stabilize a 
homomultimeric channel complex present at the cell surface. This specificity in the 
intersubunit crosslinking of the ASIC1a channel complex can explain the high 
reproducibility in the estimated mass of the four ASIC1a oligomers identified on SDS-
PAGE among different ASIC1a constructs, using different crosslinkers or different cell 
expression systems.  
The crosslink between G433C on the TM2, and native C59 or C61 in the TM1 of the 
adjacent subunit (figures 3A and 4A) is important for the stabilization of ASIC1a 
oligomers of higher order than dimers. In addition, the native cysteines at the C-
terminus also participate in crosslinking of the ASIC1a. When all these cysteines are 
available for crosslinking by BMOE, this leads to the stabilization of a predominant 
ASIC1a oligomer at the cell surface that corresponds by mass to a tetrameric channel. An 
ASIC1a oligomer of similar mass is detected as well as the predominant ASIC1a complex 
at the cell surface after crosslinking with 4% formaldehyde. Furthermore, it is 
remarkable that the increase in the intensity of the signal obtained for the tetrameric 
form of ASIC1a-G433C correlates with the decrease in the band intensity of the trimer 
(figure 5B). The likely explanation for these observations is that the putative trimeric 
complex detected by western blot results from an incomplete crosslinking of all the 
subunits of the ASIC1a tetrameric complex leading to the dissociation of the non-linked 
subunit during SDS-PAGE. Our data are consistent with a recent report on the effects of 
hydrogen peroxide on the formation of ASIC1a intersubunit disulfide bonds; hydrogen 
peroxide stabilizes ASIC1 dimers on SDS-PAGE under non-reducing conditions, but also 
higher order ASIC1 oligomers of apparent molecular weight similar to those observed in 
our study (19). These high order ASIC1 oligomers are predominant at the cell surface 
and were interpreted as inter-trimer complexes (19). Our experiments provide no 
evidence for a crosslinking between two functional channel complexes at the cell 
surface. 
Our observations are also in accordance with previous functional studies that 
reported a four subunit stoichiometry of ENaC and FaNaCh (9-12, 26). The epithelial 
sodium channel, ENaC, and FaNaCh belong to the same ion channel family as ASICs. 
ENaC is made of 3 homologous subunits, α, β, and γ that share 15-20% identity with 
ASIC1 and a similar membrane topology (2). Most of the functional studies on ENaC 
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including channel interaction with different blockers, analysis of specific mutations, 
expression of subunit concatemeric constructs, and biochemical studies came to the 
conclusion that ENaC is made of four subunits, 2α, 1β, and 1γ arranged 
pseudosymmetrically around a single channel pore (9, 10). Similar functional studies 
have not been performed on ASIC1 before our present report.  
The available crystal structures of the C-terminally truncated chicken ASIC1 reveal a 
trimer (3, 4, 6, 27). These structures are consistent with the predicted membrane 
topology of ENaC but challenge both the evidence that ENaC is a tetramer, and our 
present data on the ASIC1a oligomeric state at the cell surface. ASIC1 crystal structures 
reveal two different conformation states: a closed, non-conducting state that is 
considered to reflect the desensitized state, and a toxin-bound state with a large open 
pore. The extracellular domain contains several cavities and vestibules in series along 
the 3-fold axis of symmetry. Two potential pathways for ions to access the 
transmembrane pore can be identified: the first one consists of lateral fenestrations at 
the intersubunit interface, the second along the 3-fold axis of the extracellular domain of 
the channel. The latter ion pathway remains occluded in all ASIC1 crystal structures 
available. Nevertheless a crystal structure of a non-functional ASIC1 bound with 
Psalmotoxin 1 revealed an anomalous density feature consistent with a cation trapped 
in a central vestibule of the extracellular domain (27). In another ASIC1 crystal structure 
bound to Psalmotoxin-1 showing an expanded extracellular vestibule and pore, an ion-
binding site was identified at the extracellular end of the TM1, close to the entrance of 
the lateral fenestration of the channel complex (6). However, no electron density 
features consistent with the presence of cations deep into the pore could be observed in 
any of the ASIC1 structures interpreted as corresponding to either desensitized or open 
states. In contrast, the presence of permeant ions and their interactions with pore-lining 
residues could be resolved  from the crystals of KcsA K+ channels, the prokaryotic Cl- 
channel, the Ca2+ Orai channel or the ligand-gated GLIC channel (28-31). The absence of 
permeant ions on the ASIC1 channel pore raises pertinent questions regarding the 
functional relevance of this non-conducting channel structure. Atomic force microscopy 
(AFM) imaging on purified ENaC and ASIC1 channel complexes bound to specific 
antibodies revealed angles between the Fab fragments that are consistent with trimeric 
channels (7, 8). Since the molecular mass of the ASIC1 or ENaC channel complexes was 
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not determined biochemically, the relevance of these data remains difficult to assess. 
Finally, the crystal structure of cASIC1 has been successfully used to provide a structural 
rationale for different biophysical properties of ASIC1 channel function such as their 
activation and desensitization (20, 32, 33). However these studies were not designed to 
specifically address the question of the subunit stoichiometry of ASIC1, and their 
conclusions cannot be used to refute the tetrameric organization of native ASIC1 
channel. 
Different subunit stoichiometries have been reported for members of the MscL ion 
channel family. The early model for the Escherichia coli MscL (EcMscL), based on 
crosslinking and electron microscopy studies was a hexamer (15, 16). The subsequent 
elucidation of the crystal structure of the Mycobacterium tuberculosis (MtMscL) 
orthologs revealed a pentameric oligomerization (17). Finally, the crystal structure of a 
form of Staphylococcus aureus MscL (SaMscL) truncated at the C-terminus was shown to 
be a tetramer (18). Furthermore, a single type of MscL can assemble in a mixture of 
different oligomeric states (22). The structural requirements for the generation of 
multiple oligomeric forms of MscL channels are unknown. Regarding cASIC1, there is no 
doubt that the protein, fused to GFP and carrying a truncation of its C-terminus, 
assembles as a trimer, at least when expressed in insect cells (3, 4, 6, 27). It remains 
possible that, under these expression conditions, cASIC1 assembles as a mixture of 
trimeric and tetrameric oligomers, but that only the former are able to generate 
diffraction-quality crystals. In contrast, we show that when the functional fraction of 
ASIC1a is chemically stabilized, the oligomeric state of ASIC1a corresponds by size to 
that of a tetramer.  
Knowledge about the structure of ASIC and ENaC channels still remains incomplete. 
On one hand, the different cASIC1 crystal structures available to date lack sound 
evidence for their functional relevance. On the other hand, the ASIC1a complex 
identified at the cell surface as a tetramer requires further structural information to 
better define subunit organization of the channel complex. Our results will certainly not 
provide the last words on the subunit stoichiometry of the ENaC/ASIC channels, but 
hopefully will promote the reevaluation of the cASIC1 crystal structure for its functional 
relevance. 
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Methods 
Detailed materials and methods are provided in the SI Text. 
 
Cloning, site-directed mutagenesis, in vitro RNA transcription, and expression in 
Xenopus laevis oocytes 
Healthy stage V and VI Xenopus laevis oocytes were pressure-injected with 10 ng of 
cRNA. ASIC1a wt and mutants constructs were carried out as detailed in the SI Text. 
 
Electrophysiology 
Electrophysiological measurements were performed 24–48 h after oocyte injection 
with cRNA. Macroscopic ASIC1a currents were elicited every 40 s by extracellular pH 
changes from 7.4 to 6.0 and were measured using either the two-electrode voltage-
clamp for whole-cell currents or the cut-open oocyte technique.  
 
Biochemistry 
Cell-surface crosslinking and biotinylation of ASIC1a expressed in Xenopus oocytes 
Triton 1% (v/v) was used as detergent for the lysis. Crosslinking was done with 
BMOE at 19°C and biotinylation with NHS-SS-biotin on ice. The lysis buffer was 
supplemented with 10 mM N-Ethylmaleimide. 
 
Transfection, biotinylation, cross-linking, and lysis of CHO-K1 cells. Cells were transfected 
with Lipofectamine-2000. Cell-surface crosslinking with BMOE or formaldehyde and 
biotinylation were carried out as for oocytes. Membrane fractions were isolated by 
centrifugation after lysis of CHO cells in a solution without detergent, and subsequently 
solubilized.  
 
Pull-Down with nickel-NTA- or Streptavidin-agarose beads, 
The Triton X100 soluble fractions from Xenopus oocytes or CHO membranes were used 
for pull-down assays using either Ni2+NTA- or streptavidin-agarose. The thus isolated 
fractions were analyzed by western blot using either anti-ASIC1a or anti-His-tag 
antibody and IRDye-conjugated secondary antibodies. Bands were quantified from 
images obtained with a LiCor Odyssey scanner using the Odyssey v2.1 software.  
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Figure 1 
Effects of intracellularly applied BMOE on hASIC1a activity and oligomerization. A,
Cut-open oocytes expressing either ASIC1a wild type (solid circles, n=18) or ASIC1a-ΔCCt
(open circles, n=17) were intracellularly perfused with 2 mM BMOE; time 0 corresponds
to the onset of perfusion with BMOE; currents (m±SD), elicited at pH 6.0 were
normalized to the peak current at time zero in the absence of BMOE. B, Oligomerization
of ASIC1a identified by an anti-ASIC1 western blot from oocytes, not injected (n.i.), or
expressing ASIC1a or ASIC1a-ΔCCt lacking cysteines in the C-terminus, that were either
untreated, internally perfused (perf.), or intracellularly injected (inj.) with 2 mM BMOE.
Numbers I to IV identify bands that are specific for ASIC1a and represent by Mw
multiples of band I. 
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Figure 2 
Homology model of a human ASIC1a subunit with cysteine substitutions. A, Model
structure of a human ASIC1a subunit based on the chicken ASIC1 crystal structure as
published in ref (4): the subunit is made on 2 transmembrane α helices (TM1 and TM2);
the cysteines C49, C59 and C61 in the transmembrane α helix 1 (TM1) are shown in
green. The G430C and G433C in TM2 are exposed to the channel pore (20). The V74C
and Y426C are located at the entrance of the channel pore in the extracellular vestibule
(ECV). B, Top view of the transmembrane α helices TM1 and TM2 of a single ASIC1a
subunit, with the pore lining residues G433C and G430C. 
Figure 3 
ASIC1 oligomeric states revealed by SDS-PAGE separation after crosslinking of
cysteines in the ECV. A, Anti-His-tag western blot of the biotinylated fractions of
surface proteins from non-injected oocytes (n.i.), from oocytes expressing either the
His8-tagged forms ASIC1a/ΔCCt (ΔCCt) lacking cysteines in the C-terminus, or the
substitution mutants V74C/ΔCCt, Y426C/ΔCCt, G430C/ΔCCt, and G433C/ΔCCt. The
crosslinking with 2 mM BMOE was performed at the cell surface; the biotinylated
surface proteins were affinity-purified on streptavidin beads. Numbers I to IV, as in
figure 1.  B, Apparent Mw values of the ASIC1 oligomers (kDa, mean ±SD) estimated for
each of the four main bands (I to IV) resolved by SDS-PAGE (see Methods) for the
different constructs, as in A. C, Relative intensities (mean, vertical bars ±SD) of the four
distinct bands I-IV identified in A:  horizontal bars represent SD for the apparent Mw
value for each band. 
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Figure 4 
Contribution of the cysteines in the first transmembrane helix (TM1) to the
subunit crosslinking by BMOE. A, ASIC1a oligomeric states identified by anti-His-tag
western blot (using the same experimental procedure as in figure 3A) of the His8-tagged
forms of ASIC1a-ΔCCt (ΔCCt), and the cysteine substitution mutant G433C-ΔCCt associated
or not with the C59V or C59V/C61S substitutions (G433C/C59V/ΔCCt or
G433C/C59V/C61S/ΔCCt). Numbers I to IV have the same meaning as in figure 1. B,
Relative intensities (arbitrary units, mean ±SD, n=4) of the bands identified on SDS-
PAGE estimated for ASIC1a-ΔCCt, G433C/ΔCCt, G433C/C59V/ΔCCt, and
G433C/C59V/C61S/ΔCCt. Horizontal bars represent ±SD of apparent molecular weight
sizes. 
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Figure 5 
Stabilization of the ASIC1a channel complex at the cell surface of transfected CHO
cells. A, Anti-His-tag western blot showing ASIC1a oligomeric states obtained from cell
surface fractions of proteins expressed by CHO cells and transiently transfected with an
empty vector (n.t.), or His8-tagged forms of ASIC1a wt, ASIC1a-G433C/ΔCCt, or ASIC1a-
G433C mutants, and treated with 2 mM BMOE or vehicle. Surface proteins were
biotinylated, purified on streptavidin beads and analyzed by western blot.. Numbers I to
IV have the same meaning as in figure 3. B, Relative intensities (mean ±SEM) measured
of the different bands detected for the different constructs without (open circles) or
with  2mM BMOE (filled circles). Horizontal bars represent apparent Mw values (±SEM)
estimated for each band. Significant (** = p<0.01) difference in intensity between bands
III and IV for each protein was determined by a paired, two-tailed t-test.  
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Figure 6.  
ASIC1a channel complex at the cell surface of CHO cells after crosslinking with
formaldehyde. A, Anti-His-tag western blot of the biotinylated fractions of surface
proteins in CHO cells transiently transfected either with empty vector (ctrl), or with
His8-tagged ASIC1a, or ASIC1a-G433C mutant (G433C). Cells were treated either with
vehicle (DMSO), or BMOE (2 mM), or with 1 or 4% formaldehyde (1F, 4F, respectively).
Surface proteins were biotinylated, purified on streptavidin beads before western blot
analysis. Numbers I to IV have the same meaning as in figure 1.  B, relative intensities of
the bands I-IV identified in A from CHO cells expressing ASIC1a or ASIC1a-G433C
treated with 4% formaldehyde. 
Supplementary Information 
 
Chemicals 
Bis(maleimido)ethane (BMOE #22323) was purchased from Pierce Biotechnology (USA). Anti-
His-tag monoclonal antibody was from GE Healthcare (#27-4710-01). Polyclonal anti-ASIC1 
(#ASC-014) was purchased from Alomone Labs (Israel). Polyclonal goat antibody anti-rabbit 
IRDye® 800CW (#926-32211), IRDye® 680CW (#926-32221) and goat anti-mouse IRDye® 680CW 
(#926-68070) were from Li-Cor® Biosciences GmbH (Bad Homburg, Germany). Pre-stained 
protein molecular weight ladders were from PeqLab Biotechnologie GmbH, Erlangen, Germany 
(peqGold Protein Marker, #27-2210) or from Thermo Scientific (Spectra Multicolor High Range 
Protein Ladder, #26625). EZ-link sulfo-NHS-SS-biotin (Pierce, #21331) was used as biotinylation 
reagent. Immunopure immobilized streptavidin gel was from Thermo Scientific (#20349). 
 
Cloning, site-directed mutagenesis, in vitro RNA transcription, and expression in Xenopus 
laevis oocytes 
The coding sequence of human ASIC1a was cloned in the pSDEasy vector. An octahistidine 
coding sequence (H8) was introduced into the multiple cloning site using XhoI and SalI 
restriction sites (H8-ASIC1a).  
The ASIC1a construct lacking the cysteine in the C-terminus, H8-hASIC1a-
C466A/C471A/C497A/C528Stop (ASIC1a-ΔCCt) was used as template for mutagenesis. V74C, 
Y426C, G430C and G433C cysteine substitutions were introduced by site-directed mutagenesis 
with the QuickChange kit from Stratagene (see Supplementary Table 1 for primers). C49A, C59V 
and C61S primers were already described (1). Mutations were verified by sequencing 
(Synergene Biotech, Zurich, Switzerland). 
Complementary RNAs were synthesized in vitro with SP6 RNA-polymerase (Promega, 
Dübendorf, Switzerland) from H8-ASIC1a cDNA encoding vectors previously linearized with FspI. 
Healthy stage V and VI Xenopus laevis oocytes were pressure-injected with 10 ng of cRNA. 
 
  
Electrophysiology 
Electrophysiological measurements were performed 24–48 h after oocyte injection with ASIC 
cRNA. Macroscopic ASIC1a currents were elicited every 40 s by rapid changes in extracellular pH 
from 7.4 to 6.0 and were measured using either the two-electrode voltage-clamp for whole-cell 
currents or the cut-open oocyte technique when intracellular perfusion was needed, as 
previously described (1). For the two-electrode voltage clamp experiments, reagents were 
directly added to the extracellular solutions: Cd2+ 10, 100 and 1000 μM, or BMOE 2 mM. In 
experiments investigating the effects of intracellular BMOE on ASIC1a activity, 100nl of a 10mM 
BMOE or vehicle (DMSO) solution were injected per oocyte 60 to 180min before 
electrophysiological measurements. In the cut-open oocyte experiments, he voltage clamp was 
performed using a Dagan cut-open oocyte voltage clamp apparatus (Dagan Corporation, 
Minneapolis, MN; model CA-1 high performance oocyte clamp). 24 hours after RNA injection, 
oocytes were perfused extracellularly and intracellularly. Extracellular solutions contains, in 
mM: 80 Na-gluconate, 10 HEPES, 10 TEA-Cl, 5 BaCl2, 1 MgCl2 and 0.5 CaCl2, pH 7.5/6.0 adjusted 
with NMDG. Intracellular side of oocytes was perfused either using a control solution (in mM: 90 
K-gluconate, 10 HEPES, 10 KCl, 2 Na-gluconate, 1 MgCl2, 0.2 BAPTA, pH 7.35 adjust with NMDG) 
or a solution supplemented with 2mM of BMOE. The BMOE perfusion lasts 6 minutes. Oocytes 
were then intracellularly washed with the control solution. 
 
Expression, cell-surface labeling and crosslinking of His-tagged hASIC1a in CHO cells. 
The XhoI-XbaI fragments encoding the His-tagged ASIC constructs were subcloned into 
pCDNA3.1(+)_zeo (Life Technologies, Zug, Switzerland). CHO-K1 cells were plated on P100 
dishes and transfected with 15 µg plasmid DNA per plate using Lipofectamine-2000 (Life-
Technologies), according to the manufacturer instructions. After 8-12 h incubation with the 
transfection mix, fresh medium (DMEM:F12, 3.6% FCS, 1% PenStrep) was added and cells were 
further incubated for ~24h. 
 
  
Biochemistry 
Pull-Down with nickel-NTA-Agarose beads 
Oocytes were lysed with a lysis buffer (LB) containing 1% Triton and, in mM: 100 NaCl, 20 
Tris-HCl at pH 7.5, 10 N-Ethylmaleimide (NEM), and a protease inhibitor cocktail containing 1 
PMSF and 10 μg/ml each of Leupeptin, Pepstatin and Aprotinin (20 µl LB/oocyte). After 10 min 
centrifugation at ~15,000g (4°C), the intermediate phase comprising the solubilized protein 
fraction was recovered and subjected to batch affinity chromatography on nickel-NTA-Agarose 
beads (Qiagen, Hombrechtikon, Switzerland), incubating 2 h at 4°C in the presence of 20 mM 
imidazole to reduce non-specific binding. 
After 2 min centrifugation at 2,000 rpm, the beads were washed 3 times with LB. 40 μl of 
sample buffer (25 mM DTT, final concentration) were added to the pellet containing the drained 
beads and heated at 95°C for 5 min. Bound proteins were then recovered by centrifuging 
through Evergreen mini-filters (EVE-208). 
 
Cell-surface crosslinking and biotinylation of ASIC1a expressed in Xenopus oocytes.  
48h hours after cRNA injection, 30 oocytes were incubated in 1 ml MBS solution 
supplemented with 2 mM BMOE (5 and 120 min at 19°C). Oocytes were then washed three 
times and then cell-surface biotinylated as described above. After lysis in SBB supplemented 
with 10 mM NEM, the biotinylated fraction was affinity-purified as described below.  
Control- and BMOE-treated oocytes were labeled by 15 min incubation in ice in 1 ml of 
biotinylation buffer (in mM: 10 Triethanolamine, 150 NaCl and 2 CaCl2) supplemented with 1 
mg/ml biotinylation reagent. After aspiration of the bathing solution, oocytes were incubated 
for 5 min in 1 ml of quenching buffer (in mM: 192 Glycine, 25 Tris-HCl at pH 7.5, in MBS 
solution) and subsequently washed 3 times with MBS. Oocytes were finally lysed with a 
Streptavidin binding buffer (SBB, 20 μl LB/oocyte) containing 1% (v/v) Triton and, in mM: 5 
EDTA, 100 NaCl, 40 Tris-HCl (pH 7.5), and protease inhibitor cocktail. The biotinylated fraction 
was affinity purified from the intermediate phase as described below.  
 
 
Cell-surface crosslinking and biotinylation of ASIC1a expressed in CHO cells. 
Transfected cells were washed with PBS containing 0.1 mM CaCl2 and 1 mM MgCl2 (PBS-CM) 
and then treated for 5 min at 22°C in the presence of 4 ml PBS-CM containing 2 mM BMOE or 
vehicle (DMSO, 2% final). Alternatively, cells were incubated with either ¼ diluted (in PBS-CM) 
or undiluted formaldehyde solution (~4%, SIGMA #HT5014) with CaCl2 and MgCl2 
concentrations adjusted to 0.1 and 1 mM, respectively. After washing with chilled PBS-CM, 
plates were placed on ice in a cold room and cells were incubated for 15 min in the presence of 
5 ml PBS-CM supplemented with 0.25 mg/ml of biotinylation reagent. The reaction was 
quenched by replacing the biotinylation solution with 10 ml of 100 mM Glycine in PBS-CM and 
further incubation for 20 min in the cold. Lysates were prepared by scraping cells in 3 ml 
membrane isolation buffer: 50 mM Tris/HCl (pH 7.0 at RT), 150 mM NaCl, 5 mM MgCl2, and 
protease inhibitor cocktail. Lysates were snap-frozen in liquid nitrogen and stored at -70°C. After 
thawing, raw lysates were incubated for 30 min on an orbital shaker at 4°C in the presence of 
0.1 mg/ml DNaseI (Roche Diagnostics AG, Rotkreuz, Switzerland). The membrane pellet 
obtained after 30 min centrifugation at 20,000g (4°C) was resuspended in SBB and proteins 
were solubilized by 45 min incubation on an orbital shaker at 4°C, and centrifuged for 12 min as 
before.  
 
Affinity purification of biotinylated fractions from oocytes and CHO cells.  
The intermediary phase from oocyte lysates and the Triton-soluble fraction from CHO cells 
were incubated for 1 h at 22°C with 50μl of streptavidin-bead suspension. Beads were washed 
three times in SBB and bound proteins were then eluted as described for pull-down 
experiments with nickel beads. Pilot studies using lysates from non-biotinylated oocytes and 
cells were carried out to assess the absence of non-specific binding of His-tagged hASIC1a to 
streptavidin (not shown). 
In certain experiments, after two washing steps, the streptavidin beads were incubated on an 
orbital shaker for 20 min at 4°C in the presence of either 1 mM BMOE or vehicle. Reagent was 
removed by thorough washing before elution with sample buffer. 
 
Western-Blot, Infrared detection. 
Proteins were resolved by SDS-PAGE on 5-15% acrylamide gradient minigels for 1 h at 200V 
along with pre-stained molecular weight markers. Proteins were then electrotransferred onto 
nitrocellulose (Whatman Protran #10401396) for 2-3h at 100V. After 1 h of blocking at RT in 
0.1% (w/v) casein solution, the membrane was incubated overnight with the primary antibody 
in 1 % milk-TBS-Tween. After three rounds of washing over 20-30 minutes in TBS-Tween, the 
blot was incubated 1 h in the presence of IRDye-conjugated secondary antibodies diluted 
1/12,000 in casein solution. After washing, the blot was scanned with an Odyssey® Infrared 
Imaging System (LI-COR Biosciences). 
 
Quantitative analysis of intensities and apparent molecular weights of western blot bands. 
The intensities of bands were analyzed using the Odyssey 2.1 software. For samples obtained 
after crosslinking experiments, the intensities of the four bands were added and the relative 
intensity of each band was calculated. Finally, the average of the ratios measured for each band 
in individual experiments was calculated and reported for each of the ASIC1a constructs (± SD). 
To determine the apparent molecular weight of each band, we analyzed the raw scans with 
the ImageJ software in order to measure the distances migrated by the molecular weight 
marker’s bands. Then, we plotted those distances against the respective theoretical weight of 
each band and fitted it to an exponential curve in an Excel sheet (Microsoft). The function of the 
corresponding curve was used to calculate in each blot the apparent molecular weight value of 
the ASIC1a-immunostained bands on the basis of their respective migration distances (see 
supplementary Fig. S1). This protocol was repeated for each gel and lane. Finally, the mean of 
the thus estimated apparent molecular weights was calculated and reported for each ASIC1a 
construct (± SD). 
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Supplementary Table 1 Sequences of the primers used for the PCR mutagenesis 
Mutant Forward primer Reverse primer 
V74C ccactaccaccattgcaccaagctcgacg cgtcgagcttggtgcaatggtggtagtgg
Y426C gagaccattgaacagaagaaagcctgtga
gattgcagggctcctg 
caggagccctgcaatctcacaggctttctt
ctgttcaatggtctc 
G430C ggcctatgagattgcatgtctcctgggtg
acatcg 
cgatgtcacccaggagacatgcaatctcat
aggcc 
G433C gcagggctcctgtgtgacatcgggg ccccgatgtcacacaggagccctgc 
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4. Structure of the methanethiosulfonate reagents and labeling reaction 
 
Figure 47 Methanethiosulfonate reagents. A-F, MTSEA-biotin, MTSEA-biotinCap, MTSET, MTS-PTrEA, MTS-TBAE, 
MTSEA-fluorescein, respectively. MTS pictures come from the Toronto Research Chemicals Inc. company website: 
http://www.trc-canada.com/search_cat.php?Search=MTS&qsearch=Quick+Search. 
 
Figure 48 MTS reaction. The cysteinyl group makes a nucleophilic attack on the alkylthio group of the MTS reagent. As result, it 
forms a disulfide bridge to the thioalkyl moiety and the methanesulfonate part leaves. 
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Abbreviation Name Reference 
MTSET (2-(trimethylammonium)ethyl methanethiosulfonate, Bromide) T795900 
MTSEA-biotin 
N-Biotinoylaminoethyl methanethiosulfonate 
B394750 
MTSEA-
BiotinCAP 
N-Biotinylcaproylaminoethyl Methanethiosulfonate B395750 
MTS-PTrEA 3-(Triethylammonium)propyl Methanthiosulfonate Bromide T776300 
MTS-TBAE 2-(Tributylammonium)ethyl Methanethiosulfonate Bromide T773250 
MTSEA-
Fluorescein 
(R)-2-Amino-2-[(5-fluoresceinyl)aminocarbonyl]ethyl 
Methanethiosulfonate, Trifluoroacetate Salt 
A609615 
Table 5 Chemical formula and reference numbers of the MTS reagents. 
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5. Amiloride dose-response curves 
 
 
Figure 49 Amiloride dose-response curves. hASIC1a wt is blocked by amiloride with an IC50 of 7.27±1.22 M (n=8, black 
curve). The amiloride inhibition of G440A is completely disrupted (in red, n=6). 
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6. A homozygous missense mutations in SCNN1A is responsible for a transient 
neonatal form of pseudohypoaldosteronism type 1 
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Dirlewanger M, Huser D, Zennaro MC, Girardin E, Schild L,
Schwitzgebel VM. A homozygous missense mutation in SCNN1A is
responsible for a transient neonatal form of pseudohypoaldosteronism
type 1. Am J Physiol Endocrinol Metab 301: E467–E473, 2011. First
published June 7, 2011; doi:10.1152/ajpendo.00066.2011.—Pseudohy-
poaldosteronism type 1 (PHA1) is a monogenic disorder of mineralo-
corticoid resistance characterized by salt wasting, hyperkalemia, high
aldosterone levels, and failure to thrive. An autosomal recessive form
(AR-PHA1) is caused by mutations in the epithelial sodium channel
ENaC with usually severe and persisting multiorgan symptoms. The
autosomal dominant form of PHA1 (AD-PHA1) is due to mutations in
the mineralocorticoid receptor causing milder and transient symptoms
restricted to the kidney. We identified a homozygous missense muta-
tion in the SCNN1A gene (c.727TC/p.Ser243Pro), encoding -sub-
unit of ENaC (-ENaC) in a prematurely born boy with a severe
salt-losing syndrome. The patient improved rapidly under treatment,
and dietary salt supplementation could be stopped after 6 mo. Inter-
estingly, the patient’s sibling born at term and harboring the same
homozygous Ser243Pro mutation showed no symptom of salt-losing
nephropathy. In vitro expression of the Ser243Pro ENaC mutant
revealed a slight but significant decrease in ENaC activity that is
exacerbated in the presence of high Na load. Our study provides the
first evidence that ENaC activity is critical for the maintenance of salt
balance in the immature kidney of preterm babies. Together with
previous studies, it shows that, when the kidney is fully mature, the
severity of the symptoms of AR-PHA1 is related to the degree of the
ENaC loss of function. Finally, this study identifies a novel functional
domain in the extracellular loop of ENaC.
hyponatremia; hyperkalemia; mineralocorticoid resistance; aldoste-
rone; salt wasting
PSEUDOHYPOALDOSTERONISM TYPE 1 (PHA1) is a rare disease
characterized by a resistance to mineralocorticoids that pres-
ents in the neonatal period or early infancy with a salt-wasting
nephropathy, dehydration, hyperkalemia, and failure to thrive.
Two major clinical forms of PHA1 have been described (17).
The autosomal dominant renal form of PHA1 (AD-PHA1)
involves loss-of-function mutations of the mineralocorticoid
receptor (MR), encoded by the NR3C2 gene located on chro-
mosome 4q31.1 (38, 39). More than 40 mutations have been
described in both sporadic and familial cases (7, 16, 26, 36).
This form of mineralocorticoid resistance is restricted to the
kidney and shows moderate clinical features, with renal symp-
toms typically improving with age. The autosomal recessive
form of PHA1 (AR-PHA1) is caused by loss-of-function mu-
tations in the genes encoding the epithelial Na channel (ENaC)
-, -, and -subunits. Symptoms are usually multisystemic,
including a severe salt-losing nephropathy causing dehydration
with hyperkalemia and recurrent episodes of pulmonary infec-
tion, congestion, coughing, and wheezing (21, 32); a cutaneous
phenotype with eczematous rash of the skin has been reported
(23, 34). The symptoms are usually persistent and more severe
than in AD-PHA1. Recently, clinical improvement with age
has been reported in patients with AR-PHA1 (2, 18, 28).
In the kidney, the MR is expressed exclusively in the
aldosterone-sensitive distal nephron (ASDN), which includes
the connecting tubule and the collecting duct (12). The ASDN
is the site involved in the fine regulation of Na absorption and
K secretion to balance the daily intake of these electrolytes.
After binding aldosterone the MR undergoes a conformational
change, and the ligand-receptor complex is translocated to the
nucleus, allowing transcription of aldosterone-induced genes,
including ENaC and various signaling factors (4–6, 15, 16, 27,
37–39).
ENaC colocalizes with the MR and is expressed in the
ASDN of the kidney but also in other tight epithelia such as the
colon, the respiratory tract, and salivary glands. In the kidney,
ENaC is essential for the maintenance of the extracellular fluid
and blood pressure and also plays a crucial role in K homeo-
stasis. In the distal lung airways, ENaC regulates fluid absorp-
tion at the air-liquid interface, thereby determining the rate of
mucociliary transport (11).
ENaC is a heteromeric protein composed of homologous
subunits and provides an electrogenic sodium transport path-
way from the lumen into the cell (20). The -subunit is
required for ENaC function, whereas the - and -ENaC are
important for maximal channel activity. The reabsorbed Na is
then transported out of the cell into the interstitium by the
Na/K ATPase pump located on the basolateral membrane.
In the ASDN, ENaC is the rate-limiting step in Na reabsorp-
tion. The electrogenic ENaC-mediated Na absorption in the
ASDN provides the necessary driving force for K secretion in
this part of the nephron.
In the present study, we describe a novel Ser243 to Pro
mutation in the -ENaC subunit that is associated with a
* These authors contributed equally to this work.
Address for reprint requests and other correspondence: V. M. Schwitzgebel,
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transient AR-PHA1 diagnosed in a preterm patient with a
severe salt-losing nephropathy. Our observations shed a new
light on the role of ENaC in the maturating kidney and on the
genotype-phenotype relations found in AR-PHA1.
METHODS
Subjects. We studied a family presenting with an autosomal reces-
sive form of PHA1 and sequenced the MR and ENaC genes. The
parents were Sri Lankan first-degree cousins in good general health.
The older child presented with clinical and laboratory characteristics
of PHA1 at 16 days of age and was the index case. Informed consent
was obtained from all of the family members.
Biochemical assays. Aldosterone concentrations were measured in
the serum by direct radioimmunoassay with a Diagnostic Products kit
(ISO 15189). The plasma renin activity (PRA) (ng·ml1·h1) was
measured by direct radioimmunoassay after an incubation period at
37°C (INC Biomedical). Sweat tests and concentrations of Cl, Na,
and K were measured according to the cystic fibrosis foundation
consensus report: normal values of Cl  39 mmol/l and Na  60
mmol/l (14).
Genomic DNA isolation and sequencing. Genomic DNA was
extracted from peripheral blood leukocytes by salt extraction, as
described previously (26). All coding exons and the intron-exon
flanking regions of the NR3C2 gene, coding for the MR, as well as the
SCNN1A, SCNN1B, and SCNN1G genes were amplified with 13 pairs
of primers (see Supplemental Table S1; Supplemental Material for
this article is available online at the AJP-Endocrinology and Metab-
olism web site). Direct sequencing of PCR products was then per-
formed by the ABI Prism Big Dye Terminator version 3.1 Cycle
Sequencing Kit (Applied Biosystems, Foster City, CA) on an ABI
Prism 3700 DNA Analyzer. The identified mutation was confirmed on
a second PCR product and on a second DNA sample.
Site-directed mutagenesis, RNA in vitro transcription, and expres-
sion in Xenopus laevis oocytes. The human -, -, and -ENaC
subunits were cloned in the pBSK vector and linearized by NotI, and
capped cRNA was in vitro synthesized by SP6 polymerase. -ENaC
Ser243 to proline mutant (-S243P) and Ser243 to cysteine (-S243C)
were obtained by site-directed mutagenesis using Stratagene’s Quick-
Change protocol. Healthy stage V and VI Xenopus laevis oocytes
were pressure-injected with 10 ng of human ENaC cRNA (with equal
amounts of -, -, and -subunits). Oocytes were kept at 19°C in
either a low Na incubation solution containing (in mM) 10 NaCl,
0.82 MgSO4, 0.41 CaCl2, 0.33 Ca(NO3)2, 80 N-methyl-D-glucamine
(NMDG), 2 KCl, and 5 HEPES or a high Na incubation solution
containing (in mM) 85 NaCl, 1 KCl, 2.4 NaHCO3, 0.82 MgSO4, 0.41
CaCl2, 0.33 Ca(NO3)2, 10 HEPES, and 4.08 NaOH.
Electrophysiology. Electrophysiological measurements were made
16–24 h after injection. The oocytes expressing ENaC were studied
using the standard two-electrode voltage clamp technique, using a
Dagan TEV voltage clamp amplifier (Dagan, Minneapolis, MN), the
Digidata 1322 digitizer, and the PClamp 9 data acquisition and
analysis package (Axon Instruments, Molecular Devices, Sunnyvale,
CA). The two electrodes contained a 1 M KCl solution. All electro-
physiological experiments were performed at room temperature
(22°C). The holding potential was 100 mV. The composition of the
perfusion solution was (in mM) 120 NaCl, 2.5 KCl, 1.8 CaCl2-2H2O,
and 10 HEPES-H for the Na solution; NaCl was replaced by 120
mM NMDG-HEPES or KCl for the perfusion solutions devoid of
Na. To determine amiloride-sensitive currents, we added amiloride
(Sigma) in a separated fraction of each test solution at a final
concentration of 10 M. Inward Na current was generated by
switching solution without Na (NMDG or KCl) to perfusion solution
containing 120 mM of Na. In the experiment with proteases, the
oocytes were exposed to 5 g/ml trypsin (Sigma-Aldrich Chemie) in
the 120 mM NaCl perfusion solution.
Biotinylation. For surface biotinylation 16–30 h after cRNA injection,
oocytes were incubated in 1 ml of biotinylation buffer containing 1
mg/ml NHS-SS-Biotin (Sigma-Aldrich Chemie) or MTSEA-biotin (N-
biotinylaminoethyl methanethiosulfonate; Toronto Research Chemicals)
for 15 min at 4°C. Oocytes were washed twice and then incubated 5 min
at 4°C with 2 ml of the high Na incubation solution. Thirty oocytes per
condition was lysed with 20 l lysis buffer/oocyte. Oocytes were vor-
texed and centrifuged for 10 min at 12,000 rpm (4°C). The intermediate
phase was withdrawn, and a sample of each lysate was kept as a control
of “total lysate fraction.” Lysates were then incubated overnight with 40
l of streptavidin beads (Immunopure Immobilized Streptavidin Gel;
Perbio) at 4°C.
Statistical analyses. Student’s t-test was used for statistical analy-
sis. Data are expressed as means  SE.
RESULTS
Clinical course. The index case issuing from consanguine-
ous parents was born prematurely at 32 wk of gestation by
vaginal delivery following premature rupture of the mem-
branes. The patient’s birth weight was 1,645 g (between the
10th and 50th percentile, growth curve adjusted for ethnicity
and age) (24). The newborn developed hypotonia and feeding
problems, and no respiratory distress was noted. On day 16 of
life, severe hyponatremia associated with hyperkalemia and
mild metabolic acidosis (pH 7.30) was discovered. Plasma
renin activity was elevated, as was the plasma aldosterone level
(Table 1). Fractional sodium excretion (FENa) was increased,
and the urinary Na/K ratio was 7.6 (normal value 	2),
confirming salt wasting (Table 1) (18, 25). These results
were consistent with the diagnosis of PHA1. Treatment with
cation exchange resin (0.5 g·kg1·day1) and NaCl (6
mmol·kg1·day1) supplementation was introduced. At 7
wk after birth, evolution of the FENa and serum Na values
normalized under treatment, reaching values comparable
with the patient’s sibling born at term (Fig. 1). Salt supple-
mentation could be stopped at 6 mo of life without subse-
quent salt-losing episodes.
Table 1. Clinical characteristics of the family members with PHA1
ID Age Genotype Aldosterone, ng/dl PRA, ng  ml1  h1 Na, mmol/l K, mmol/l FENa, %
Index patient 2 wk / 2088 500 106 7.9 5.52
Index patient 6 mo / 148 2.33 139 4.5 0.11
Brother 2 wk / 1058 220 136 5.9 0.12
Brother 4 mo / 140 4.7
Mother 36 yr  5.0 1.00 139 4.1 NA
Father 40 yr  14.0 1.93 140 4.2 NA
PHA1, pseudohypoaldosteronism type 1; PRA, plasma renin activity; FENa, fractional sodium excretion. /homozygous; heterozygous for Ser243Pro
(S243P) mutation. Normal values for aldosterone 19–141 (premature infant), 5–90 (full-term infant), and 4–30 ng/dl (adult). Normal values for PRA 11–167
(premature infant), 2.35–37 (full-term infant), and 0.82–3.68 ng  ml1  h1 (adult). Na 131–145 mmol/l (newborn). K 3.6–5.9 mmol/l (newborn). FENa	2%.
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The second child of the same parents was born at term also
by vaginal delivery and did not develop any electrolyte abnor-
mality, and urinary Na/K ratio, as well as the FENa, was
normal (0.36; Table 1). However, the aldosterone level and
PRA at 2 wk of age was above the normal range for age (Table 1).
Sweat tests were performed in both brothers. The chloride
concentration was normal for both children [38 and 16 mmol/l,
respectively, (n  39 mmol/l)], excluding the diagnosis of
cystic fibrosis. Sweat sodium concentrations were normal [53
and 27 mmol/l (n 
 9–72 mmol/l)]. Both parents showed
normal values of aldosterone and PRA without any electrolyte
disturbances (Table 1).
Genetic analysis. Given the exclusive renal symptoms of
index case, we initially hypothesized an AD-PHA1 and per-
formed direct sequencing of the NR3C2 coding exons and the
intronic exon-flanking regions for confirmation. No mutation
was found in the NR3C2 amplified from the index case.
Subsequent analysis of the genes coding for the subunits of the
epithelial sodium channel ENaC revealed a homozygous
c.727TC mutation in exon 4 of the SCNN1A gene, substitut-
ing a proline (Pro) for serine (Ser) at position 243 (Ser243Pro)
in the -ENaC subunit. No other mutations were detected in
the SCNN1B and SCNN1G genes coding for the - and
-ENaC subunits, respectively. Both the index case and the
patient’s younger asymptomatic brother were homozygous
carriers of the same Ser243Pro mutation (-S243P), whereas
the mother and the father were heterozygous. The Ser243
residue lies in the large extracellular domain of ENaC within
the second cysteine-rich domain and is highly conserved
among the -, -, and -ENaC subunits of different species
from amphibian to mammalian (Supplemental Fig. S1).
Functional analysis of the mutant -ENaC. The ENaC
-S243P mutant was expressed in Xenopus oocytes for func-
tional analysis. Representative tracings of the Na current
mediated by ENaC wild type (WT) and ENaC -S243P mutant
are shown in Fig. 2, A and B. The rapid substitution of an
external solution devoid of Na ions to a solution containing
120 mM Na generated a robust inward current characterized
by a large peak current followed by a current relaxation to a
steady-state current after 10 s. The steady-state current was
inhibited by the addition of 10 M amiloride to the bathing
solution. The -S243P mutant exhibits an amiloride-sensitive,
inward Na current that is qualitatively similar to WT, but
quantitatively the current magnitude is lower. This decrease in
the steady-state current magnitude is summarized in Fig. 2, C
and D. ENaC current was measured in oocytes expressing
either ENaC WT or the -S243P mutant after overnight incu-
bation of the oocytes in a high or low Na-containing medium.
Since ENaC is constitutively open when expressed at the cell
surface, extracellular Na equilibrates with the intracellular
Na and thus determines both the extra- and intracellular Na
loads (1). Under both conditions, the S243P mutant exhibits a
lower amiloride-sensitive current (Fig. 2C). The overnight
incubation in a high Na medium (85 mM NaC1) of oocytes
expressing ENaC WT or the S243P mutant results in a signif-
icant decrease in ENaC current compared with oocytes prein-
cubated overnight in a low Na medium (10 mM NaC1). This
phenomenon has been described extensively and is called
feedback inhibition of the channel in response to an increase in
intracellular Na load (1). The feedback inhibition of ENaC
serves to prevent excessive accumulation of intracellular Na
ions that could be toxic for the cell. Compared with WT ENaC,
the reduction in the amiloride-sensitive Na current expressed
by the -S243P mutant was more pronounced (80%) after
overnight incubation in the high Na-containing medium than
in the low Na medium (30% decrease) (Fig. 2, C and D).
These experiments show that the -S243P mutation is associ-
ated with a partial but significant loss of function. In addition,
this loss of function is exacerbated under conditions favoring a
high intracellular Na load as if the -S243P mutation makes
the channel hypersensitive to feedback inhibition in the pres-
ence of a high Na load.
The ENaC current relaxation from the maximal peak current
to its steady state is a fast adaptive process dependent on the
permeating Na ions, termed ENaC self-inhibition (8). We
asked whether this physiological inhibitory response to extra-
Fig. 1. Serum Na and K as well as fractional excretion
for sodium (FENa) in the 2 family members harboring
the homozygous S243P -epithelial Na channel muta-
tion. Postnatal normalization of FENa in the index case
born prematurely (black dots). Hyponatremia (black
squares) improves as K and FENa decrease in the index
case (black diamonds and dots). Normonatremia, kal-
emia, and normal FENa in the brother born at term (gray
squares, diamonds, and dots, respectively).
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cellular Na ions was modified in the -S243P mutant. Self-
inhibition was defined as the ratio of the maximal peak current
over the steady-state current measured at 20 s (Iss/Ipeak); the
higher the ratio, the lower the ENaC self-inhibition. The data in
Fig. 3 show that for ENaC WT and -S243P mutant, the
self-inhibition is independent of the incubation conditions in
high or low Na medium. The ratio Iss/Ipeak for the -S243P
mutant was significantly decreased for the S243P mutant com-
pared with ENaC WT, indicating a slightly stronger apparent
self-inhibition for the channel mutant. The kinetic parameters
of the self-inhibition of the S243P mutant, obtained from the
exponential fit of the Na current decrease, were similar for
both the ENaC WT and mutant channel (data not shown). Thus
the apparent stronger feedback inhibition determined by the
Iss/Ipeak ratio is likely due to a lower steady-state current for
the -S243P mutant, as shown in Fig. 2.
We have verified that the reduction of ENaC-mediated
current for the -S243P mutant was not due to a lower
expression of ENaC at the cell surface. Mutant and WT
channels at the cell surface were labeled with biotin and
affinity purified on streptavidin beads. Western blots in Fig. 4
using an anti--ENaC antibody show the intracellular (un-
bound fraction to streptavidin beads) and surface expression
(bound fraction to streptavidin beads) of the ENaC mutant
compared with the WT. Both intracellular and surface expres-
sion of the ENaC WT or -S243P mutant were comparable,
and therefore, changes in the expression of the -S243P mutant
at the protein level cannot account for the observed decrease in
amiloride-sensitive current. In addition, we also tested the
possibility that the -S243P mutation may change channel
affinity for amiloride. Both ENaC WT and S243P mutant have
comparable affinities for amiloride with an IC50 of 0.29 (
0.08; n 
 12) and 0.15 M ( 0.04; n 
 12), respectively.
The parents of the index case are heterozygous for the
-S243P mutation and do not show any phenotype related to
alterations in the Na balance or to changes in the plasma level
of aldosterone. We have reproduced the heterozygous geno-
type in the Xenopus oocytes by coinjecting equal amounts of
cRNA encoding for the ENaC WT and the -S243P mutant
(1.5 ng of each cRNA), with - and -subunits. Compared with
the ENaC WT, the -S243P shows a significant reduction in
the channel activity (60%), and the coexpression of the ENaC
WT and mutant generated an amiloride-sensitive current that in
magnitude was intermediate to that of the WT and the mutant
(Fig. 5). Such reduction in ENaC activity observed upon
expression of the -S243P mutant alone or with the ENaC WT
is consistent with a gene dosage effect. Considering the ab-
sence of phenotype of the heterozygous parents, our data
suggest that the kidney can tolerate a 40% reduction in ENaC
activity without any consequence for the maintenance of Na
homeostasis.
What is the mechanism underlying the partial loss of ENaC
function due to the -S243P mutation? Several mechanisms
regulate ENaC at the cell surface. One mechanism associated
with the activation of ENaC at the cell surface involves a
proteolytic cleavage of the - and the -subunit of the ENaC
Fig. 2. Epithelial Na channel (ENaC)-mediated
Na currents in oocytes expressing ENaC wild
type (WT) and ENaC -S243P mutant. A and
B: representative recordings of amiloride-sen-
sitive Na current in oocytes expressing ENaC
WT -WT and ENaC -S243P mutant.
C: absolute amiloride-sensitive steady-state
Na currents measured in oocytes incubated
for 24 h (see METHODS) in a low Na-contain-
ing solution (closed bars; n 
 12 experi-
ments) and in a high Na solution (open bars;
n 
 8 experiments). Oocytes expressed either
-WT or -S243P mutant. D: relative
changes in the ENaC-mediated amiloride-
sensitive current in oocytes expressing the
-S243P mutant relative to those express-
ing ENaC -WT after incubation in a low
Na-containing solution (closed bars) and in
a high Na solution (open bars). **P 	 0.01;
***P 	 0.001.
Fig. 3. ENaC self-inhibition of the WT channel and the -S243P mutant.
Channel self-inhibition was defined as the ratio of the steady-state current (Iss)
measured after 20 s over the peak current (Ipeak) (see Fig. 2, A and B). Closed
and open bars, low and high Na incubation conditions, respectively. Iss/Ipeak
ratio for the -S243P and the WT was 0.57  0.04 and 0.70  0.03,
respectively (Student’s t-test; P 	 0.05, n 
 12), and 0.51  0.04 vs. 0.65 
0.04 (Student’s t-test; P 	 0.01, n 
 8).
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complex by serine proteases at specific sites in the extracellular
domain (29); this channel activation can be reproduced using
low concentrations of external trypsin in Xenopus oocytes (9).
Although -S243 is not part of a consensus target sequence for
serine proteases, we verified that the loss of function of the
-S243P mutant channel was not due to a resistance to cleav-
age and channel activation by serine proteases. Experiments in
Fig. 6 confirm the partial loss of function of the -S243P
mutant after overnight incubation in a low or high Na me-
dium. In the presence of trypsin, both the WT and the mutant
show an approximately twofold increase in channel activity;
the reduced activity of the -S243P still remained significant
compared with the WT, even in the presence of trypsin. These
experiments indicate that the -S243P mutant retains its sen-
sitivity to activation by extracellular trypsin, but the loss of
function of the channel mutant cannot be overcome by trypsin;
thus the mechanism underlying the channel loss of activity is a
more general mechanism that is independent of the channel
activation by proteolytic cleavage.
The substitution of the -Ser243 by a proline is expected to
markedly change the architecture of the protein at this specific
site, since Pro is often found in bends of folded proteins. We
could observe that a more conserved substitution of the Ser243
by cysteine was without effect on ENaC activity. Actually,
after overnight incubation in a high Na medium, -S243C,
did not display a steady-state current that was significantly
different from the WT (15.7 A  3.14; n 
 24, P 
 0.08).
Thus it is likely that the S243P mutation in the -ENaC
introduces important steric changes in an extracellular domain
that is important for ENaC activity and its modulation.
DISCUSSION
In this study, we have identified in a patient with a transient
form of AR-PHA1 a novel homozygous mutation in the
SCNN1A gene, leading to a Ser243 to Pro substitution of the
-ENaC subunit. This patient was born prematurely at week 32
and presented renal symptoms only, characterized by a severe
salt-wasting nephropathy with extremely high levels of aldo-
sterone. Within 2 wk of treatment with salt supplementation
and cation exchange resin, clinical symptoms rapidly im-
proved, and serum and urinary Na values normalized. Blood
analyses performed at 6 mo of age still revealed an elevated
aldosterone level but without electrolyte disturbances. The
patient’s younger brother born at term with the same homozy-
gous -S243P mutation did not show any renal salt-wasting
phenotype, only an elevated plasma aldosterone.
In premature infants the urinary loss of sodium exceeds the
daily intake, leading to a negative Na balance in most infants
less than 28 wk of gestational age (GA) (3, 10). A positive
balance is achieved only after 32 wk of GA, which is due to
continuing kidney maturation responsible for a decrease in
renal fractional excretion of sodium. The cellular mechanisms
for the limited capacity of the kidney to retain Na before term
have not been completely elucidated.
Microperfusion of cortical collecting ducts isolated from
1-wk-old rabbits with immature kidneys showed no significant
Na transport, and no conducting ENaC channels could be
observed by patch-clamp technique (30, 31). To the extent that
the immature kidney of newborn rabbits is a representative
model of the premature human kidney, the paucity of active
ENaC channels may certainly contribute to the reduced capac-
ity of the immature kidney to reabsorb Na ions. In addition,
a relative insensitivity of the immature kidney to aldoste-
rone has been demonstrated in the newborn rat and rabbit,
suggesting that the plasma mineralocortocoids play a lim-
ited role in regulating renal distal Na absorption in the
early postnatal life (35).
The transition from the fetal to the neonatal life is charac-
terized by a dramatic decrease in the urinary Na excretion.
Clearance studies using diuretics have suggested that nephron
segments downstream of the proximal tubule are responsible
Fig. 5. Reconstitution of the heterozygous genotype for the -S243P mutation.
Equal amounts of cRNA (1.5 ng) for the ENaC WT and for the -S243P
mutant were injected. Oocytes were incubated overnight in a high Na-
containing medium (85 mM NaC1); n 
 10 oocytes/condition obtained from
2 frogs. *P 	 0.05. ns, Not significant.
Fig. 4. Surface expression of ENaC WT and
-S243P mutant. A: Western blot using anti--
ENaC (hENaC) and anti-actin antibodies of the
unbound fraction to streptavidin beads (non-
biotinylated fraction) of total proteins from
oocytes expressing ENaC WT or the -S243P
mutant. B: similar Western blot of the biotinyl-
ated fraction of total proteins bound to strepta-
vidin beads representing the surface expression
of -ENaC WT and mutant. Ni, negative con-
trol.
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for the sharp increase in Na absorption during the early
postnatal life (33). Patch-clamp studies on rabbit neonates have
shown that the product of the number of ENaC channel times
the channel open probability increases 30-fold between the 1st
and the 2nd wk after birth (31).
The index case shows a urinary Na excretion, as measured
by the UNa/K ratio, more than three times higher than
expected for a preterm infant of 32 wk of GA (3). The
identification of the -S243P ENaC loss of function mutation
in this patient is the most likely explanation for the patient’s
abnormally high UNa/K and the high plasma aldosterone
level. The evidence -S243P mutation results in a channel loss
of function confirms the diagnosis of AR-PHA1. Our observa-
tion represents the first direct evidence that ENaC plays a
crucial role for achieving a Na balance starting a 32 wk of
GA, since a slight decrease in ENaC activity due to the
-S243P mutation has dramatic consequences on distal Na
absorption and can precipitate a severe salt-wasting nephrop-
athy in a premature baby.
The rapid clinical improvement of our patient during the first
weeks of life is likely due to kidney maturation associated with
an increase in the expression of ENaC channels as well as other
Na transporters in or upstream of the distal nephron. This is
supported by the fact that the patient’s younger brother, car-
rying the same genotype but born at term, never developed the
renal symptoms but had a slightly elevated plasma aldosterone
level. This further indicates that limited loss of function of the
-S243P ENaC mutation is not sufficient to precipitate an
AR-PHA1 when the kidney maturation is nearly completed at
term. However, we cannot exclude potential epigenetic
changes contributing to the different phenotypes, as sometimes
observed in monozygotic twins.
The parents of the index case, heterozygous for the muta-
tions, do not show any sign of a Na-losing nephropathy
despite an estimated 40% reduction in ENaC activity. Simi-
larly, the partial loss of ENaC function due to the mutation
-S243P has no effects on airway fluid clearance or on the
electrolyte composition of the sweat. These observations point
out the importance of compensatory mechanisms in the kid-
neys, lungs, and other organs expressing ENaC to overcome a
limited reduction of its activity.
Clinical improvements of AR-PHA1 have already been
reported, but in most cases patients exhibit salt-losing episodes
if they are not supplemented with dietary salt (13, 18, 28).
Clinical improvement is usually associated with missense mu-
tations or mutations in the - or -subunits, resulting in only
partial but not in complete loss of ENaC function. The slight
reduction in ENaC activity of the -S243P mutant fully sup-
ports the notion that the clinical evolution of the AR-PHA1 is
related to the degree of ENaC loss of function caused by the
genetic mutations. A partial loss of function of ENaC in the
ASDN is likely to be compensated by an increased Na
absorption in the upstream nephron segments. The late distal
nephron also responds to elevated plasma levels of aldosterone
by increasing the expression of the thiazide-sensitive NaCl
cotransporter (NCC) (22). Recently, an increased level of NCC
protein in the urine of a patient with AR-PHA1 was reported
and supports the hypothesis of a compensatory Na absorption
in the distal nephron (2, 19). This upregulation of the activity
of the NCC likely represents a compensatory mechanism to
reabsorb Na and to maintain Na balance in the mature
kidney but not in an immature kidney at the GA of 32 wk.
In the premature kidney, an elevated delivery of Na is
expected in the distal part of the nephron where ENaC is
expressed and can result from upstream immature functional
Na transporters; we tried to experimentally reproduce this
situation with oocytes expressing ENaC by overnight incuba-
tion in a high Na medium, leading to intracellular Na load.
Interestingly, it was under such a high Na load that we
observed the most important loss of ENaC function. We still do
not understand the molecular mechanism underlying this ef-
fect, but it may also contribute to the salt-losing episode after
birth and the rapid clinical improvement of our preterm patient.
Indeed, as the Na transporters mature in the nephron seg-
ments upstream of the ASDN, the distal Na delivery de-
creases, and under these conditions we can expect from our
data that the degree of ENaC loss of function is reduced.
Finally, the S243P mutation identifies a novel functional
domain in the extracellular loop of the channel that may link
ENaC activity to changes in chronic extracellular Na load.
The S243 residue is located in the extracellular loop of ENaC.
Further studies are needed to investigate the precise mecha-
nisms involved in the ENaC sensing of external Na ions.
In conclusion, our study provides the first genetic evidence
that ENaC activity is critical for the maintenance of salt
balance in the immature kidney of preterm babies. Further-
more, it shows that the severity of the symptoms of AR-
PHA1 is related to the degree of the ENaC loss of function.
Finally, this study identifies a novel functional domain in
the extracellular loop of ENaC that is important for channel
regulation.
Fig. 6. ENaC channel activation by trypsin. The addi-
tion of trypsin (5 g/ml) in the external medium (open
bars) significantly increased the current of the mutant
-S243P and the WT 2.6- and 1.9-fold, respec-
tively, after incubation in a low Na medium and 3-
and 2.2-fold, respectively, after incubation in a high
Na medium. The number of oocytes ranged from 17
to 26. ***P 	 0.001; **P 	 0.01.
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